MicroRNA implications in chemotherapy-induced cardiac toxicity by Roca-Alonso, Laura
	  	  
 	  
MicroRNA	  implications	  in	  
chemotherapy-­‐induced	  cardiac	  toxicity	  
	  
by	  Laura	  Roca-­‐Alonso	  
Thesis	  submitted	  for	  the	  degree	  of	  Doctor	  of	  Philosophy	  at	  	  






Department	  of	  Oncology,	  1st	  floor	  ICTEM	  
Imperial	  College	  London	  
Hammersmith	  Hospital,	  Du	  Cane	  Road	  





Supervisor:	  Prof.	  Justin	  Stebbing	  
Co-­‐supervisor:	  Dr.	  Leandro	  Castellano	  
	  	   2	  
	  
	  
Dedicated to:  
	  
	  
My mum and role model - for always staying strong and for an amazing 
upbringing, thanks for giving us so many chances 
 
My little sister - for everything we’ve gone through together, for 
believing in me 
 
My family (those who are with us and those who passed away) – for their 
unconditional love and understanding, for missing me when I’m away 
 
My boyfriend Guille – for your support, for making me a better person every 
day and for encouraging me to enjoy every step of the journey	  	   	  









The	   copyright	   of	   this	   thesis	   rests	  with	   the	   author	   and	   is	  made	   available	   under	   a	   Creative	  
Commons	  Attribution	  Non-­‐Commercial	  No	  Derivatives	  licence.	  Researchers	  are	  free	  to	  copy,	  
distribute	  or	  transmit	  the	  thesis	  on	  the	  condition	  that	  they	  attribute	  it,	  that	  they	  do	  not	  use	  
it	   for	  commercial	  purposes	  and	  that	   they	  do	  not	  alter,	   transform	  or	  build	  upon	   it.	  For	  any	  
reuse	   or	   redistribution,	   researchers	   must	   make	   clear	   to	   others	   the	   licence	   terms	   of	   this	  
work.	  
	   	  
	  	   4	  
Abstract	  	  
	  
The	  use	  of	  anthracyclines	  such	  as	  doxorubicin	  (DOX)	  has	  improved	  mortality	  and	  morbidity	  
in	   cancer	   patients,	   yet	   associated	   risks	   of	   cardiomyopathy	   have	   limited	   their	   clinical	  
application.	   DOX-­‐associated	   cardiotoxicity	   typically	   progresses	   to	   heart	   failure	   (HF).	   The	  
knowledge	   of	   the	   mechanisms	   underlying	   DOX-­‐related	   cardiac	   dysfunction	   is	   currently	  
limited,	  hampering	  the	  development	  of	  cardioprotective	  strategies.	  	  
MicroRNAs	   (miRNAs)	   are	   gene	   expression	   regulators	   that	   play	   potent	   roles	   in	   both	  
cardiovascular	  disease	  and	  cancer.	  We	  wished	  to	  investigate	  DOX-­‐induced	  changes	  in	  cardiac	  
miRNA	  expression	  and	  the	  potential	  alteration	  of	  cellular	  processes	  downstream.	  
Myocardial	  miRNA	  profiling	  was	  performed	  after	  DOX	  injury,	  either	  via	  acute	  administration	  
to	  cardiomyocytes	  in	  vitro	  or	  chronic	  exposure	  in	  vivo,	  and	  compared	  to	  miRNA	  profiles	  from	  
infarcted	  hearts.	  We	   identified	  an	  overlapping	  down-­‐regulation	  of	   several	  members	  of	   the	  
miR-­‐30	  family.	  Subsequent	  experimental	  validation	  of	  a	  bioinformatically	  predicted	  subset	  of	  
target	   genes	   allowed	   us	   to	   confirm	   four	   novel	   miR-­‐30	   targets:	   β1-­‐	   and	   β2-­‐adrenoceptors	  
(β1AR,	  β2AR),	  Gi	  alpha	  2	  (Giα-­‐2)	  and	  the	  pro-­‐apoptotic	  gene	  BNIP3L,	  all	  of	  which	  are	  essential	  
in	   cardiomyocytes.	   The	   implications	   of	   the	   β-­‐adrenergic	   pathway	   in	   HF	   are	   extensively	  
described.	  Importantly,	  we	  show	  a	  preferential	  βAR	  inhibition	  by	  miR-­‐30,	  having	  a	  β-­‐blocker	  
like	  effect.	  Additionally,	  we	  demonstrate	  that	  high	  miR-­‐30	  levels	  are	  protective	  against	  DOX	  
insults	   and	   correlate	   with	   lower	   reactive	   oxygen	   species	   generation	   in	   cardiac	   cultures.	  
Upstream	  of	  these	  mechanisms,	  we	  describe	  the	  transcription	  factor	  GATA-­‐6	  to	  be	  involved	  
in	  mediating	  DOX-­‐induced	  miR-­‐30	  down-­‐regulation.	  	  
Finally,	  when	  assessing	  the	  implications	  of	  miR-­‐30	  in	  breast	  cancer,	  we	  observed	  an	  inverse	  
correlation	   between	   miR-­‐30	   expression	   levels	   and	   breast	   cancer	   cell	   migration	   in	   vitro.	  
Moreover,	  bioinformatic	  analyses	  revealed	  reduced	  miR-­‐30	  levels	  in	  breast	  cancer	  patients.	  
Taken	  together,	  our	  findings	  encourage	  a	  potential	  translational	  use	  for	  miR-­‐30	  as	  an	  early	  
biomarker	   as	   well	   as	   a	   therapeutic	   strategy,	   combining	   a	   cardioprotective	   action	   with	  
pleiotropic	  anti-­‐cancer	  effects.	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1.1 Cardiomyopathy	  and	  heart	  failure	  
	  
Cardiovascular	   disease	   is	   the	  most	   common	   cause	   of	  morbidity	   and	  mortality	   worldwide,	  
accounting	   for	   approximately	   30%	   of	   all	   deaths	   1.	   Although	   mortality	   and	   hospitalisation	  
rates	   have	   recently	   decreased	   in	   the	   UK,	   heart	   disease	   still	   constitutes	   a	   huge	   economic	  
burden	  for	  the	  national	  health	  service	  2.	  	  
	  
1.1.1 The	  cardiomyocyte	  	  
	  
Cardiomyocytes	  are	  the	  main	  cell	  type	  to	  form	  the	  myocardium,	  which	  is	  the	  striated	  cardiac	  
muscle.	   Each	   cardiomyocyte	   constitutes	   a	   single	   contractile	   unit.	   Rod-­‐shaped	  
cardiomyocytes	  are	  arranged	   in	  myofibers	   that	  are	  arrayed	   in	  a	  determined	  3-­‐dimensional	  
structure	   and	   give	   rise	   to	   the	   ventricular	   myocardium	   3.	   Cardiomyocytes	   contain	   the	  
myofilaments	   responsible	   for	   cardiac	   contraction	   and	   communicate	   with	   adjacent	   cells	  
through	   gap	   junctions	   that	   allow	   spreading	   of	   polarising/depolarising	   waves	   to	   ensure	   a	  
synchronised	  heart	  beat	  4.	  There	  are	  two	  types	  of	  cardiac	  myocytes,	  the	  ‘working’	  cells	  and	  
the	  pacemaker	   cells.	   ‘Working’	   cardiomyocytes	  have	  a	   stable	   resting	  membrane	  potential,	  
which	  is	  determined	  by	  the	  baseline	  permeability	  of	  the	  cell	  to	  ions.	  In	  contrast,	  pacemakers	  
are	   unstable	   and	   able	   to	   spontaneously	   depolarise.	   Pacemaker	   cardiomyocytes	   form	   the	  
sinoatrial	   and	   atrioventricular	   nodes,	   and	   also	   the	   Purkinje	   fibres	   –	   located	   within	   the	  
ventricular	  myocardial	  walls	  5.	  	  
	  These	  polarising/depolarising	  waves	  are	  known	  as	  the	  action	  potential	  (AP).	  The	  generation	  
and	   propagation	   of	   the	   AP	   is	   the	   basis	   of	   cardiac	   electrophysiology	   and	   results	   from	   ion	  
currents,	   creating	   a	   high	   voltage	   in	   the	   cardiomyocyte	   membrane.	   T-­‐tubules	   are	  
invaginations	   of	   the	   sarcolemma	   (cardiomyocyte	   plasmatic	   membrane)	   designed	   to	   allow	  
depolarisation	  to	  quickly	  spread	  through	  the	  cytoplasm	  6.	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Ca2+	   currents	   play	   a	   key	   role	   in	   controlling	   cardiomyocyte	   contraction.	   Following	   initial	  
depolarisation,	   Ca2+	   enters	   the	   cell	   through	   voltage-­‐dependent	   Ca2+	   current	   channels	   (ICa)	  
located	   in	   the	   sarcolemma	   and	   triggers	   Ca2+	   induced	   Ca2+	   release	   (CICR)	   from	   the	  
sarcoplasmic	   reticulum	   (SR).	   Two	   types	   of	   ICa	   channels	   are	   important	   at	   different	   stages:	  
transient	   Ca2+	   channels	   (T-­‐type)	   are	   important	   to	   initiate	   the	   AP,	   whilst	   long	   lasting	   Ca2+	  
channels	   (L-­‐type)	   are	   responsible	   for	   sustaining	   the	   excitation.	   The	   excitation-­‐contraction	  
coupling	   largely	   depends	   on	   the	   intracellular	   concentration	   of	   Ca2+	   ([Ca2+]i).	   High	   [Ca2+]i	  
activates	   the	   myofilaments	   through	   Ca2+	   binding	   by	   Troponin	   C	   (TnC),	   which	   induces	   a	  
conformational	   change	   in	   the	   tropomyosin/troponin	   regulatory	   complex	   and	   allows	  
actin/myosin	  (thick	  filaments)	  to	  contract	  7.	  Subsequently,	  the	  drop	  in	  [Ca2+]i	  switches	  off	  the	  
contractile	  machinery	  and	  causes	  diastolic	   relaxation.	   Intracellular	  Ca2+	   is	   cleared	   from	  the	  
cytosol	  through	  diverse	  mechanisms	  including	  active	  ATP-­‐dependent	  transport	  back	  into	  SR	  
store	  (mediated	  by	  the	  SR	  Ca2+	  ATPase	  transporter	  2a,	  SERCA2a),	  exported	  out	  of	  the	  cell	  by	  
the	  sodium-­‐calcium	  exchanger	  (NCX)	  or	  into	  mitochondria	  5,	  8,	  9.	  	  
Calcium	   handling	   is	   regulated	   by	   Ca2+	   levels,	   and	   by	   cyclic	   adenosine	   monophosphate	  
(cAMP).	   cAMP	   is	   able	   to	   activate	   cAMP-­‐dependent	   protein	   kinase	   A	   (PKA),	   which	   in	   turn	  
phosphorylates	   Ca2+	   channels	   and	   myosin-­‐binding	   protein	   C,	   as	   well	   as	   other	   proteins	  
involved	   in	   Ca2+	   handling	   such	   as	   Phospholamban	   (PLB,	   a	   SERCA2a	   inhibitor),	   Troponin	   I,	  
ryanodine	   receptor	   (RyR).	   Hence,	   PKA	   activation	   promotes	   sustained	   Ca2+	   influx,	  
cardiomyocyte	  contraction	  and	  also	  aids	  rapid	  Ca2+	  re-­‐uptake	  (Figure	  1)	  10,	  11.	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Figure	  1.	  Calcium	  handling	  and	  cardiomyocyte	  contraction.	  When	  depolarisation	  occurs,	  Ca2+	  enters	  the	  cell	  
via	  ICa	  channels	  and	  NCX	  (which	  exchanges	  3	  Na
+	  to	  bring	  one	  Ca2+	  into	  the	  cell).	  Other	  types	  of	  ion	  transporters	  
are	   located	   in	   the	  membrane	   and	   contribute	   to	   the	   action	   potential,	   although	   not	   shown	   in	   this	   simplified	  
version.	   The	   Ca2+	   entry	   then	   triggers	   Ca2+	   release	   from	   the	   SR	   store	   (CICR)	   via	   RyR.	   At	   high	   intracellular	  
concentrations,	  Ca2+	  binds	  to	  TnC	  allowing	  thick	  myofilaments	  (actin	  and	  myosin)	  to	  contract.	  cAMP	  production	  
resulting	   from	  β-­‐adrenergic	   stimulation	  activates	  PKA,	  which	   is	  able	   to	  phosphorylate	   ICa	  and	  myosin-­‐binding	  
protein	   C,	   promoting	   cardiomyocyte	   contraction.	   In	   the	   repolarisation	   phase,	   leading	   to	   diastolic	   relaxation,	  
Ca2+	  is	  cleared	  form	  the	  cytoplasm	  by	  re-­‐uptake	  into	  the	  SR	  (through	  SERCA	  active	  transport)	  and	  mitochondria,	  
as	  well	  as	  being	  exported	  by	  NCX.	  Solid	  arrows	  indicate	  processes	  increasing	  [Ca2+]i	  during	  depolarisation,	  while	  
dashed	  arrows	  indicate	  mechanisms	  leading	  to	  a	  drop	  in	  [Ca2+]i	  during	  repolarisation.	  	  
	  
1.1.1.1 The	  beta-­‐adrenergic	  pathway	  
	  
Catecholamines	  (adrenaline	  and	  noradrenaline)	  are	  essential	  regulators	  in	  the	  cardiovascular	  
system.	   Cardiac	   adrenergic	   receptors	   (or	   adrenoceptors,	   AR)	   are	   in	   charge	   of	   recognising	  
catecholamine	   stimulation	   and	   transmitting	   the	   signal	   downstream.	   Two	   families	   of	  
adrenoceptors	   were	   described	   initially	   in	   relation	   to	   their	   effects	   in	   the	   vasculature:	   α	  
(vasoconstrictor)	   and	   β	   (vasodilator),	   both	   being	   transmembrane	   guanine	   (G)-­‐protein	  
coupled	  receptors	  (GPCR)	  12.	  Both	  α	  and	  β	  adrenoceptors	  are	  divided	  into	  subtypes	  13,	  14.	  β-­‐
adrenoceptors	  (βAR)	  are	  predominantly	  expressed	  in	  the	  heart,	  although	  varying	  expression	  
levels	   are	   observed	   for	   each	   of	   the	   three	   βAR	   subtypes	   (β1AR,	   β2AR,	   β3AR).	   The	   most	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and	   lastly	   the	   minimally	   expressed	   β3AR.	   Under	   physiological	   conditions	   β3AR	   is	   mostly	  
inactive,	   and	   the	   existence	   of	   truly	   functional	   β3AR	   still	   remains	   controversial	   15,	   16.	   In	  
contrast	  to	  β1AR	  and	  β2AR,	  activation	  of	  β3AR	  seems	  to	  decrease	  contraction	  17.	  	  
ARs	   are	   coupled	   to	   G-­‐proteins	   that,	   upon	   activation,	   translate	   the	   signal	   to	   intracellular	  
secondary	  messengers.	  There	  are	  approximately	  20	  subtypes	  of	  G-­‐proteins	  (Gs,	  Gi,	  Gq,	  etc.)	  
and	  are	  all	  heterotrimeric,	  being	  formed	  by	  three	  subunits:	  α,	  β	  and	  γ.	  The	  activation	  of	  βAR	  
by	  agonists	  results	  in	  a	  guanine	  triphosphate	  (GTP)	  to	  guanine	  diphosphate	  (GDP)	  exchange	  
in	   the	  Gα	   subunit,	  which	   in	   turn	  becomes	  active	  and	  dissociates	   from	   the	  heterotrimer	   18.	  
The	   remaining	   GβΥ	   heterodimer	   can	   also	   transduce	   signals	   independently	   11.	   Signalling	  
through	   activation	   of	   β1AR	   and	   β2AR	   increases	   myocyte	   contractility	   (positive	   inotropic	  
effect),	   beating	   rate	   (positive	   chronotropic	   effect)	   and	   also	   relaxation	   (lusitropic	   effect).	  
Therefore,	  βAR	  stimulation	  enhances	  cardiac	  output	  (CO)	  18.	  
Physiologically,	  βAR	  activation	  results	  in	  Gs	  protein-­‐dependent	  activation	  of	  adenylyl	  cyclase	  
(AC),	   enhancing	   cAMP	   production	   from	   adenosine	   triphosphate	   (ATP).	   At	   least	   10	  
mammalian	   AC	   enzyme	   isoforms	   have	   been	   identified,	   being	   AC	   type	   V	   and	   VI	   the	  most	  
abundant	  in	  the	  heart	  19,	  20.	  Whilst	  Gsα	  activates	  cardiac	  AC,	  Giα	  proteins	  (isoforms	  1,	  2	  and	  3)	  
inhibit	  its	  enzymatic	  activity	  21.	  cAMP	  is	  the	  main	  mediator	  of	  the	  β-­‐adrenergic	  pathway	  and	  
it	   activates	   PKA,	   which	   is	   responsible	   for	   phosphorylating	   proteins	   involved	   in	   Ca2+	  
metabolism	   and	   contraction	   (e.g.	   ICa	   and	  myosin).	  While	   β1AR	   is	   only	   able	   to	   couple	   and	  
activate	  Gs,	  β2AR	  can	  also	  bind	  to	  Gi.	  β2AR-­‐Gi	  activation	   functions	  as	   ‘break’	   for	  contractile	  
pathways	   (negative	   inotropic	   effect)	   via	   both	   cAMP-­‐dependent	   and	   independent	  
mechanisms	   11,	   22.	   Notably,	   β1AR	   and	   β2AR	   have	   opposing	   effects	   on	   cardiomyocyte	  
apoptosis:	   whilst	   β1AR	   stimulation	   triggers	   cAMP-­‐dependent	   cell	   death,	   β2AR	   activation	  
leads	  to	  increased	  PI3K/Akt	  survival	  signalling	  through	  Gi	  (GβΥ)	  	  (Figure	  2)	  23,	  24.	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Figure	  2.	  Beta-­‐adrenergic	   signalling.	  βARs	  respond	  to	  catecholamine	  stimulation	  by	  transducing	  the	  signal	  to	  
the	  cytoplasm	  and	  regulating	  cardiomyocyte	  contractility.	  β1AR	  stimulation	  results	  in	  Gs	  activation,	  with	  the	  Gα	  
subunit	   in	   turn	   activating	   AC	   and	   therefore	   promoting	   cAMP	   production.	   cAMP	   then	   activates	   PKA,	   which	  
phosphorylates	  several	  proteins	  involved	  in	  Ca2+	  handling	  and	  promotes	  contraction.	  On	  the	  other	  hand,	  β1AR	  
stimulation	   is	  associated	  with	   increased	  apoptosis	  due	   to	  cAMP	  accumulation.	  β2AR	  can	  couple	  both	  with	  Gs	  	  
(sharing	   the	   same	   downstream	   pathway	   with	   β1AR)	   and	   with	   Gi.	   Active	   Gi	   (subunit	   α)	   represses	   AC	   and	  
decreases	   intracellular	   cAMP,	   having	   an	   inhibitory	   effect	   on	  myofilament	   contraction	   (negative	   inotropism).	  
The	   βΥ	   subunits	   of	   Gi	   promote	   PI3K/Akt	   signalling,	   having	   the	   β2AR-­‐	   Gi	   pathway	   an	   anti-­‐apoptotic	   effect	   in	  
cardiomyocytes.	  	  
	  
Given	   the	   importance	   of	   β-­‐adrenergic	   signalling	   in	   controlling	   the	   cardiac	  
contraction/relaxation	   cycle,	   the	   β-­‐adrenergic	   pathway	   is	   tightly	   regulated	   to	   prevent	   the	  
toxic	   effects	   deriving	   from	   catecholamine	   overstimulation.	   Two	   types	   of	   regulation	   have	  
been	   described,	   spatial	   and	   temporal.	   The	   spatial	   control	   of	   responsiveness	   to	   βAR	  
stimulation	  refers	  to	  the	  compartmentalisation	  of	  β2AR,	  which	  are	  mainly	   located	   in	  the	  T-­‐
tubules,	   whilst	   β1AR	   are	   evenly	   distributed	   25,	   26.	   The	   temporal	   control	   is	   based	   on	   the	  
prolonged	   exposure	   to	   agonists	   causing	   βAR	   down-­‐regulation,	   internalisation	   and	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PKA-­‐mediated	   phosphorylation	   of	   β2ARs,	   inducing	   Gs	   to	   Gi	   coupling	   switch	   25,	   28.	   Also,	   G-­‐
protein	  coupled	  receptor	  kinases	   (GRKs)	  mediate	   inactivating	  phosphorylation	  of	  βARs	  and	  
act	   in	   combination	   with	   β-­‐arrestin	   binding	   to	   active	   receptors	   to	   prevent	   coupling	   with	  
effector	  G	  proteins	  29,	  30.	  Overall,	  a	  blunted	  response	  to	  βAR	  stimulation	  is	  observed.	  	  
	  
1.1.2 Cardiomyopathy	  	  
	  
Cardiomyopathy	   refers	   to	   a	   pathological	   state	   where	   the	  myocardium	   (cardiac	  muscle)	   is	  
damaged.	  Cardiomyopathies	  are	  considered	  a	  heterogeneous	  group	  of	  diseases	  where	   the	  
dysfunction	  can	  occur	  either	   in	   isolation	  or	   in	  association	  with	  another	  syndrome	  that	  also	  
affects	  other	  tissues	  31.	  Cardiologists	  established	  two	  types	  of	  cardiomyopathy	  more	  than	  30	  
years	   ago.	   Those	   named	   ‘primary	   cardiomyopathies’	   are	   idiopathic	   conditions,	   whilst	   the	  
‘secondary	   cardiomyopathies’	   have	   similar	   features	   but	   could	   be	   linked	   to	   an	   identifiable	  
source	   (e.g.	   ischaemia,	   hypertension,	   alcohol,	   pregnancy).	   Notably,	   some	   cases	   of	  
myocardial	   pathology	   are	   clinically	   difficult	   to	   classify	   as	   one	   of	   these	   two	   types	   32.	   An	  
updated	   classification	   proposed	   by	   the	   European	   Society	   of	   Cardiology	   emphasises	   the	  
distinction	  between	  familiar	  (genetic	  component	  identified)	  and	  non-­‐familiar,	  which	  can	  be	  
subdivided	   as	   idiopathic	   and	   acquired	   33.	   	   The	   establishment	   of	   a	   new	   molecular	  
classification	   has	   been	   proposed	   as	   the	   knowledge	   of	   genetic	   mechanisms	   underlying	  
cardiomyopathy	  increases	  34.	  
Regardless	   of	   the	   cause,	   there	   are	   five	   subgroups	   of	   cardiomyopathies	   according	   to	   the	  
morphological/functional	  phenotypes	  observed	  (Figure	  3).	  All	  of	  these	  are	  tightly	  associated	  
with	  the	  development	  of	  cardiac	  dysfunction.	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Figure	  3.	  Types	  of	  primary	  cardiomyopathy.	  Schematic	  representation	  of	  hearts	  affected	  by	  different	  types	  of	  
cardiomyopathy,	   following	   the	   classification	   established	   by	   the	   World	   Health	   Organization.	   DCM:	   dilated	  
cardiomyopathy,	   HCM:	   hypertrophic	   cardiomyopathy,	   RCM:	   restrictive	   cardiomyopathy,	   ACM:	   arrhythmic	  
cardiomyopathy,	  UCM:	  unclassified	  cardiomyopathy.	  Figure	  reproduced	  from	  35.	  
	  
1.1.3 The	  failing	  heart	  
	  
Heart	   failure	   (HF)	   is	  an	   increasing	  problem,	  especially	  with	   the	  ageing	  of	   the	  population	   in	  
Western	  countries.	  Hospital	  admissions	  and	  treatment	  of	  HF	  patients	  account	  for	  up	  to	  1-­‐2%	  
of	  the	  public	  healthcare	  expenditure	  in	  developed	  nations.	  Notably,	  a	  60%	  mortality	  rate	  is	  
recorded	   within	   5	   years	   of	   diagnosis	   36.	   HF	   is	   the	   most	   common	   endpoint	   of	   myocardial	  
damage,	  regardless	  the	  initiating	  aetiology.	  The	  failing	  heart	  has	  been	  widely	  studied	  and	  it	  
appears	  to	  be	  a	  tightly	  regulated	  complex	  syndrome.	  Generally,	  HF	  progression	  starts	  with	  
remodelling	  of	  the	  ventricles,	  mainly	  the	  left	  ventricle	  (LV),	  in	  order	  to	  achieve	  a	  functional	  
compensation	   in	   the	   damaged	   muscle.	   This	   process	   involves	   important	   changes	   in	   gene	  
expression,	   such	   as	   re-­‐activation	   of	   foetal	   genes	   (e.g.	   switch	   to	   the	   foetal	   β	   form	   of	   the	  
myosin	  heavy	  chain,	  βMHC),	  apoptosis	  and	  myocyte	  hypertrophic	  growth	  37.	  Eventually,	  this	  
compensatory	   hypertrophy	   causes	   myocardial	   wall	   stress	   and	   contractile	   dysfunction,	  
leading	   to	  a	   stage	  of	   failure	  where	   the	  heart	   is	  not	  capable	  of	  efficiently	  pumping	  enough	  
blood	  to	  the	  organs.	  Importantly,	  other	  cardiac	  cell	  types	  (non-­‐myocytes)	  play	  active	  roles	  in	  
cardiac	   remodelling.	   Fibroblasts,	   for	   instance,	   control	   extracellular	   matrix	   production,	   are	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able	   to	   respond	   to	   signals	   and	   to	   affect	   cardiomyocytes.	   Indeed,	   increased	   fibroblastic	  
proliferation	  becomes	  problematic	  in	  maladaptive	  myocardial	  remodelling	  38.	  
Evaluation	  of	  LV	  function	  by	  measuring	  the	  ejection	  fraction	  (LVEF)	  is	  the	  most	  common	  first	  
line	  diagnostic	  strategy	  for	  HF	  39.	  LVEF	   is	  a	  volumetric	  measure	  of	  the	  percentage	  of	  blood	  
that	   is	   pumped	   out	   of	   the	   LV	   chamber	   in	   every	   heartbeat.	   LVEF	   values	   of	   >50%	   are	  
considered	  normal,	  40-­‐50%	  borderline	  and	  <40%	  dysfunctional.	   Importantly,	  some	  cases	  of	  
severe	   HF	   remain	   undiagnosed	   because	   patients	   are	   asymptomatic	   40.	   Moreover,	   some	  
patients	  present	  with	  HF	  with	  preserved	  ejection	  fraction	  (HFpEF),	  having	  the	  same	  mortality	  
risk	   as	   HF	   with	   reduced	   LVEF	   but	   being	   particularly	   challenging	   to	   diagnose.	   The	   cause	  
underlying	   HFpEF	   (or	   diastolic	   HF)	   is	   an	   impaired	   relaxation	   of	   the	   ventricles,	   entailing	   a	  
limited	  filling	  of	  the	  chamber	  41,	  42.	  	  
The	  aetiologies	  of	  HF	  are	  varied,	  encompassing	  genetic,	  structural,	  mechanical	  and	  electrical	  
abnormalities.	  Although	  no	  detailed	  and	  overlap-­‐free	  classification	  of	  HF	  causes	  is	  available	  
to	  date,	  the	  most	  commonly	  recognised	  precursors	  are	  43:	  
	  
*	   Myocardial	   disease	   –	   Coronary	   artery	   obstruction	   (myocardial	   infarction,	   MI),	  
dilated	  cardiomyopathy,	  infection/inflammation	  (myocarditis),	  etc.	  
*	   Toxic	   or	   drug-­‐induced	   –	   alcohol,	   cytotoxic	   agents	   (e.g.	   anthracyclines),	  
immunomodulating	   molecules,	   anti-­‐inflammatories,	   antidepressants,	   anaesthesia,	  
Ca2+	  channel	  blockers	  44.	  
*	  Valvular	  disease	  
*	  Arrhythmias	  
*	  Defects	  in	  action	  potential	  conduction	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MI	  is	  the	  commonest	  cause	  of	  ventricular	  dysfunction	  in	  the	  developed	  world	  and	  ischaemic	  
heart	  disease	  ranks	  the	  number	  one	  cause	  of	  global	  deaths	  43,	  45.	  MI	  can	  be	  described	  from	  
different	  perspectives,	  all	  of	  which	  can	  be	  integrated	  into	  a	  simplified	  definition:	  MI	  is	  a	  case	  
of	   myocardial	   ischaemia	   (lack	   of	   oxygen)	   resulting	   from	   impaired	   coronary	   blood	   flow,	  
leading	  to	  abrupt	  cardiomyocyte	  death	  and	  altered	  myocardial	  contractility	  in	  the	  late	  onset	  
46.	  Post-­‐MI	  remodelling	  encompasses	  all	  the	  mechanisms	  by	  which	  the	  myocardium	  adapts	  
to	   the	   newly	   compromised	   working	   conditions.	   During	   early	   remodelling,	   there	   is	   an	  
expansion	  of	  the	  infarct	  size	  and	  immune	  cell	  infiltration	  triggered	  by	  cardiomyocyte	  death.	  
During	   the	   late	   phases	   of	   remodelling	  many	   changes	   take	   place	   in	   the	   ventricle	   including	  
dilatation,	   hypertrophy	   and	   fibrosis	   47,	   48.	   The	   formation	   of	   fibrotic	   scar	   tissue	   ‘heals’	   the	  
infarcted	  heart,	  albeit	  causing	  myocardial	  stiffness	  that	  subsequently	  impairs	  contraction	  46.	  
Consequently,	  although	  medical	  advances	  have	  increased	  post-­‐MI	  survival,	  there	  has	  been	  a	  
resultant	  increase	  in	  overall	  HF	  prevalence	  36.	  
	  
1.1.3.1 Implications	  of	  the	  beta-­‐adrenergic	  pathway	  	  
	  
Alterations	   in	   myocardial	   responses	   to	   catecholamines	   are	   well	   described	   in	   HF.	   Chronic	  
sympathetic	   activation	   leads	   to	   reduced	  βAR	  expression	  and/or	  desensitisation	  of	  βARs	   to	  
catecholamine	   stimulation.	   For	   example,	   increased	   GRK1	   levels	   are	   detected	   in	   HF,	  
mediating	  the	  β1AR	  desensitisation	  that	  is	  characteristic	  of	  the	  functionally	  impaired	  heart	  11,	  
49.	   Although	   reduced	   expression	   levels	   are	   only	   detected	   for	   β1AR,	   a	   shift	   in	   G-­‐protein	  
binding	   by	   β2AR	   towards	   Gi	   has	   been	   demonstrated,	   additionally	   blunting	   the	   cellular	  
response	   to	   β1AR	   activation	   11,	   22,	   50.	   Moreover,	   changes	   in	   β2AR	   compartmentalisation	  
involving	  redistribution	  from	  T-­‐tubules	  to	  everywhere	  in	  the	  sarcolemma	  are	  also	  involved	  in	  
HF.	   This	   seems	   to	   be	   an	   adaptive	   mechanism	   to	   compensate	   desensitisation,	   as	   active	  
redistributed	  β2ARs	  can	  mimic	  the	  cAMP	  signal	  generated	  by	  β1AR	  25.	  In	  any	  case,	  a	  reduced	  
overall	  response	  to	  βAR	  stimulation	  features	  in	  the	  failing	  heart	  51.	  	  
βAR	   down-­‐regulation/desensitisation	   is	   considered	   an	   adaptive	   mechanism	   to	   prevent	  
detrimental	   chronic	   stimulation.	   Indeed,	   sustained	   overexpression	   of	   β1AR	   has	   been	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described	   to	   trigger	   hypertrophy	   leading	   to	   HF	   in	   vivo	   52,	   53.	   Increased	   expression	   of	   Gi	  –
particularly	   of	   the	   alpha-­‐2	   subunit	   (Giα-­‐2)-­‐	   is	   observed	   in	   the	   failing	   heart,	   with	   enhanced	  
β2AR-­‐Gi	   coupling	   contributing	   to	   the	   diminished	   basal	   contractility	   and	   reduced	   inotropic	  
response	   following	   catecholamine	   stimulation	   54-­‐57.	   This	   is	   consistent	   with	   the	   reported	  
increase	  of	  Gi	  expression	  in	  failing	  hearts	  56-­‐58.	  However,	  the	  mechanism(s)	  underpinning	  Gi	  
up-­‐regulation	  in	  chronic	  HF	  have	  remained	  unknown	  to	  date.	  	  
Upstream	  of	  βAR	   function,	  at	   the	  genetic	   level,	   single	  nucleotide	  polymorphisms	   (SNPs)	   in	  
βAR	   genes	   have	   also	   been	   associated	   with	   differential	   outcomes	   in	   HF	   patients	   59.	  
Considering	   all	   these	   implications,	   βARs	   are	   key	   therapeutic	   targets	   in	   HF.	   Indeed,	   β-­‐
adrenoceptor	   antagonists	   (β-­‐blockers)	   are	   one	   of	   the	   most	   effective	   pharmacological	  
treatments	   for	   chronic	   HF	   60.	   Alterations	   in	   the	   β-­‐adrenergic	   system	   are	   also	   appealing	  
targets	  for	  the	  design	  of	  tailored	  gene	  therapies,	  which	  aim	  to	  tackle	  the	  underlying	  causes	  
of	  HF	  and	   restore	  myocardial	   function	   rather	   than	  merely	   stopping	  disease	  progression	  or	  
neutralising	  symptoms	  61.	  
	  
1.1.3.2 Cardiomyocyte	  cell	  loss	  in	  heart	  failure	  
	  
Only	   recently	   has	   cardiomyocyte	   loss	   been	   identified	   as	   a	   critical	   driver	   of	   progressive	  
myocardial	  dysfunction	  in	  HF	  62.	   	  The	  vast	  majority	  of	  cardiomyocyte	  death	  occurs	  through	  
programmed	  mechanisms	  (apoptosis,	  autophagy	  and	  necrosis),	  which	  has	  key	  implications	  in	  
myocardial	   disease.	   As	   mentioned	   previously,	   βAR	   stimulation	   plays	   an	   important	   role	   in	  
modulating	   cardiomyocyte	   death,	   being	   β1AR	   signalling	   pro-­‐apoptotic	   and	   β2AR	   anti-­‐
apoptotic	  via	  Gi	  23,	  24,	  63.	  The	  pro-­‐apoptotic	  mechanisms	  resulting	  from	  β1AR	  stimulation	  are	  
believed	   to	   be	   cAMP-­‐mediated,	   given	   that	   β1AR	   overexpression	   52,	   53	   causes	   similar	  
detrimental	   effects	   in	   vivo	   to	   constitutive	   PKA	   activation	   and	  Gs(α)	   overexpression	   64,	  65.	   In	  
contrast,	   the	   protective	   effects	   deriving	   from	   the	   β2AR/Gi	   pathway	   are	   mediated	   by	   the	  
activation	  of	  PI3K/Akt	  pro-­‐survival	  signalling	  through	  interaction	  with	  active	  Gi(βγ)	  	  24.	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In	  addition,	  mitochondria	  have	  central	  implications	  in	  programmed	  death	  66.	  As	  the	  heart	  is	  
an	   organ	   with	   huge	   energetic	   demands,	   cardiomyocytes	   have	   a	   particularly	   large	  
mitochondrial	   content	   (~30%).	   Therefore,	   mitochondrial	   death	   pathways	   are	   of	   great	  
importance	   in	   HF	   and	   other	   cardiac	   pathologies	   67,	   68.	   Notably,	   inhibition	   of	   caspase-­‐
dependent	  apoptosis	  has	  been	  demonstrated	  to	  protect	  against	  heart	  disease	  in	  transgenic	  
mice	  69.	  
An	   important	   apoptotic	   effector	   is	   the	   Bcl-­‐2/adenovirus	   E1B	   interacting	   protein	   3-­‐like	  
(BNIP3L,	   also	   known	   as	  NIX).	   BNIP3L	   belongs	   to	   the	  Bcl-­‐2	   family,	  which	   is	   composed	  by	   a	  
heterogeneous	   group	   of	   genes	   that	   can	   either	   promote	   (e.g.	   Bax,	   Bak,	   BNIP3,	   BNIP3L)	   or	  
supress	  (e.g.	  Bcl-­‐2,	  Bcl-­‐x,	  Mcl-­‐1)	  apoptosis	  70,	  71.	  BNIP3L	  is	  capable	  of	  mediating	  mitochondrial	  
death	   and,	   more	   importantly,	   of	   triggering	   cardiomyopathy	   72-­‐75.	   Apart	   from	   inducing	  
canonical	   caspase-­‐dependent	   apoptosis	   (Figure	   4),	   BNIP3L	   has	   been	   described	   to	   also	  
mediate	  necrosis	  when	  co-­‐localising	  with	  the	  endoplasmic	  reticulum	  76.	  The	  stress-­‐induced	  
expression	  of	  both	  BNIP3	  and	  BNIP3L/NIX	  has	  been	  an	   interesting	  discovery	   in	   relation	   to	  
detrimental	   ventricular	   remodelling.	   Strategies	   for	   therapeutic	   targeting	   of	   BNIP3	   and	  
BNIP3L	  have	  been	  explored	  in	  animal	  models	  with	  promising	  results	  77.	  
	  
	  
Figure	  4.	  BNIP3L	  mediates	  mitochondrial	   cell	   death.	  BNIP3L	  (as	  well	  as	  BNIP3)	   interact	  with	  Bak	  and	  Bax	  to	  
induce	  permeabilisation	  of	  the	  outer	  mitochondrial	  membrane.	  The	  subsequent	  release	  of	  cytochrome	  c	  (Cyt	  c)	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1.1.3.3 Heart	  failure	  treatment	  
	  
Epidemiological	  predictions	  indicate	  that	  HF	  incidence	  is	  likely	  to	  increase	  over	  the	  next	  few	  
decades.	   This	   is	   not	   surprising,	   given	   the	  global	   ageing	  of	   the	  population	   78.	  HF	   treatment	  
depends	  on	  the	  severity	  of	  the	  condition	  and	  the	  cause	  of	  the	  syndrome.	  Transplantation	  or	  
surgical	  procedures,	  such	  as	  the	  implantation	  of	  Left	  Ventricle	  Assist	  Devices	  (LVAD),	  are	  the	  
remaining	  options	  for	  end	  stage	  HF	  when	  all	  other	  non-­‐invasive	  measures	  fail	  2,	  39.	  Early	  and	  
advanced	   stage	   HF	   patients	   both	   benefit	   from	   pharmacological	   treatments,	   such	   as	   beta-­‐
blockers	  and	  angiotensin	  converting	  enzyme	  (ACE)	  inhibitors,	  which	  have	  proven	  to	  be	  highly	  
effective	  79-­‐81.	  Even	  though	  the	  available	  treatments	   improve	  the	  symptoms	  of	  HF,	  there	   is	  
no	   real	  way	  of	   rescuing	   ventricular	   function	   and	   therefore	   the	   risk	   of	  mortality	   remains	   a	  
threat.	   For	   this	   reason,	   there	   is	   still	   a	   need	   to	   develop	   novel	   therapies	   to	   treat	   HF	   and	  




β-­‐adrenergic	   antagonists	   (β-­‐blockers)	   constitute	   an	   important	   clinical	   advance	   in	   the	  
treatment	  of	  HF,	  despite	  initially	  being	  contraindicated	  in	  patients	  suffering	  from	  chronic	  HF,	  
due	   to	   the	   predicted	   negative	   effect	   on	   CO	   84,	   85.	   Certainly,	   acute	   administration	   of	   β-­‐
blockers	  depresses	  myocardial	  function.	  However,	  chronic	  administration	  is	  able	  to	  improve	  
CO	   and	   reverse	   pathological	   remodelling	   86.	   Indeed,	   β-­‐blockers	   have	   beneficial	   cardiac	  
effects	  by	  counteracting	  catecholamine	  overstimulation.	  Some	  of	  these	  positive	  actions	  are:	  
reduction	  of	  heart	  rate	  (HR)	  and	  oxygen	  requirements,	  lower	  toxic	  Gs	  signalling	  and	  reduced	  
βAR	   desensitisation	   11,	   18.	   Moreover,	   β-­‐blockers	   have	   also	   been	   shown	   to	   improve	  
abnormalities	  in	  Ca2+	  handling,	  restoring	  physiological	  expression	  levels	  of	  implicated	  genes	  
87.	   In	   aggregate,	   chronic	   β-­‐blocker	   treatment	   has	   been	   demonstrated	   to	   reduce	   sudden	  
cardiac	  death	  rates	  by	  preventing	  arrhythmias	  and	  improving	  survival	  in	  general	  88.	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β-­‐blocker	   compounds	   are	   classified	   into	   three	   groups	  depending	  on	   their	  mode	  of	   action.	  
First	   generation	   β-­‐blockers	   (e.g.	   propranolol)	   are	   able	   to	   equally	   block	   β1AR	   and	   β2AR	   89.	  
Second	   generation	   β-­‐blockers	   (e.g.	   bisoprolol,	   metaprolol)	   are	   β1AR-­‐selective	   in	   order	   to	  
preserve	   the	   positive	   anti-­‐apoptotic	   effects	   of	   β2AR	   signalling.	   In	   fact,	   β2AR	   agonists	   have	  
proven	   beneficial	   for	   dilated	   cardiomyopathy,	   indicating	   the	   importance	   of	  
maintaining/stimulating	  β2	  signalling	  90.	  These	  inhibitors	  have	  been	  shown	  to	  increase	  β1AR	  
expression	   and	   to	   dampen	  βAR	  desensitisation	   86,	  91.	   The	   third	   generation	  β-­‐blocker	   drugs	  
were	   developed	   to	   treat	   hypertension	   and	   target	   α1AR	   rather	   than	   βARs	   (e.g.	   carvedilol),	  
although	   some	   are	   designed	   to	   selectively	   block	   β1AR	   whilst	   also	   being	   vasodilators	   (e.g.	  
nevibolol)	  89,	  91.	  	  
	  
1.1.3.3.2 Gene	  therapy	  
	  
The	  increasing	  knowledge	  of	  the	  mechanisms	  underlying	  the	  development	  of	  HF	  has	  enabled	  
the	  identification	  of	  target	  candidates	  for	  gene	  therapy.	  In	  contrast	  to	  the	  currently	  available	  
pharmacological	  treatments,	  gene	  therapy	  would	  permit	  a	  functional	  rescue	  of	  the	  damaged	  
myocardium.	  The	  most	  investigated	  pathways	  for	  gene	  therapy	  approaches	  are	  β-­‐adrenergic	  
signalling	  and	  Ca2+	  handling	  61,	  92.	  	  
The	  administration	  of	  naked	  DNA	  results	  in	  an	  extremely	  inefficient	  uptake	  of	  the	  transgene	  
by	  cardiomyocytes.	  DNA	  carriers,	  such	  as	  liposomal	  particles,	  have	  been	  developed	  with	  the	  
aim	  to	   increase	  transduction.	  However,	   the	  highest	  cellular	  uptake	   is	  achieved	  when	  using	  
viral	  vectors	  93.	  Of	  the	  existing	  viral	  vectors,	  adenovirus	  and	  adeno-­‐associated	  virus	  (AAV)	  are	  
the	   most	   common	   choices	   in	   cardiac	   gene	   therapy	   trials	   92.	   AAVs	   can	   provide	   long-­‐term	  
transgene	  expression	  and	  low	  immunogenicity,	  making	  them	  the	  most	  suitable	  viral	  vector	  
for	  clinical	  applications	  94.	  Importantly,	  there	  is	  no	  evidence	  associating	  AAVs	  to	  any	  human	  
pathology	   95.	  Moreover,	   recombinant	   AAV	   vectors	   (rAAV),	   where	   viral	   genes	   essential	   for	  
replication	   and	   encapsidation	   (rep	   and	   cap)	   have	   been	   removed	   and	   replaced	   by	   the	  
therapeutic	   transgene,	   allow	   a	   safe	   translational	   use.	   The	   only	   drawback	   to	   contemplate	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about	  AAVs	   is	   the	   limited	   capacity	   for	   the	   transgene	   sequence	   (~4.5kb),	   in	   comparison	   to	  
other	  types	  of	  viral	  vectors	  like	  retrovirus	  or	  adenovirus	  96.	  	  
The	  heart	   has	   proven	   a	   challenging	   organ	   for	   gene	   transfer,	   as	   a	   large	   proportion	  of	   viral	  
particles	  are	  cleared	  through	  the	  liver.	  Systemic	  injection	  of	  gene	  therapy	  vectors	  results	  in	  
an	  extremely	  diluted	  viral	  concentration	  in	  the	  bloodstream,	  making	  it	  highly	  inefficient	  for	  
cardiac	  gene	  transfer.	  Localised	  delivery	  routes	  (e.g.	   intra-­‐pericardial,	   intravascular	  through	  
coronary	   arteries	   or	   jugular	   vein,	   or	   intra-­‐myocardial)	   have	   been	   shown	   to	   increase	   the	  
percentage	   of	   transduced	   cardiomyocytes	   92,	   94,	   97.	   To	   further	   contribute	   to	   transduction	  
efficiency	   and	   in	   turn	   minimise	   viral	   dose,	   AAVs	   have	   been	   engineered	   to	   increase	   their	  
tropism	  to	  the	  desired	  tissues.	  For	  cardiac	  gene	  therapy,	  the	  serotype	  AAV9	  has	  proven	  to	  
have	   the	   most	   tropic	   capsid	   98.	   Additional	   targeting	   can	   be	   achieved	   by	   including	   tissue-­‐
specific	  promoters	  to	  drive	  transgene	  expression	  99,	  100.	  Mutagenesis	  of	  capsid	  residues	  has	  
provided	   an	   effective	   method	   for	   the	   generation	   of	   custom	   serotypes,	   liver	   detachment	  
being	  one	  of	  the	  main	  objectives	  101-­‐104.	  
Successful	   AAV-­‐mediated	   therapeutic	   cardiac	   effects	   have	   been	   observed	   using	   in	   vivo	  
models	  of	  heart	  disease	  105,	  106	  and	  even	  in	  human	  clinical	  trials	  107,	  108.	  	  
	  
1.2 Cancer	  treatment	  and	  adverse	  cardiac	  effects	  
	  
Cancer	   is	  a	  disease	  process	  characterised	  by	  uncontrolled	  cellular	  proliferation	   resulting	   in	  
the	   formation	  of	  a	   compact	  heterogeneous	  mass	  or	  primary	   tumour.	  Tumours	  are	  able	   to	  
evade	  pro-­‐apoptotic	   signals	  and	  can	  also	   stimulate	  angiogenesis	   to	  ensure	  survival.	  As	   the	  
disease	   progresses,	   epithelial	   cancer	   cells	   accumulate	   genetic	   mutations	   and	   become	  
invasive,	   eventually	  migrating	   through	   the	   bloodstream	   to	   establish	   a	   new	   distal	   focus	   of	  
cancerous	  growth	  referred	  to	  as	  a	  metastasis	  or	  secondary	  deposit	  109.	  Ever	  since	  cancer	  was	  
recognised	   as	   a	   life-­‐threatening	   disease,	   the	  medical	   community	   has	   been	   devoting	   their	  
efforts	  to	  establishing	  optimal	  anticancer	  therapies	  110.	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The	   origins	   of	   chemotherapy	   date	   back	   to	   the	   beginning	   of	   the	   20th	   century,	   when	   Paul	  
Ehrlich	   started	   using	   arsenicals	   to	   fight	   tumours.	   During	   1900s	   there	   was	   a	   increase	   in	  
anticancer	   drug	   development	   worldwide.	   Radiotherapy,	   nitrogen	   mustard	   and	   antifolates	  
were	  the	  main	  drugs	  in	  the	  mid-­‐1900s;	  until	  the	  discovery	  of	  anthracycline	  antibiotics	  (ANT)	  
as	   anti-­‐neoplastic	   agents	   in	   early	   1960s.	   The	   concept	   of	   adjuvant	   therapy	  was	   introduced	  
during	   the	  1970s	   and	   lead	   to	   important	   changes	   in	   regime	  prescription	   111.	  More	   recently	  
(late	  1990s	  –early	  2000s),	   the	  development	  of	   targeted	  anticancer	   therapy,	   in	   the	   form	  of	  
tyrosine	  kinase	  inhibitors	  (TKI),	  heralded	  a	  great	  breakthrough	  in	  the	  field.	  This	  was	  lead	  by	  
the	   FDA	   (Food	  and	  Drug	  Administration)	   approval	  of	  Herceptin®	   (Trastuzumab,	  Roche)	   for	  
HER2-­‐positive	  breast	  cancer	  in	  1998	  112,	  and	  Glivec®	  (Imatinib,	  Novartis)	  for	  the	  treatment	  of	  
chronic	  myeloid	  leukemia	  (CML)	  in	  2001	  	  111	  113.	  	  
The	  obvious	  criterion	  to	  determine	  the	  likelihood	  of	  response	  for	  any	  anticancer	  treatment	  is	  
its	  anti-­‐tumour	  effect.	  However,	  given	  the	  ever	  increasing	  life	  expectancy,	  current	  anticancer	  
treatments	  need	  to	  not	  only	  prolong	  the	  patient’s	  life,	  but	  also	  provide	  an	  acceptable	  quality	  
of	  life	  throughout	  the	  regime,	  as	  well	  as	  in	  the	  future.	  The	  equilibrium	  between	  therapeutic	  
efficacy	  and	  related	  side	  effects	  therefore	  becomes	  crucial.	  	  
	  
1.2.1 Anthracycline-­‐based	  chemotherapy:	  Doxorubicin	  
	  
Doxorubicin	  (DOX),	  also	  known	  by	  its	  commercial	  name	  Adriamycin,	  was	  the	  first	  ANT	  to	  be	  
isolated	   from	   Streptomyces	   peucetius	   during	   the	   1960s,	   together	  with	   danorubicin	   (DNR).	  
Since	  its	  discovery	  and	  despite	  constant	  efforts	  to	  develop	  improved	  ANT	  drugs,	  DOX	  is	  still	  
the	  most	  widely	  used	  one	  in	  the	  oncology	  clinic	  114.	  Due	  to	  its	  broad-­‐spectrum	  nature,	  DOX	  is	  
a	   common	  chemotherapy	   regime	  and	  delivers	  high	  anti-­‐tumour	  efficacy	  against	  numerous	  
types	  of	  cancer	  115.	  The	  exact	  mechanisms	  accounting	  for	  the	  anticancer	  action	  of	  ANT	  are	  
poorly	  understood	  116.	  Nevertheless,	  several	  cellular	  processes	  have	  been	  described:	  
-­‐	  Inhibition	  of	  DNA	  and	  RNA	  synthesis	  through	  intercalation	  in	  nucleic	  acids	  117,	  118	  
-­‐	  Generation	  of	  reactive	  free	  radicals	  after	  DOX	  redox	  cycling	  119,	  120	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   -­‐	  Interference	  with	  DNA	  helicases	  121	  
-­‐	   Induction	  of	  DNA	  damage	  through	  inhibition	  of	  type	  II	  topoisomerases	  (Top2s)	  116,	  
120,	  122	  
-­‐	  Apoptosis	  (p53	  dependent	  or	  independent)	  123	  
-­‐	  Growth	  arrest	  29,	  64,	  91	  
	  
Of	   the	  DOX	   functions	   listed	  above,	  Top2	   inhibition	   is	   likely	   to	  be	   the	  main	  pathway	   for	   its	  
anti-­‐tumour	  effect,	  given	  that	  mutations	  in	  Top2s	  in	  cancer	  cells	  compromise	  ANT	  efficacy	  99,	  
124-­‐136.	  Top2s	  are	  nuclear	  enzymes	  capable	  of	  cleaving	  DNA	  strands	  to	  release	  tensions	  and	  
tangles	  in	  the	  genome,	  which	  is	  essential	  during	  replication.	  Once	  the	  DNA	  is	  relaxed,	  Top2s	  
re-­‐ligate	  the	  cut	  ends.	  When	  chemotherapeutic	  agents	  are	  used	  to	  inhibit	  Top2s,	  DNA	  breaks	  
are	  not	  resealed	  due	  to	  the	  formation	  of	  a	  DOX-­‐Top2-­‐DNA	  complex	  and	  genomic	  instabilities	  
result	  in	  cell	  death	  137.	  	  
	  
1.2.1.1 Doxorubicin-­‐associated	  cardiotoxicity	  
	  
Given	   the	   lack	   of	   specificity	   of	   DOX,	   patients	   under	   treatment	   can	   have	   several	   adverse	  
effects.	  Whilst	  the	  acute	  side	  effects	  are	  common	  to	  other	  anticancer	  therapies	  and	  clinically	  
manageable,	  cardiomyopathy,	  typically	  leading	  to	  HF,	  has	  been	  extensively	  described	  as	  the	  
main	   long-­‐term	  complication	  of	  ANT	   regimes,	   thereby	   limiting	   their	   clinical	   application	   138,	  
139.	   Such	   impaired	   cardiac	   function	   has	   been	   shown	   to	   occur	   as	   a	   late	   onset	   problem,	  
affecting	   patients	   up	   to	   20	   years	   after	   completion	   of	   ANT	   treatment	   140.	   A	   retrospective	  
study	   including	  399	  DOX-­‐treated	  patients	   showed	   that	  HF	  was	  diagnosed	  even	   in	  patients	  
without	  a	  history	  of	  previous	  cardiac	  conditions.	  It	  affected	  4%	  of	  the	  patients	  treated	  with	  
500-­‐550mg/m2	  DOX,	  18%	  of	  those	  treated	  with	  551-­‐600mg/m2	  and	  36%	  of	  patients	  treated	  
with	  higher	   cumulative	  doses.	  Due	   to	   the	  appearance	  of	   adverse	   cardiac	  events	   in	  a	   clear	  
dose-­‐dependent	  manner,	  500mg/m2	  has	  been	  established	  as	   the	  maximum	  safe	  DOX	  dose	  
Introduction	  
	   41	  
141.	  In	  addition,	  a	  variety	  of	  preventive	  measures	  are	  generally	  followed	  for	  cancer	  patients	  
undertaking	   ANT-­‐based	   treatments.	   These	   include	   a	   thorough	   study	   of	   the	   baseline	  
cardiovascular	   state	   of	   the	   patient,	   as	   well	   as	   monitoring	   during	   and	   post-­‐chemotherapy	  
(Figure	  5)	  141,	  142:	  
	  
	  
Figure	   5.	   Prevention	   and	  management	   of	   ANT-­‐related	   cardiac	   conditions.	   Schematic	   timeline	   showing	   diverse	  
techniques	  used	  for	  monitoring	  cardiac	  status	  of	  patients	  under	  ANT	  (DOX)-­‐based	  cancer	  treatment	  (LVEF:	  Left	  
Ventricular	  Ejection	  Fraction,	  BNP:	  Brain	  Natriuretic	  Peptide)	  143.	  	  	  
	  
Good	   preventive	   measures	   and	   appropriate	   methods	   for	   early	   diagnosis	   of	   DOX-­‐induced	  
cardiotoxicity	   are	   essential.	   Indeed,	   there	   are	   no	   specific	   treatments	   available	   for	   DOX-­‐
induced	  cardiac	  damage	  and	  it	  has	  proven	  somewhat	  resilient	  to	  the	  conventional	  therapies	  
for	   HF	   144.	   In	   pursuit	   of	   cardioprotection,	   improved	   formulations	   have	   been	   tested	   in	   the	  
past	   decade	   with	   the	   aim	   of	   more	   directed	   ANT	   delivery.	   The	  most	   promising	   to	   date	   is	  
liposomal	   DOX,	   which	   seems	   to	   reduce	   the	   drug	   uptake	   in	   the	   myocardium,	   resulting	   in	  
reduced	  cardiac	  toxicity,	  but	  preserved	  anticancer	  efficacy	  145-­‐150.	  In	  fact,	  Doxil®	  was	  the	  first	  
nanodrug	  to	  be	  approved	  by	  the	  FDA	  in	  1995	  151.	  Even	  more	  specific	  variants	  of	  engineered	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1.2.1.2 Possible	  mechanisms	  of	  doxorubicin-­‐induced	  cardiomyopathy	  
	  
The	  tissue-­‐specific	  toxicity	  of	  ANT	  is	  intriguing.	  In	  contrast	  to	  fast-­‐dividing	  cancer	  cells,	  adult	  
cardiomyocytes	   are	   quiescent	   cells,	   which	   suggests	   that	   the	  mechanisms	   underlying	   DOX	  
cytotoxicity	   in	   the	   tumour	   and	   in	   the	   heart	   are	   likely	   to	   be	   different.	   Admittedly,	   the	  
existence	  of	  differential	  mechanisms	  would	  facilitate	  the	  development	  of	  better	  ANT-­‐based	  
therapies	  153.	  On	  the	  other	  hand,	  there	  is	  published	  evidence	  indicating	  that	  cardiomyocytes	  
lacking	  Top2β	  are	  protected	  against	  DOX	  injury	  154.	  
The	  generation	  of	  free	  radicals	  seems	  to	  play	  a	  vital	  role	  in	  DOX-­‐associated	  cardiotoxicity	  119,	  
155-­‐157.	  Although	  mammalian	   tissues	  have	  enzymatic	   resources	   to	  protect	   against	  oxidative	  
stress,	   the	   heart	   has	   been	   shown	   to	   present	   remarkably	   low	   levels	   of	   enzymes	   such	   as	  
catalase,	   superoxide	   dismutase	   and	   glutathione	   peroxidase,	   all	   of	  which	   help	   to	  minimise	  
reactive	   oxygen	   species	   (ROS)	   stress.	   Such	   reduced	   levels	   of	   antioxidant	   enzymes	   in	   the	  
heart,	  in	  comparison	  to	  other	  tissues,	  may	  explain	  the	  tissue-­‐specific	  toxicity	  associated	  with	  
DOX	   158.	   Cardiomyocytes	   are	   rich	   in	   mitochondria,	   which	   contain	   reducing	   enzymes	   that	  
mediate	  a	  one-­‐electron	  reduction	  of	  ANT	  into	  a	  free-­‐radical	  semiquinone	  form	  shortly	  after	  
they	  enter	  the	  cell.	  This	  reaction	  produces	  high	  quantities	  of	  ROS,	  such	  us	  superoxide	  anion	  
(O2.-­‐)	  or	  hydrogen	  peroxide	  (H2O2)	  114.	  Some	  research	  suggests	  that	  DOX	  not	  only	  generates	  
new	  damaging	   free	  radicals,	  but	  also	  contributes	   to	  a	  decrease	  of	  endogenous	  antioxidant	  
levels.	  Altogether,	  this	  leads	  to	  oxidative	  stress	  that	  will	  cause	  cytotoxicity	  through	  multiple	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Figure	   6.	   Adverse	   effects	   of	   oxidative	   stress	   in	   cardiomyocytes.	   After	   redox	   cycling	   of	   ANT	   (i.e.	   DOX),	   the	  
generation	  of	  free	  oxygen	  radicals	  can	  be	  detrimental	  to	  the	  cells	  through	  diverse	  mechanisms.	  ROS	  can	  cause	  
DNA	   damage,	   alter	   gene	   expression,	   deregulate	   Ca2+	   levels	   affecting	   contraction	   and	   lead	   to	  mitochondrial	  
dysfunction,	  amongst	  other	  effects	  150.	  	  
	  
The	   explanation	   of	   DOX-­‐induced	   cardiotoxicity	   through	   oxidative	   stress	   pathways	   has	  
become	  a	  popular	  hypothesis	  in	  the	  last	  decade	  and	  has	  been	  supported	  by	  several	  studies	  
demonstrating	   cardioprotective	   effects	   when	   administering	   antioxidants	   in	   vivo,	   without	  
interfering	  with	  the	  anti-­‐tumour	  efficacy	  of	  DOX	  157,	  159,	  161.	  Certainly,	  benefits	  have	  also	  been	  
observed	  in	  the	  clinic	  when	  combining	  the	  antioxidant	  dexrazoxane	  with	  DOX	  treatment	  162,	  
163.	  This	  positive	  outcome	  seems	  to	  be	  related	  to	  the	  preservation	  of	  mitochondrial	  function	  
164.	  
There	   is	   a	   considerable	   amount	   of	   evidence	   indicating	   that	   mitochondria	   are	   highly	  
susceptible	   to	   damage	   by	   generation	   of	   superoxide	   radicals	   after	   redox	   cycling	   of	   DOX.	  
Mitochondrial	   dysfunction	   has	   been	   demonstrated	   after	   DOX	   treatment	   in	   vitro,	   with	  
cytochrome	   c	   release	   leading	   to	   caspase	   9–mediated	   caspase	   3	   activation,	   triggering	  
apoptosis	   in	   both	   primary	   isolated	   cardiomyocytes	   and	   the	   relevant	   cell	   line	   H9c2	   165-­‐168.	  
Although	  beyond	  the	  scope	  of	  this	  thesis,	  an	  important	  role	  has	  also	  been	  described	  for	  p53	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1.2.2 Molecular	  targeted	  therapy:	  Tyrosine	  Kinase	  Inhibitors	  
	  
Medical	   and	   technological	   advances	  have	  enabled	   the	  development	  of	  molecular	   targeted	  
therapies;	  the	  main	  advantage	  being	  that	  they	  are	  more	  specifically	  directed	  to	  cancer	  cells,	  
thus	  being	  less	  harmful	  to	  healthy	  cells.	  Each	  of	  these	  new	  therapies	  is	  usually	  designed	  to	  
target	  a	  certain	  ‘oncogene	  addiction’,	  which	  refers	  to	  a	  scenario	  whereby	  the	  progression	  of	  
a	   specific	   tumour	   relies	   dominantly	   on	   a	   single	   oncogene	   170,	  171.	   In	   the	   context	   of	   breast	  
cancer,	  the	  human	  epidermal	  growth	  factor	  receptor	  type	  2	  (HER2)	  –	  also	  known	  as	  erbB2	  
(v-­‐erb-­‐b2	   erythroblastic	   leukemia	   viral	   oncogene	   homolog	   2,	   neuro/glioblastoma	   derived	  
oncogene	  homolog	   (avian))	  was	  described	   to	  be	  overexpressed	   in	  20-­‐30%	  of	   the	  patients.	  
Such	  overexpression	  was	  associated	  with	  particularly	  aggressive	  forms	  of	  disease	  and	  poorer	  
prognosis.	   Since	   this	  was	   recorded,	  HER2	  has	  become	  an	   important	   therapeutic	   target	   for	  
breast	  cancer	  172-­‐174.	  	  
Different	  types	  of	  TKI	  are	  approved	  by	  the	  FDA	  and	  have	  been	  successfully	  commercialised.	  
Two	   different	   HER2	   blockers	   are	   mostly	   used	   in	   the	   clinic	   to	   treat	   HER2+	   breast	   cancer:	  
trastuzumab	   and	   lapatinib.	   Trastuzumab	   (TRZ,	   Herceptin®)	   is	   a	   humanised	   monoclonal	  
antibody	   (mAb)	   that	  binds	   to	   the	  extracellular	  domain	  of	   the	  HER2	   receptor,	   impairing	   its	  
activation	   and	  downstream	   cascade	  of	   survival	   signals.	   Apart	   from	   the	  direct	   inhibition	   of	  
the	   HER2	   pathway,	   TRZ	   is	   thought	   to	   also	   contribute	   to	   tumour	   cell	   death	   via	   antibody-­‐
directed	  cell	   cytotoxicity	   (ADCC)	   175.	  On	   the	  other	  hand,	   lapatinib	   (LAP,	  Tyverb®)	   is	  a	   small	  
molecule	  capable	  of	  inhibiting	  both	  HER2	  and	  EGFR	  (Epidermal	  Growth	  Factor	  Receptor,	  so-­‐
called	  HER1)	  by	   interacting	  with	  their	   intracellular	  tyrosine	  kinase	  (tyrK)	  domain	  (Figure	  7).	  
HER1	   and	   HER2-­‐overexpressing	   tumours	   undergo	   either	   apoptosis	   or	   growth	   arrest	   after	  
treatment	  with	  LAP	  176.	  The	  blockade	  of	  HER2	  signalling	  pathway	  by	  both	  TRZ	  and	  LAP	  has	  
proven	  to	  be	  an	  efficient	  anticancer	  treatment	  for	  candidate	  breast	  cancer	  patients	  during	  
respective	   clinical	   trials.	   Nevertheless,	   maximum	   therapeutic	   results	   were	   achieved	   in	  
combination	  with	  ANT-­‐based	  chemotherapy	  176,	  177.	  	  
	  
Introduction	  
	   45	  
	  
Figure	  7.	  Inhibition	  of	  HER	  family	  members	  by	  TRZ	  and	  LAP.	  	  	  HER2	  belongs	  to	  a	  family	  of	  growth	  factor	  receptors	  
with	  intracellular	  tyrK	  domains	  (4	  members:	  HER1-­‐4).	  Although	  HER2	  is	  the	  only	  member	  that	  does	  not	  have	  a	  
known	  ligand,	  it	  forms	  dimers	  with	  other	  HERs	  acting	  as	  a	  co-­‐receptor.	  The	  humanized	  mAb	  TRZ	  recognizes	  the	  
extracellular	  domain	  of	  HER2,	  preventing	  dimerisation	  with	  other	  members.	  The	  small	  inhibitor	  LAP	  blocks	  the	  
tyrK	  domains	  of	   both	  HER2	  and	  HER1	   (EGFR).	   The	  downstream	   signalling	  pathway	   inhibited	  by	   TRZ	   and	   LAP	  
usually	  results	  in	  the	  transcription	  of	  survival	  and	  proliferation	  promoting	  genes	  178.	  	  
	  
1.2.2.1 Cardiotoxicity	  of	  HER2	  blockers	  
	  
Given	  the	  predicted	  advantages	  of	  molecular	  targeted	  therapies	   in	  terms	  of	  specificity,	  the	  
cardiac	  toxicity	  observed	  in	  some	  patients	  treated	  with	  HER2	  blockers	  arose	  as	  a	  surprise.	  In	  
spite	  of	  inhibiting	  the	  same	  pathway,	  different	  rates	  of	  cardiotoxicity	  are	  observed	  upon	  TRZ	  
and	  LAP	  treatment.	  Although	  some	  cardiac	  events	  were	  recorded	  for	  both	  agents,	  LAP	  was	  
better	  tolerated	  than	  TRZ	  during	  clinical	  trials	  176,	  179,	  180.	  Sole	  administration	  of	  TRZ	  resulted	  
in	  an	  8%	   incidence	  of	   cardiac	  events.	  The	   rate	  of	  associated	  cardiac	  dysfunction	   increased	  
remarkably	   in	   ANT-­‐combined	   regimes,	   affecting	   27%	   of	   the	   patients	   under	   TRZ+DOX	  
treatment.	  In	  contrast,	  the	  cardiotoxicity	  incidence	  for	  LAP+DOX	  remained	  as	  low	  as	  2.2%	  177,	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be	   related	   to	   the	  nature	  of	   each	  molecule.	  Although	   the	  ADCC	  activity	  of	   TRZ	   is	   the	  main	  
obvious	   differential	   mode	   of	   action,	   it	   does	   not	   seem	   to	   be	   responsible	   for	   the	   higher	  
cardiotoxicity	  182,	  183.	  
Neuregulins	  are	  an	  essential	  family	  of	  growth	  factors	  during	  development	  and	  bind	  to	  HER3	  
and	   HER4	   receptors.	   Neuregulin-­‐1	   (NRG1,	   also	   known	   as	   heregulin	   or	   neu	   differentiation	  
factor)	  has	  particularly	  been	  described	  as	  required	  for	  an	  adequate	  heart	  development	  and	  
function	   70,	  184.	  Moreover,	   the	   lack	   of	  HER2	   and	  HER4	   receptors	   is	   associated	  with	   cardiac	  
defects	  during	  embryogenesis	  185-­‐187.	  Given	  the	  requirement	  of	  functional	  HER2	  in	  the	  heart	  
and	   the	  stimulation	  of	  HER2-­‐HER3/4	  dimerisation	  by	  NRG1,	  administration	  of	   such	  growth	  
factor	   has	   been	   considered	   as	   an	   option	   to	   counteract	   the	   toxicity	   of	   HER2-­‐targeted	  
therapies	  toxicity	  and	  prevent	  heart	  failure	  188,	  189.	  Interestingly,	  NRG1	  administration	  to	  rat	  
cardiomyocytes	   was	   protective	   of	   DOX-­‐induced	   toxicity	   by	   reducing	   oxidative	   stress.	   This	  
may	  partly	  explain	  the	  increased	  risk	  of	  cardiotoxicity	  recorded	  when	  combining	  ANT-­‐based	  
chemotherapy	  with	  HER2	  inhibitors	  190.	  	  
	  
1.2.3 Management	  of	  cancer	  therapy-­‐related	  cardiac	  toxicity	  
	  
The	  main	   difference	   between	   the	   cardiotoxicity	   caused	   by	   HER2	   blockers	   and	   ANT	   is	   the	  
reversibility	  of	  the	  former,	  versus	  the	  persistence	  of	  the	  latter	  upon	  treatment	  interruption	  
191,192.	  This	  has	   implications	   in	   the	  management	  and	   treatment	  of	  adverse	  effects.	  Current	  
guidelines	  state	  both	  ANT	  and	  TKI	  as	  risk	   factors	   to	   include	   in	   the	  consideration	  of	  cardiac	  
diagnosis,	  and	  recommend	  the	  cessation	  of	  these	  anticancer	  treatments	  if	  LVEF	  is	  <40%	  (i.e.	  
10%	  below	  the	  normal	  limit	  of	  50%)	  39,	  193.	  	  
It	  is	  important	  to	  combine	  different	  techniques	  for	  the	  detection	  of	  adverse	  cardiac	  effects,	  
given	  that	  they	  often	  start	  as	  asymptomatic	  and	  can	  be	  challenging	  to	  identify.	  Establishing	  
reliable	  biomarkers	  for	  the	  early	  detection	  of	  impaired	  cardiac	  function	  is	  therefore	  urgently	  
required.	  Diverse	   imaging	  methods	  can	  help	   recognising	  subclinical	  dysfunction,	  whilst	   the	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assessment	  of	  reductions	  in	  LVEF	  by	  echography	  is	  the	  classical	  parameter	  for	  the	  diagnosis	  
of	  a	  compromised	  heart	  194.	  	  	  
Cardinale	   et	   al.	   described	   the	   quantification	   of	   circulating	   troponin	   I	   (TnI)	   as	   a	   consistent	  
prediction	   of	   chemotherapy-­‐induced	   cardiotoxicity,	   correlating	  with	   a	   subsequent	   drop	   in	  
the	  LVEF	  of	  affected	  patients	  195,	  196.	  TnI	  is	  a	  highly	  specific	  protein	  to	  myocardial	  tissue	  and	  is	  
released	  to	  the	  bloodstream	  by	  damaged	  cardiomyocytes.	  Elevated	  TnI	  levels	  correlate	  with	  
several	   types	   of	   cardiac	   injury	   and	   are	   considered	   an	   extremely	   sensitive	  
diagnostic/prognostic	  assay	  197.	  	  
The	   management	   of	   cardiomyopathy	   resulting	   from	   ANT	   is	   the	   most	   relevant	   in	   cancer	  
patients,	   given	   that	   TKI-­‐induced	   cardiac	   toxicity	   is	   broadly	   reversible.	   In	   the	   first	   instance	  
prevention	   is	   essential,	   and	   if	   cardioprotection	   cannot	   be	   successfully	   achieved,	   early	  
diagnosis	   becomes	   then	   the	   maximum	   priority.	   Indeed,	   rapid	   diagnosis	   combined	   with	  
conventional	   HF	   treatment	   can	   partially	   rescue	   LVEF	   in	   patients	   suffering	   ANT-­‐induced	  




Cardiac	  disease	  can	  diminish	  the	  quality	  of	  life	  of	  already	  compromised	  cancer	  patients,	  both	  
during	   the	   treatment	   course	   and	   later	   on.	   Considering	   the	   progressive	   ageing	   of	   the	  
population,	  there	  is	  a	  burgeoning	  incidence	  of	  both	  cardiovascular	  disease	  and	  cancer.	  This	  
automatically	   increases	   the	   chances	   for	   patients	   to	   present	   with	   co-­‐morbidities	   200.	   As	   a	  
result,	   cardiologists	   and	  oncologists	  have	   started	  working	   closer	  and	   communicating	  more	  
about	  these	  specific	  adverse	  effects.	  Cardioncology	  has	  thus	  emerged	  as	  an	  interdisciplinary	  
field	  with	   the	   objective	   of	   endorsing	   individualised	   treatment	   choices	   for	   cancer	   patients,	  
considering	  the	  potential	  cardiac	  consequences	  in	  each	  case.	  	  
Importantly,	   cardiac	   toxicity	   has	   often	   been	   detected	   in	   association	   with	   drugs	   targeting	  
molecules	   that	   are	   essential	   in	   the	   heart,	   as	  well	   as	   for	   tumour	   cells.	   Therefore,	   systemic	  
inhibition	  of	  these	  molecules	  able	  promote	  cancer	  progression	  (e.g.	  pro-­‐angiogenic	  factors	  –
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vascular	  endothelial	  growth	  factor,	  VEGF-­‐,	  HER2,	  etc.)	  might	  result	  in	  adverse	  cardiac	  effects.	  
This	   emphasises	   the	   need	   for	   a	   careful	   choice	   of	   molecular	   targets	   in	   the	   design	   of	  
oncogene-­‐based	  therapies	  179,	  201.	  Constant	  expert	  screening	  of	  cardiac	  function	  is	  essential	  
prior,	  during	  and	  following	  cancer	  treatment.	  Moreover,	  pre-­‐existing	  cardiac	  complications	  
should	  be	  addressed	   to	  allow	  the	  safe	  prescription	  of	   the	  preferred	  anticancer	   therapy	   202	  
198.	  	  
The	   International	   CardiOncology	   Society	   (ICOS)	   was	   created	   in	   2009,	   with	   the	   aim	   of	  
stopping	  cardiac	  disease	  from	  being	  an	  obstacle	  in	  the	  effective	  treatment	  of	  cancer	  203.	  The	  
organisers	  propose	  the	  establishment	  of	  a	  global	  evidence-­‐based	  database	  to	  implement	  an	  
inter-­‐institutional	  system	  for	  guideline	  consultation	  and	  event	  reporting.	   In	  addition,	  state-­‐
of-­‐the-­‐art	  technologies	  have	  been	  imported	  into	  the	  oncology	  clinic	  for	  appropriate	  cardiac	  
monitoring.	   This	  much-­‐needed	   collaboration	   between	   specialists	   has	   already	   had	   positive	  
outcomes,	  such	  as	  the	   incorporation	  of	   insight	  from	  cardiologists	   into	  the	  design	  of	  cancer	  
trials	  204.	  	  
	  
1.3 MicroRNAs	  	  
	  
The	  discovery	  of	  microRNAs	  (miRNAs)	  dates	  back	  to	  1993,	  when	  the	  lin-­‐4	  gene	  (coding	  for	  a	  
short	  RNA)	  was	  identified	  to	  be	  essential	  in	  Caenorhabditis	  elegans	  205.	  Let-­‐7	  was	  the	  second	  
miRNA	   to	   be	   discovered,	   in	   the	   same	   organism	   206.	   These	   exciting	   breakthroughs	   were	  
followed	  by	  the	  annotation	  of	  thousands	  of	  miRNAs	  in	  the	  2000s	  across	  biological	  kingdoms	  
207.	  Nowadays	  we	  know	  that	  miRNAs	  are	  abundant	  endogenous	  short	  (~22	  nucleotides,	  nt)	  
non-­‐coding	   RNA	   (ncRNA)	   molecules	   that	   play	   an	   important	   and	   evolutionary-­‐conserved	  
regulatory	   role	   in	  gene	  expression,	  affecting	  up	   to	  60%	  of	   the	  human	  coding	  genes	   208,	  209.	  
MiRNAs	   act	   at	   a	   post-­‐transcriptional	   level,	   base-­‐pairing	   with	   the	   3’	   untranslated	   region	  
(3’UTR)	   of	   target	   messenger	   RNAs	   (mRNAs)	   210.	   The	   resulting	   impairment	   of	   protein	  
synthesis	  from	  target	  mRNAs	  will	  determine	  the	  net	  effects	  in	  key	  biological	  processes	  211.	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1.3.1 MicroRNAs	  in	  the	  code	  and	  microRNA	  expression	  regulation	  	  
	  
NcRNAs	   arising	   from	   genomic	   regions,	   previously	   known	   as	   ‘junk	   DNA’,	   have	   gathered	  
importance	   in	   the	   last	   decade,	   mainly	   emerging	   as	   regulatory	   molecules.	   Different	  
populations	  of	  ncRNAs	  have	  been	   identified	   in	  addition	  to	  miRNAs,	   including	  small	  nuclear	  
RNAs	  (snRNA),	  small	  nucleolar	  RNAs	  (snoRNA)	  and	  long	  non-­‐coding	  RNAs	  (lncRNA)	  212,	  213.	  	  
DNA	   sequences	   giving	   rise	   to	  miRNAs	   are	   highly	   conserved	   across	   species	   and	   evolution,	  
suggesting	   important	   cellular	   roles	   214.	   The	   increasing	   number	   of	   miRNA	   genes	   being	  
discovered	  in	  the	  last	  10	  years	  highlighted	  the	  need	  to	  establish	  a	  standard	  nomenclature	  for	  
miRNA	   annotation.	   Detailed	   criteria	   were	   set	   for	   the	   consideration	   of	   a	   short	   ncRNA	   as	  
miRNA	  215.	  A	  miRNA	  registry	  was	  established	  to	  allow	  the	  assignment	  of	  uniform	  names	  to	  
newly	  discovered	  miRNAs	  and	  to	  provide	  and	  updated	  database	  for	  the	  scientific	  community	  
216.	   The	   agreed	   miRNA	   nomenclature	   includes	   an	   abbreviation	   for	   the	   specie	   of	   origin,	  
followed	  by	  ‘miR’	  and	  a	  number	  assigned	  in	  order	  of	  discovery	  (e.g.	  Homo	  sapiens:	  hsa-­‐miR-­‐
1).	   The	   mature	   sequence	   is	   what	   determines	   the	   number	   and	   if	   more	   than	   one	   mature	  
miRNAs	  are	  codified	  in	  different	  loci,	  a	  second	  number	  will	  be	  added	  for	  each	  (e.g.	  hsa-­‐miR-­‐
1-­‐2,	  hsa-­‐miR-­‐1-­‐2).	  Mature	  miRNAs	  with	  identical	  sequences	  except	  for	  one	  or	  two	  bases	  will	  
share	  the	  name	  with	  an	  added	  letter	  (e.g.	  a/b/c/d)	  after	  the	  identification	  number	  216,	  217.	  	  
MiRNA	   genes	   can	   be	   monocistronic,	   where	   one	   promoter	   controls	   the	   transcription	   of	   a	  
single	  miRNA	  gene;	  or	  polycistronic,	  where	  the	  expression	  of	  several	  miRNAs	  is	  driven	  by	  a	  
shared	  promoter.	   The	   latter	   arrangement	   is	   also	   known	   as	   ‘clustered’	   and	   all	   the	  miRNAs	  
controlled	  by	  the	  same	  promoter	  form	  a	  single	  transcriptional	  unit	  or	  ‘miRNA	  cluster’	  218.	  In	  
terms	  of	  genomic	  location,	  miRNA	  genes	  (mono	  or	  polycistronic)	  can	  be	  coded	  in	  intergenic	  
areas,	   as	   well	   as	   in	   intronic	   regions	   of	   protein-­‐coding	   genes.	   If	   a	   whole	   intron	   accounts	  
exactly	  for	  the	  precursor	  miRNA	  sequence,	  such	  miRNA	  will	  be	  called	  a	  ‘mirtron’	  and	  will	  be	  
able	  to	  bypass	  the	  nuclear	  microprocessor	  step	  of	  the	  maturation	  219.	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Figure	  8.	  miRNAs	  in	  the	  genome.	  Genomic	  sequences	  coding	  for	  miRNAs	  can	  be	  both	  intergenic	  or	  intragenic,	  
and	  organized	  either	  as	  monocistronic	  or	  clustreded	  (polycistronic).	  In	  the	  first	  case,	  the	  expression	  of	  a	  miRNA	  
is	  driven	  by	  its	  own	  promoter,	  while	  in	  the	  latter	  several	  miRNAs	  share	  the	  same	  promoter.	  In	  the	  event	  of	  a	  
full	   intron	  coding	  exactly	   for	  the	  precursor	   form	  of	  the	  miRNA	  (pre-­‐miR),	   the	  miRNA	   is	  called	  a	   ‘mirtron’	  and	  
can	  skip	  the	  microprocessor	  step	  of	  the	  canonical	  miRNA	  biogenesis.	  	  
	  	  
As	  for	  coding	  genes,	  miRNA	  transcription	  and	  processing	  is	  a	  tightly	  regulated	  process	  with	  
numerous	  known	  implicated	  factors.	  This	  allows	  gene	  expression	  regulation	  by	  miRNA	  to	  be	  
precise	  and	  fine-­‐tuned	  125.	  Modulations	  can	  occur	  at	  different	   levels,	  starting	  even	  prior	  to	  
transcriptional	   initiation.	  miRNA	  genes	   seem	   to	  often	   code	   in	   fragile	   sites,	   being	  prone	   to	  
gain	   and	   loss	   of	   copy	   number.	   Histone	   deacetylation	   and	   promoter	  methylation	   will	   also	  
affect	   miRNA	   expression	   220.	   In	   terms	   of	   transcriptional	   regulation,	   binding	   of	   diverse	  
transcription	  factors	  (TFs)	  to	  the	  promoter	  will	  control	  RNA	  polymerase	  activity.	  Several	  TFs	  
implicated	   in	   disease,	   such	   as	   c-­‐Myc	   and	   p53,	   have	   been	   described	   to	   regulate	   specific	  
miRNAs	   221-­‐223.	   	   The	   role	   of	   TFs	   in	  miRNA	  expression	   regulation	   is	   currently	   an	   interesting	  
research	  avenue,	  since	  it	  can	  determine	  tissue	  specificity	  224,	  225.	  Finally,	  post-­‐transcriptional	  
modulation	  is	  also	  crucial	  for	  miRNA	  expression.	  Due	  to	  the	  complex	  maturation	  that	  miRNA	  
transcripts	   undergo	   before	   becoming	   functional,	   alterations	   affecting	   members	   of	   the	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1.3.2 MicroRNA	  biogenesis	  and	  mechanism	  of	  action	  	  
	  
miRNAs	  are	  usually	   transcribed	  by	  RNA-­‐polymerase	   II	   (RNAPII),	   generating	  primary	  miRNA	  
transcripts	   (pri-­‐miRNA)	   that	   are	   several	   kilobases	   long	   and	   poly-­‐adenylated	   226.	   After	  
transcription,	  pri-­‐miRNAs	  are	  converted	  into	  ~65nt	  hairpin	  stem	  loops	  by	  a	  subset	  of	  nuclear	  
proteins,	  which	   form	   the	   so-­‐called	  microprocessor	   complex.	   This	   complex	   is	   composed	  by	  
RNAse	  III	  Drosha,	  its	  partner	  DGCR8	  (DiGeorge	  syndrome	  critical	  region	  8)/PASHA	  and	  other	  
associated	   factors.	  Drosha	  cleaves	   the	  RNA	  duplex	  creating	  a	  >14	  bp	  double	   stranded	   (ds)	  
precursor	  RNA	  (pre-­‐miRNA)	  stem	  along	  with	  a	  short	  3’	  overhang	  (1-­‐8	  nt).	  The	  cut	  by	  Drosha	  
will	   already	   define	   one	   end	   of	   the	   mature	   miRNA.	   The	   pre-­‐miRNA	   is	   then	   actively	  
transported	   from	   the	   nucleus	   into	   the	   cytoplasm	   by	   the	   Ran-­‐GTP	   dependent	   transporter	  
Exportin	   5	   (Exp	   5)	   227,	   228.	   Further	  miRNA	   processing	   occurs	   in	   the	   cytoplasm,	   where	   pre-­‐
miRNAs	   are	   cleaved	   by	   an	   RNAse	   III	   endonuclease	   named	  Dicer	   229.	   Dicer	   recognises	   the	  
double	  strand	  region	  of	  the	  pre-­‐miRNA	  and	  eliminates	  the	  loop,	  determining	  the	  other	  end	  
of	   the	  mature	  miRNA	  as	  a	  ~22-­‐nucleotide	  dsRNA	  duplex	   (miRNA/miRNA*).	  Dicer	   is	  able	   to	  
associate	  with	  several	  dsRNA-­‐binding	  proteins	  and	  TRBP	  (TAR	  RNA-­‐binding	  protein).	  Finally,	  
Dicer	  also	  interacts	  with	  Argonaute	  (AGO)	  proteins,	  giving	  rise	  to	  the	  RNA-­‐induced	  silencing	  
complex	   (RISC).	   In	   mammals,	   4	   members,	   named	   AGO1	   to	   AGO4,	   form	   the	   AGO	   protein	  
family	  230.	  After	  the	  Dicer	  cleavage	  step,	  the	  dsRNA	  duplex	  (miRNA/miRNA*)	  is	  loaded	  onto	  
the	  RISC	  complex	  (miRISC).	  An	  unknown	  helicase	  then	  uncoils	  the	  duplex	  and	  the	  passenger	  
strand	   (usually	   miRNA*	   or	   miR-­‐3p)	   is	   degraded,	   allowing	   the	   remaining	   strand	   (‘guide’	  
strand,	  miRNA	  or	  miR-­‐5p)	  to	  become	  the	  functional	  mature	  miRNA.	  The	  mature	  miRNA	  then	  
guides	  the	  RISC	  complex	  to	  recognise	  target	  mRNAs	  and	  perform	  their	  regulatory	  function.	  
Mature	  miRNAs	   can	   post-­‐transcriptionally	   repress	   gene	   expression	   in	   two	   different	   ways.	  
When	   perfect	   miRNA-­‐mRNA	   annealing	   occurs,	   AGO2	   mediates	   a	   direct	   cleavage	   of	   the	  
mRNA.	  This	  step	  relies	  on	  the	  endonucleolytic	  activity	  of	  AGO2	  231,	  232	  (Figure	  9).	  However,	  in	  
the	   majority	   of	   cases,	   miRNA-­‐mRNA	   interactions	   are	   imperfect,	   leading	   to	   translational	  
repression	   and	   cleavage-­‐independent	   mRNA	   destabilisation	   by	   promoting	   deadenylation	  
through	   the	   recruitment	   of	   the	   deadenylation	   complex	   via	   the	   AGO-­‐interacting	   protein	  
GW182	   233,	  234.	   Following	   this,	   a	  miRNA-­‐dependent	  delivery	  of	   target	  mRNAs	   to	  processing	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bodies	   (P-­‐bodies)	   in	   the	   cytoplasm	   occurs.	   P-­‐bodies	   are	   sites	   for	   mRNA	   degradation	   and	  
turnover	  where	  selected	  mRNAs	  transported	  by	  the	  RISC	  complex	  are	  decapped	  and	  cleaved	  
by	  appropriate	  enzymatic	  machineries	  235-­‐237.	  
Aside	  from	  mRNA	  degradation	  and	  destabilisation,	  miRNAs	  can	  also	  repress	  gene	  expression	  
by	   interfering	   with	   the	   early	   steps	   of	   mRNA	   translation.	   Such	   translational	   inhibition	   can	  
occur	   either	   pre-­‐initiation	   (i.e.	   ribosomal	   binding	   is	   prevented)	   238,	   239	   or	   post-­‐initiation,	  
where	   ribosomes	   are	   caused	   to	   ‘drop	   off’	   from	   the	   messenger	   and/or	   proteins	   being	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Figure	   9.	   Simplified	   view	   of	   the	   canonical	   miRNA	   biogenesis	   process.	   miRNA	   maturation	   requires	   the	  
transcription	  of	  the	  miRNA	  gene	  into	  a	  primary	  transcript	  (pri-­‐miRNA)	  by	  RNAPII	  and	  the	  subsequent	  cleavage	  
of	  the	  pri-­‐miRNA	  by	  the	  nuclear	  microprocessor	  complex	  (Drosha-­‐DGCR8).	  The	   latter	  step	  results	   in	  a	  hairpin	  
RNA	   (pre-­‐miRNA)	   that	   is	   exported	   to	   the	   cytoplasm	   by	   Exportin	   5.	   Importantly,	   some	   miRNAs	   encoded	   in	  
intronic	  regions	  are	  able	  to	  skip	  the	  Drosha	  processing	  step,	  being	  exported	  straight	  after	  transcription.	  Once	  in	  
the	  cytoplasm,	  the	  RNAse	  III	  Dicer	  together	  with	  TRBP	  trims	  the	  pre-­‐miRNA	  hairpin	  down	  to	  a	  length	  of	  around	  
22nt.	  The	  functional	  strand	  of	  the	  mature	  miRNA	  is	  next	   loaded	  by	  AGO	  proteins	   into	  the	  RISC	  complex.	  The	  
mature	  miRNA	  guides	  then	  the	  RISC	  to	  the	  target	  mRNAs,	   recognizing	   its	  3’UTR.	  Expression	  of	   target	  mRNAs	  
will	  be	  silenced	  either	  by	  degradation	  of	  the	  messenger,	  deadenylation	  or	  translational	  repression	  depending	  
on	  the	  extent	  of	  miRNA-­‐mRNA	  base-­‐pairing.	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This	  miRNA-­‐mRNA	   interaction	   is	  based	  on	  the	  recognition	  of	  an	   interacting	  site	   (or	  miRNA	  
binding	   site,	   MBS)	   in	   the	   messenger’s	   3’UTR	   that	   is	   complementary	   to	   the	   miRNA	   seed	  
region	   (nucleotides	  2	   to	  7	   at	   the	  5’	   end).	   The	  nucleotide	  annealing	   in	   this	   region	  must	  be	  
perfect	   209.	   	   A	   common	   and	   less	   stringent	   base-­‐pairing	   towards	   the	   3’	   end	   of	   the	  miRNA	  
sequence	  contributes	  to	  the	  stability	  of	   the	  miRNA-­‐mRNA	  interaction	  and	  can	  compensate	  
poor	  seed	  pairing	  242.	  
	  
	  
Figure	  10.	  Schematic	  representation	  of	  miRNA-­‐mRNA	  interaction	  by	  base-­‐pairing.	  The	  annealing	  between	  the	  
seed	  region	  of	  the	  miRNA	  (positions	  2	  to	  8)	  and	  the	  interacting	  site	  in	  the	  3’UTR	  of	  the	  target	  mRNA	  must	  be	  
perfect.	  Additional	   less-­‐stringent	  base-­‐pairing	  ocurring	  at	  the	  3’	  end	  of	  the	  miRNA	  sequence	  can	  aid	  effective	  
mRNA	  repression.	  
	  
The	  miRNA	   classification	   into	   families	   groups	   together	   those	  miRNAs	   that	   share	   the	   seed	  
region,	  meaning	  that	  all	  members	  of	  a	  miRNA	  family	  are	  predicted	  to	  target	  the	  same	  subset	  
of	  genes	  209.	  The	  fact	  that	  perfect	  base-­‐pairing	   is	  only	  required	   in	  the	  short	  seed	  sequence	  
for	  mRNA	  targeting	  makes	   the	  one-­‐to-­‐many	   relationship	  between	  a	  miRNA	  and	   its	   targets	  
not	   surprising.	   Equally,	   several	  miRNA	   can	   also	   repress	   the	   same	  mRNA	   243.	   Interestingly,	  
sole	  seed	  pairing	   is	  not	  always	  sufficient	  to	  allow	  gene	  expression	   inhibition.	  Other	   factors	  
that	   can	   contribute	   to	   maximise	   mRNA	   targeting	   include:	   AU-­‐rich	   regions	   near	   the	  MBS,	  
proximity	  of	  binding	  sites	  for	  other	  miRNAs,	  additional	  base-­‐pairing	  between	  nucleotides	  13	  
and	  16	  of	  the	  miRNA	  and	  the	  MBS	  position	  within	  the	  3’UTR	  being	  away	  from	  the	  centre	  and	  
at	   least	  15	  nucleotides	  from	  the	  stop	  codon	  244.	  Moreover,	  target	  abundance	  and	  turnover	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1.3.3 MicroRNAs	  in	  cancer	  
	  
The	   association	   between	   altered	   miRNA	   signatures	   and	   cancer	   has	   been	   extensively	  
explored.	  Physiological	  miRNA	  expression	  levels	  contribute	  to	  maintaining	  the	  optimal	  gene	  
expression	   for	   cellular	   ‘housekeeping’.	   Therefore,	   miRNA	   dysregulation	   can	   lead	   to	  
cancerous	   cell	   transformation	  and	   subsequent	  disease	  progression	   220.	   Those	  miRNAs	   that	  
are	   up-­‐regulated	   or	   overexpressed	   in	   cancer	   cells	   compared	   to	   healthy	   cells	   act	   as	  
oncogenes,	   whilst	   miRNAs	   at	   reduced	   levels	   in	   cancer	   are	   considered	   tumour	   suppressor	  
genes.	   The	   molecular	   facts	   underlying	   this	   classification	   depend	   on	   the	   functions	   of	   the	  
genes	   targeted	   by	   the	   dysregulated	   miRNAs	   247,	   248.	   Performing	   integrated	   analyses	   of	  
predicted	  miRNA-­‐mRNA	  interactions	  can	  aid	  the	  identification	  of	  implicated	  target	  genes	  in	  
the	  altered	  pathways	  downstream	  126,	  249,	  250.	  	  
Different	   tumours	   present	   separately	   altered	   miRNA	   profiles.	   This	   interesting	   specificity	  
highlights	   the	   importance	   of	   post-­‐transcriptional	   regulation	   and	   allows	   the	   possibility	   of	  
miRNAs	   to	   be	   used	   for	   cancer	   type	   classification	   250,	   251.	   In	   addition,	   circulating	   levels	   of	  
tumour-­‐associated	  miRNAs	  can	  be	  measured	  in	  the	  bloodstream	  as	  non-­‐invasive	  diagnostic	  
and	  prognostic	  indicators	  252.	  Therapeutically,	  protective	  effects	  against	  tumourigenesis	  and	  
metastasis	   have	   been	   reported	   in	   vivo	   when	   ectopically	   replenishing	   tumour	   suppressor	  
miRNA	  levels	  253,	  254.	  	  
	  
1.3.4 MicroRNAs	  in	  heart	  development	  and	  disease	  	  
	  
Although	   miRNA	   alterations	   have	   been	   extensively	   studied	   in	   cancer,	   the	   importance	   of	  
these	  short	  regulatory	  RNAs	  within	  the	  cardiovascular	  system	  has	  only	  been	  highlighted	   in	  
the	  past	   few	  years	   255.	  MiRNAs	  have	  emerged	  as	   important	   regulators	   that	  enable	  healthy	  
heart	  development	  and	  function.	  MiRNAs	  have	  also	  been	  found	  to	  contribute	  to	  maintaining	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cell	  homeostasis,	  and	  deviations	  in	  their	  physiological	  expression	  are	  linked	  to	  pathological	  
processes	  affecting	  the	  whole	  organ	  256.	  	  
Spatiotemporal	  miRNA	  expression	  has	  been	  demonstrated	  to	  be	  key	  in	  the	  development	  of	  
different	   tissues,	   including	   the	   heart	   257.	   In	   fact,	   impairment	   of	   miRNA	   biogenesis	   by	   the	  
somatic	   deletion	   of	   Dicer	   has	   been	   shown	   to	   result	   in	   embryonic	   lethality	   with	   poor	  
myocardium	  formation	  258.	  Cardiac-­‐specific	  knock	  out	  of	  Dicer	  leads	  to	  cardiomyopathy	  and	  
failure	   in	   both	  embryonic	   and	  postnatal	  models,	   indicating	   that	  miRNAs	   are	  necessary	   for	  
both	  correct	  cardiogenesis	  and	  later	  function	  255,	  256,	  259.	  	  
The	   discovery	   of	   specific	  miRNA	   dysregulations	   associated	  with	   heart	   disease	   has	   been	   a	  
great	   breakthrough	   in	   the	   field,	   adding	   an	   extra	   layer	   of	   complexity	   to	   the	   molecular	  
landscape	  of	  cardiac	  conditions.	  Different	  studies	  have	  recently	  identified	  particular	  miRNA	  
signatures	  associated	  with	  several	  cardiac	  pathologies,	  with	  the	  majority	  of	  research	  focused	  
on	  hypertrophy	  and	  HF	  131,	  260,	  261.	  For	  instance,	  Van	  Rooij	  et	  al.	  described	  a	  particular	  miRNA	  
expression	  pattern	   in	  cardiac	  hypertrophy	  and	   failure,	  which	  was	   translatable	   from	  animal	  
models	   to	   human	   patients	   262.	   Several	   other	   whole-­‐heart	   miRNA	   profiling	   studies	   have	  
highlighted	  the	   importance	  of	  maintaining	  physiological	  miRNA	  expression	   in	   the	  heart	   261,	  
263.	  Notably,	  altered	  miRNA	  signatures	  affecting	  exclusively	  non-­‐myocyte	  cardiac	  cell	   types	  
(e.g.	  fibroblasts,	  endothelial	  cells)	  have	  been	  determined	  to	  also	  play	  a	  role	  in	  heart	  disease	  
264-­‐266.	  	  
Various	   independent	   studies	   have	   demonstrated	   concrete	   roles	   for	   certain	   miRNAs	   in	  
specific	  cardiac	  conditions.	  Some	  examples	   include	  the	  down-­‐regulation	  of	  miR-­‐1	  and	  miR-­‐
133	   being	   linked	   to	   arrhythmia,	   and	   the	   up-­‐regulation	   of	  miR-­‐21	   and	  miR-­‐195	   associated	  
with	   apoptosis	   and	   myocardial	   death.	   Numerous	   miRNAs	   are	   known	   to	   be	   implicated	   in	  
hypertrophy	  (miR-­‐21,	  150,	  195,	  214,	  133);	  miR-­‐126	  regulates	  angiogenesis	  post-­‐myocardial	  
infarction	   and	   miR-­‐29,	   amongst	   others,	   plays	   an	   essential	   role	   in	   fibrosis	   267.	   MiR-­‐210	   is	  
involved	   in	   ischemic	   heart	   disease,	   being	  down-­‐regulated	   in	   hypoxic	   cells	   and	   its	   restored	  
expression	  is	  potentially	  therapeutic	  268.	  Particularly	  interesting	  was	  the	  identification	  of	  the	  
cardiac-­‐specific	   miR-­‐208,	   which	   is	   coded	   in	   an	   intronic	   region	   of	   the	   alpha	  myosin	   heavy	  
chain	   (αMHC).	   miR-­‐208	   is	   described	   to	   play	   a	   key	   regulatory	   role	   in	   cardiac	   growth	   and	  
contractility,	  and	  its	  inhibition	  is	  beneficial	  in	  HF	  131,	  269.	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Even	   though	   miRNAs	   are	   usually	   modest	   gene	   expression	   regulators,	   their	   effects	   are	  
enhanced	  under	  stress	  conditions,	  becoming	  crucial	   in	  disease	  270.	  This	   is	  highly	  relevant	   in	  
the	   heart,	   given	   that	   it	   seems	   to	   be	   particularly	   sensitive	   to	   minor	   modulations	   in	   gene	  
expression	  269,	  271.	  Different	  mechanisms	  have	  been	  proposed	  for	  the	  complex	  miRNA	  actions	  
in	   pathology,	   including	   stress	   signal	   mediation	   and	   modulation,	   positive	   or	   negative	  
feedback	  loops	  and	  buffering	  of	  such	  stress	  signalling.	  Indeed,	  it	  is	  not	  infrequent	  to	  observe	  
apparently	  unaltered	  phenotypes	   in	   response	   to	  miRNA	  modulation	   that	  will	  only	  become	  
evident	   once	   the	   model	   has	   been	   exposed	   to	   disease	   270,	   272.	   In	   agreement	   with	   this,	  
manipulation	   of	   single	   miRNAs	   has	   been	   proved	   sufficient	   to	   revert	   entire	   cardiac	  
pathological	  phenotypes	  in	  vivo	  131,	  268,	  273,	  274.	  
The	   increasing	   interest	   in	   developing	   miRNA-­‐based	   therapies	   for	   human	   heart	   disease	   is	  
reflected	   by	   the	   numerous	   studies	   that	   have	   shown	   successful	  modulation	   of	   biologically	  
relevant	   dysregulated	   miRNAs	   in	   vivo.	   A	   summary	   of	   the	   miRNAs	   with	   demonstrated	  
therapeutic	  potential	  is	  illustrated	  in	  Figure	  11.	  
	  
	  
Figure	  11.	  miRNAs	   identified	  as	  potential	   cardiovascular	   therapeutics.	  Picture	   taken	  from	  Dangwal	  &	  Thum	  
2014.	  275.	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1.3.5 Basics	  of	  microRNA	  research	  	  
	  
Firstly,	  essential	  molecular	  techniques	  in	  miRNA	  research	  are	  those	  that	  enable	  researchers	  
to	  precisely	  detect	  miRNA	  levels.	  In	  recent	  years,	  high	  throughput	  methods	  have	  enabled	  the	  
identification	  of	  global	  miRNA	  signatures.	  Microarray	   technology	  and	  deep-­‐sequencing	  are	  
the	   two	   main	   high	   throughput	   techniques	   currently	   used	   276.	   Data	   arising	   from	   such	  
experiments	   need	   to	   be	   carefully	   analysed	   before	   inferring	   any	   conclusions	   concerning	  
differentially	   expressed	   miRNAs.	   Besides,	   experimental	   validation	   is	   typically	   required	   to	  
confirm	  meaningful	  effects.	   The	  accuracy	  of	  miRNA-­‐specific	  detecting	  methods	   is	   arguably	  
superior	   to	   those	   that	   provide	   a	   global	   profile	   134.	   For	   this	   reason,	   quantitative	   PCR	   and	  
northern	   blot	   are	   often	   used	   for	  miRNA	   quantification.	   The	   fact	   that	   northern	   blotting	   is	  
labour	   intensive	   and	   often	   implicates	   radioactive	   work,	   together	   with	   the	   availability	   of	  
primers	  that	  allow	  specific	  detection	  of	  short	  RNA	  molecules	  like	  miRNAs,	  has	  made	  reverse	  
transcription	  (RT)	  followed	  by	  quantitative	  PCR	  (RT-­‐qPCR,	  also	  known	  as	  Real	  Time	  PCR)	  the	  
preferred	   method.	   The	   TaqMan®	   probe	   system	   most	   commonly	   used	   for	   miRNA	  
quantification	   is	   based	   on	   a	   miRNA-­‐specific	   primer	   that	   adds	   a	   stem-­‐loop	   to	   the	   miR	  
sequence,	  permitting	  the	  RT	  reaction.	  	  Another	  specific	  primer	  is	  needed	  for	  the	  quantitative	  
step,	  in	  combination	  with	  a	  universal	  TaqMan®	  probe	  276.	  
Central	  to	  understanding	  the	  phenotypic	  effects	  that	  miRNA	  dysregulation	  may	  have	  is	  the	  
identification	  of	  their	  target	  genes.	  Bioinformatic	  tools	  for	  miRNA	  target	  prediction	  are	  freely	  
available	  (miRanda,	  PicTar,	  TargetScan,	  miRBase,	  etc.)	  and	  provide	  an	  initial	  insight	  into	  the	  
potentially	   affected	   molecular	   mechanisms	   207,	   277-­‐279.	   These	   programs	   use	   different	  
algorithms	   for	   in	   silico	   predictions	   of	   gene	   targets,	   being	   seed	   pairing	   and	   evolutionary	  
conservations	  the	  main	  criteria.	  TargetScan	  is	  considered	  the	  most	  complete	  system	  because	  
it	   incorporates	  other	   factors	   into	   the	  prediction,	   such	   as	  miRNA-­‐mRNA	  annealing	   at	   other	  
locations	  than	  the	  seed	  sequence	  208.	  	  
The	   required	   experimental	   validation	   of	   the	   bioinformatically	   predicted	   miRNA	   targets	   is	  
usually	   the	   most	   tedious	   aspect	   of	   miRNA	   research.	   An	   array	   of	   techniques	   allows	  
researchers	   to	   confirm	   biologically	   relevant	   inhibition	   of	   certain	   mRNAs	   by	   a	   miRNA	   of	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interest.	  The	  first	  validation	  step	  is	  frequently	  the	  confirmation	  of	  direct	  miRNA	  interaction	  
with	  the	  target	  mRNA	  (at	  the	  3’UTR).	  This	  can	  be	  achieved	  by	  3’UTR	  luciferase	  assay,	  which	  
should	  ideally	  be	  performed	  on	  a	  relevant	   in	  vitro	  model	  to	  replicate	  the	  background	  gene	  
expression	  of	  the	  studied	  cell	  type	  280	  (Figure	  12).	   If	  encouraging	  results	  are	  obtained	  from	  
luciferase	  assays,	  effects	  of	  altered	  miRNA	  expression	  in	  target	  mRNA	  and	  protein	  levels	  are	  
generally	  assessed.	   In	  the	  event	  of	  accurate	  target	  prediction,	   increased	  miRNA	  expression	  
will	  result	  in	  decreased	  target	  gene	  expression	  and	  vice	  versa.	  As	  per	  miRNA	  quantification,	  
RT-­‐qPCR	   is	   the	   technique	   of	   choice	   for	  mRNA	  measurement.	   Changes	   in	  mRNA	   levels	   are	  
considered	  an	  accurate	  indication	  of	  true	  miRNA	  targeting.	  In	  fact,	  mammalian	  miRNAs	  are	  
known	  to	  cause	  reduction	  mainly	  at	  mRNA	  level	  281	  282.	  Nevertheless,	  subsequent	  alterations	  
at	   the	   protein	   level	   are	   often	   also	   evaluated	   by	   Western	   blot.	   MiRNA	   act	   as	   moderate	  
molecular	   dimmer	   switches,	   and	   even	   though	   their	   inhibitory	   actions	   have	   important	  
biological	  consequences,	  they	  trigger	  mild	  fold	  changes	  in	  gene	  expression	  (typically	  ~35%	  in	  
transcript	   and	   ~12%	   in	   protein	   product	   levels)	   283.	   These	   subtle	   alterations	   in	   gene	  
expression	  add	  difficulty	  to	  the	  detection	  of	  real	  effects	  from	  background	  or	  artefacts.	  In	  any	  
case,	  a	  combination	  of	  mRNA	  and	  protein	  measurements	  in	  response	  to	  miRNA	  modulation	  
is	  currently	  the	  most	  reliable	  method	  for	  miRNA	  target	  validation	  276.	  	  
	  
	  
Figure	  12.	  Basis	  of	   the	  3’UTR-­‐uciferase	  assay.	   	  A	  plasmidic	  vector,	  from	  SwitchGear	  in	  our	  case,	  containing	  a	  
reporter	  gene	  (luciferase)	  and	  the	  3’UTR	  of	  the	  putative	  target	  under	  investigation	  cloned	  as	  fusion.	  When	  co-­‐
transfecting	   container	   cultures	   with	   said	   plasmid	   and	   miRNA	   mimics	   for	   overexpression,	   a	   reduction	   in	  
luciferase	  signal	  will	  only	  be	  observed	  if	  the	  candidate	  miRNA	  is	  able	  to	  bind	  to	  the	  3’UTR	  in	  question.	  On	  the	  
other	   hand,	   if	   no	  miR-­‐3’UTR	   interaction	   occurs,	   the	   transcript	  will	   be	   translated	   and	   the	   resulting	   luciferase	  
protein	  will	  generate	  luminescence	  signal.	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Ectopic	   modulation	   of	   miRNA	   levels	   can	   be	   achieved	   in	   vitro	   by	   a	   variety	   of	   methods.	  
Thorough	  target	  validation	  is	  achieved	  by	  complementing	  gain-­‐of-­‐function	  experiments	  with	  
loss-­‐of-­‐function	   approaches	   expecting	   to	   obtain	   opposing	   results.	   For	   miRNA	  
overexpression,	   synthetic	   double	   stranded	   mimics	   are	   used	   and	   incorporated	   into	   the	  
endogenous	  processing	  cascade.	  Exogenous	  miRNA	  mimics	  trigger	  a	  substantial	   increase	   in	  
mature	  miRNA	  expression.	  To	  avoid	  false	  positive	  results	  derived	  from	  a	  supra-­‐physiological	  
expression,	  miRNA	  inhibition	  is	  recommended	  to	  confirm	  gain-­‐of-­‐function	  results	  134.	  Several	  
strategies	   can	  be	   applied	   for	  miRNA	   repression	   in	   vitro.	  Specific	   single	   stranded	   antisense	  
inhibitors	   (antimiRs)	   are	   commercially	   available,	   as	   well	   as	   Locked	   Nucleic	   Acid	   (LNA)	  
oligonucleotides.	  LNA	  technology	  consists	  of	  modifying	  nucleic	  acids	  by	  creating	  a	  methylene	  
bridge	   between	   the	   2’-­‐oxygen	   and	   the	   4’-­‐carbon	   of	   the	   riboses.	   This	   increases	  
thermodynamic	   stability	  and	  affinity	  of	   target	  RNA	  binding	   284-­‐286.	   Tiny	   LNA	  sequences	   can	  
also	   be	   designed	   for	   whole	   miRNA	   family	   inhibition	   287.	   Another	   way	   of	   achieving	   whole	  
family	  repression	  of	  miRNAs	  is	  the	  use	  of	  sponge	  vectors.	  They	  act	  as	  competitive	  inhibitors	  
that	   sequester	   endogenous	  mature	  miRNA	   by	   annealing	   to	   tandem	   repeats	   of	   sequences	  
complementary	  to	  the	  desired	  seed	  288.	  	  
Modulation	  of	  miRNA	  expression	  can	  also	  be	  achieved	  in	  vivo.	  Permanent	  alterations	  require	  
genetic	  engineering	  to	  knock	  in	  or	  knock	  out	  the	  miRNA	  gene	  of	  interest.	  However,	  a	  more	  
transient	   inhibition	  or	  overexpression	  can	  be	  accomplished	   in	  animal	  models	  by	  delivering	  
miRNA-­‐modulating	   agents.	  Modified	   single-­‐stranded	  miRNA	   inhibitors	   (e.g.	   LNA	   constructs	  
and	   antimiRs	   with	   a	   2’-­‐O-­‐methyl	   modified	   backbones)	   are	   sufficiently	   stable	   in	   the	  
bloodstream	  for	  naked	  administration	   (Figure	  13).	  More	  challenging	   is	  carrying	  out	  miRNA	  
rescue	   in	   vivo,	   since	   the	   double-­‐stranded	   oligonucleotides	   used	   for	   mimicry	   require	   a	  
dedicated	  delivery	  platform	  to	  enable	  cellular	  uptake.	  This	  is	  also	  the	  case	  of	  sponge	  vectors	  
(Figure	  13),	  whose	  size	  is	  too	  large	  to	  penetrate	  the	  cell	  membrane.	  Synthetic	  nanoparticles	  
and	  viral	  vectors	  are	  the	  current	  options	  for	  the	  delivery	  of	  miRNA	  mimics,	  as	  well	  as	  other	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Figure	  13.	  Synthetic	  miRNA	  inhibitors.	  Modifications	  of	  nucleic	  acid	  backbone,	  such	  as	  the	  addition	  of	  a	  methyl	  
group	   in	   the	   2’-­‐O	   position	   (2’-­‐O-­‐Me)	   or	   a	   bridge	   between	   the	   carbons	   2’	   and	   4’	   for	   a	   locked	   conformation	  
(locked	  nucleic	  acid,	  LNA)	   increase	  stability	  of	  RNA	  molecules.	  The	  most	  common	  synthetic	  miRNA	   inhibitors	  
are:	  antimiRs	  (antimiRNA	  antisense	  oligonucleotides,	  AMO),	  antagomiRs	  (2’-­‐O-­‐Me	  backbone	  modification	  and	  
cholesterol	   conjugation),	   miRNA-­‐specific	   LNAs	   and	   sponge	   vectors	   containing	   tandem	   repeats	   of	   miRNA	  
binding	  sites	  (usually	  the	  seed	  sequence)	  at	  the	  3’UTR	  of	  a	  reporter	  cDNA.	  	  
	  
1.3.6 Translational	  potential	  of	  microRNAs	  
	  
The	   association	   of	   altered	   levels	   of	   certain	   miRNAs	   with	   specific	   pathologies	   directly	  
translates	   in	   those	   miRNAs	   becoming	   potential	   therapeutic	   targets,	   as	   well	   as	   diagnostic	  
tools,	   for	  human	  diseases.	  Considering	   this	   translational	  potential,	   researchers	   in	  both	   the	  
academic	   and	   pharmaceutical	   sectors	   are	   investigating	   ways	   of	   exploiting	   the	   identified	  
miRNA-­‐disease	  links.	  Indeed,	  three	  companies	  were	  founded	  around	  the	  key	  cellular	  roles	  of	  
miRNAs:	  miRNA	   therapeutics,	   miRagen	   therapeutics	   and	   Regulus	   290-­‐292.	   These	   companies	  
hold	   several	   candidate	  miRNA-­‐based	   strategies,	   predominantly	   in	   the	   fields	   of	   cancer	   and	  
cardiovascular	  disease.	  As	  much	  as	  these	  candidate	  remedies	  are	  mostly	   in	  the	  pre-­‐clinical	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platform	   named	   SMARTICLES®-­‐	   has	   been	   accepted	   for	   a	   Phase	   I	   clinical	   trial	   against	   liver	  
cancer	  293.	  In	  addition,	  miR-­‐122	  inhibition	  using	  LNA	  technology	  is	  currently	  being	  trialled	  for	  
hepatitis	   C	   at	   Phase	   II	   by	   Santaris	   294-­‐296.	   Intensive	   research	   is	   also	   being	   dedicated	   to	  
standardising	   the	  measurement	   of	   circulating	  miRNA	   as	   non-­‐invasive	   biomarkers.	   Indeed,	  
there	   is	   increasing	   evidence	   supporting	   the	   potential	   use	   of	   blood-­‐based	   miRNAs	   for	  
diagnosis	  252,	  297,	  as	  well	  as	  for	  prognosis	  and	  as	  indicators	  of	  responsiveness	  to	  treatment	  298,	  
299.	  Even	  though	  miRNAs	  are	  stable	  in	  the	  bloodstream,	  normalisation	  of	  the	  detected	  levels	  
has	  proved	  challenging	  and	  technical	  reproducibility	  is	  currently	  limited	  300,	  301.	  	  
In	  terms	  of	  the	  handicaps	  for	  delivering	  miRNAs	  in	  patients,	  miRNA	  inhibition,	  mediated	  via	  
single-­‐stranded	  oligonucleotides,	  provides	  an	  easier	  option	  compared	  to	  overexpression	  by	  
double-­‐stranded	   miRNA	   mimics.	   Certainly,	   miRNA	   repression	   can	   be	   achieved	   by	   naked	  
modified	  backbones,	  not	  considering	  targeted	  delivery,	  whilst	  miRNA	  replacement	  requires	  
complex	  delivery	  platforms.	  This	  is	  probably	  the	  reason	  why	  most	  miRNA-­‐based	  therapeutic	  
strategies	   are	   being	   designed	   to	   silence	   rather	   than	   rescue	   expression.	   Nevertheless,	  
miRNAs	  seem	  to	  be	  more	  frequently	  down-­‐regulated	  in	  disease	  scenarios	  and	  it	  is	  therefore	  
necessary	  to	  develop	  optimal	  approaches	  for	  miRNA	  rescue	  302,	  303.	  	  
The	   future	   of	   miRNA	   therapeutics	   currently	   oscillates	   between	   the	   hopes	   for	   a	   powerful	  
novel	  class	  of	  biological	  drugs	  and	  the	  challenges	  that	  must	  be	  faced	  on	  the	  road	  to	  the	  clinic	  
267.	  Figure	  14	  summarises	  the	  most	  debated	  aspects	  of	  miRNA-­‐based	  therapies:	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Figure	  14.	  miRNA	  therapeutics:	  advantages	  and	  challenges.	  	   	  
	  
On	   one	   hand,	   miRNAs	   are	   able	   to	   fine	   tune	   complex	   signalling	   cascades	   that	   are	   often	  
involved	  in	  life-­‐threatening	  syndromes.	  On	  the	  other	  hand,	  the	  important	  issues	  of	  delivery	  
to	   the	   desired	   tissue	   and	   target	   gene	   specificity	   need	   to	   be	   carefully	   addressed	   to	   avoid	  
unexpected	   toxicities	   304.	   Another	   key	   factor	   that	   requires	   optimising	   is	   dosage,	   since	   the	  
introduction	   of	   small	   regulatory	   RNAs	   may	   saturate	   the	   cellular	   machinery	   and	   result	   in	  
lethal	  dysregulation	  of	  endogenous	  miRNAs	  305.	  	  
Altogether,	   the	   translational	  perspective	   for	  miRNA	   therapeutics	   is	   encouraging,	   given	   the	  
enormous	  advances	  in	  the	  field	  from	  their	  relatively	  recent	  discovery.	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1.4 Aims	  
	  
In	   spite	   of	   the	   recognised	   problem	   of	   cardiotoxicity	   in	   cancer	   patients	   receiving	   HER2	  
blockers	  and	  ANT	  (e.g.	  DOX),	  the	  molecular	  mechanisms	  underlying	  such	  adverse	  effects	  in	  
the	  heart	  are	  not	  well	  understood.	  Similarly,	  aberrant	  cardiac	  miRNA	  expression	  caused	  by	  
HER2	   inhibitors	   has	   not	   been	   described	   thus	   far.	  With	   regard	   to	  ANT,	   only	   one	   published	  
study	   had	   demonstrated	   the	   dysregulation	   of	   a	   single	   miRNA	   in	   DOX-­‐treated	   neonatal	  
cardiomyocytes	  at	  the	  start	  of	  this	  thesis.	  	  
Given	  the	  potent	  cellular	  roles	  of	  miRNAs	  as	  gene	  expression	  regulators	  and	  their	  described	  
implications	  in	  cancer	  and	  cardiovascular	  disease,	  we	  wished	  to	  investigate	  whether	  miRNA-­‐
mediated	   events	   are	   involved	   in	   the	   cardiotoxicity	   arising	   from	   HER2-­‐targeted	   and	   ANT	  
anticancer	  treatments.	  For	  this	  purpose,	  we	  aimed	  to:	  
	  
i.	   Establish	   the	  miRNA	   profiles	   induced	   by	   HER2	   blockade	   and	   DOX	   treatment	   in	  
cardiomyocytes	  using	  a	  combination	  of	  in	  vitro	  and	  in	  vivo	  models	  
ii.	  Select	  interesting	  miRNA	  candidates	  from	  the	  altered	  signatures	  identified	  in	  the	  
models	  assayed.	  	  
iii.	   Bioinformatically	   predict	   target	   genes	   for	   the	   selected	  miRNAs	  and	  attempt	   to	  
identify	   genes	   with	   known	   cardiac	   functions,	   which	   are	   more	   likely	   to	   play	  
important	  roles	  in	  the	  cardiac	  consequences	  of	  anticancer	  treatment.	  	  
iv.	  Experimentally	  validate	  target	  genes	  using	  gain	  and	  loss-­‐of-­‐function	  strategies	  in	  
order	  to	  investigate	  the	  downstream	  effects	  of	  miRNA	  alteration.	  
v.	  Gain	   insight	   into	   the	   phenotypic	   effects	   of	   cardiac	  miRNA	  modulation,	   both	   by	  
mimicking	   and	   counteracting	   the	   changes	   induced	   by	   HER2-­‐blockers	   and	   DOX.	  
Expectantly,	  these	  experiments	  will	  provide	  information	  about	  the	  functional	  effect	  
of	  miRNA	   expression	   alteration	   in	   cardiomyocytes	   and	   evidence	   potential	   clinical	  
implications.	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In	  summary,	  the	  main	  goal	  of	  this	  project	   is	  to	  unravel	  altered	  miRNA	  expression	  triggered	  
by	  some	  of	  the	  anticancer	  agents	  that	  have	  been	  associated	  with	  a	  risk	  of	  heart	  disease.	  The	  
discovery	  of	  changes	  in	  the	  expression	  of	  specific	  miRNA	  targeting	  relevant	  genes	  for	  cardiac	  
function	   would	   shed	   light	   on	   unknown	   regulatory	   pathways	   that	   might	   be	   central	   in	   the	  
development	  of	  HF.	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2.1 Materials	  
	  
2.1.1 Culture	  media	  
	  
Table	  1.	  Complete	  growth	  media	  





Medium	  (DMEM,	  Sigma)	  
	  
2mM	  Glutamine	  
50	  units/mL	  Penicillin	  
50μg/mL	  Streptomycin	  
10%	  FCS	  (foetal	  calf	  serum)	  
4°C	  
used	   within	  
one	  month	  
H9c2	   DMEM	  (Sigma)	   4mM	  Glutamine	  
50	  units/mL	  Penicillin	  
50μg/mL	  Streptomycin	  
10%	  FCS	  (foetal	  calf	  serum)	  
4°C	  
used	   within	  
one	  month	  
Primary	   isolated	  
ARVCM	  
M199	  (Invitrogen)	   1%	  Penicillin/Streptomycin	  
2g/L	  Bovine	  Serum	  Albumin	  (BSA)	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Table	  2.	  Transfection	  media	  
Transfection	  complex	  
medium	   Reagents	   Medium	  on	  the	  cultures	   Storage	  
Neat	  DMEM	   HiPerFect	  Transfection	  Reagent	  (Qiagen)	  
DMEM	  plus	  additives	  and	  
antibiotics	   4°C	  




Antibiotic-­‐free	  DMEM	  (cell	  
lines)	  or	  M199	  (ARVCM)	   4°C	  
	  
2.1.2 Buffers	  and	  solutions	  
	  
All	   buffers,	   solutions	   and	   dilutions	   were	   made	   with	   double	   distilled	   H2O	   (ddH2O),	   simply	  
referred	  to	  as	  H2O	  in	  this	  thesis.	  When	  handling	  nucleic	  acids,	  H2O	  was	  autoclaved	  to	  ensure	  
DNAse	  and	  RNAse	  free	  quality.	  	  
	  
Table	  3.	  List	  of	  reagents	  and	  buffers	  
Reagent	   Composition	   Storage	  
	  	   	  	  
	  
1M	  Dithiothreitol	  (DTT)	   1.54g	  of	  DTT	  in	  10mL	  H20	   -­‐20°C	  
	  	   	  	   	  
1M	  Tris-­‐HCl	   60.5g	  Tris	  in	  500mL	  H20,	  pH	  adjusted	  with	  pure	  HCl	   RT	  
	  	   	  	   	  
Laemmli’s	  buffer	   50mM	  Tris-­‐HCl	  pH	  6.8,	  15%	  glycerol,	  0.1%	  (w/v)	  bromophenol	  blue,	  4%	  SDS	  	   RT	  
	  	   	  	   	  
NP-­‐40	  Lysis	  Buffer	   30	  mL	  of	  5M	  NaCl,	  100	  mL	  of	  10%	  NP-­‐40,	  50	  mL	  of	  1M	  Tris	  pH	  8.0,	  in	  820mL	  of	  H20	  
4°C	  
	  	   	  	   	  
Materials	  and	  methods	  
	   69	  
Oligonucleotide	  annealing	  buffer	  
	  
	  10mM	  Tris-­‐HCl	  pH	  7.5,	  50mM	  NaCl,	  1mM	  EDTA	  	   4°C	  
	  
For	  Wester	  Blotting:	   	  	   	  
	  	   	  	   	  
2x	  SDS	  (Sodium	  Dodecyl	   125mM	  Tris-­‐HCl	  pH	  6.8,	  20%	  glycerol,	  4%	  SDS,	   4°C	  
Sulphate)	  loading	  dye	  	   	  100mM	  DTT,	  0.04%	  (w/v)	  bromophenol	  blue	   	  
	  	   	  	   	  
10x	  SDS/PAGE	  Running	  buffer	   10g	  SDS,	  30.3g	  Tris,	  144.1g	  glycine	  dissolved	  in	   RT	  
	  	   1L	  of	  H20	   	  
	  	   	  	   	  
10x	  Transfer	  buffer	   30.3g	  Tris,	  144.1g	  glycine	  dissolved	  in	  1L	  of	  H20	   RT	  
	  	   	   	  
	  	   	  	   	  
10x	  TBS	  (Tris-­‐Buffered	  Saline)	   24.23g	  Trizma	  HCl,	  80.06	  g	  NaCl	  in	  1L	  of	  H20	  (pH	  7.6)	   RT	  
	  	   	  	   	  
TBST	  buffer	  (TBS/Tween®	  20)	   100ml	  of	  TBS	  10x,	  900ml	  H20,	  1mL	  Tween®	  20	  (BDH)	   RT	  
	  	   	  	   	  
Blocking	  solution	   5%	  dried	  skimmed	  milk	  in	  TBST	   4°C	  
	  	   	  	   	  
	  	   	  	   	  
For	  IonOptix:	   	  	   	  	  





7.012g/L	  NaCL,	  0.402g/L	  KCl,	  1.332g/L	  	  MgSO4,	  
0.55g/L	  pyruvate,	  3.603g/L	  glucose,	  2.502g/L	  
taurine,	  2.383g/L	  HEPES	  and	  200μM	  CaCl2	  in	  H2O	  
(pH	  7.4)	  
4°C	  
	  	   	  	   	  
	  
Low	  calcium	  medium	  
	  
7.012g/L	  NaCL,	  0.402g/L	  KCl,	  1.332g/L	  	  MgSO4,	  
0.55g/L	  pyruvate,	  3.603g/L	  glucose,	  2.502g/L	  
taurine,	  2.383g/L	  HEPES	  and	  1.286g/L	  
nitrilloatriacetic	  acid	  (NTA)	  	  in	  H2O	  (pH	  6.96)	  
4°C	  
	  	   	  	   	  
	  
Krebs	  solution	   119.1mM	  NaCl,	  4.7mM	  KCl,	  0.94mM	  MgSO4,	  1.2mM	  KH2PO4,	  25mM	  NaHCO3	  and	  11.5mM	  
glucose,	  1mM	  Ca2+	  in	  H2O	  
4°C	  
	  	   	  	   	  
For	  chIP:	   	  	   	  




50mM	  HEPES-­‐KOH	  pH	  7.5,	  100mM	  NaCl,	  1mM	  
EDTA,	  0.5mM	  EGTA	  
RT	  
	  	   	  	   	  
Lysis	  Buffer	  1	  
	  
50mM	  HEPES-­‐KOH	  pH	  7.5,	  140mM	  NaCl,	  1mM	  
EDTA,	  10%	  Glycerol,	  0.5%	  Igepal	  CA-­‐630,	  0.25%	  
Triton	  X-­‐100	  
4°C	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  [1x	  Protease	  inhibitor	  cocktail	  –PIC-­‐	  added	  before	  
use]	  
	  	  	   	  	  
	  Lysis	  Buffer	  2	  
	  	  
	  10mM	  Tris-­‐HCL	  pH	  8.0,	  200mM	  NaCl,	  1mM	  EDTA,	  
0.5mM	  EGTA	  [1xPIC	  added	  before	  use]	  
4°C	  
	  
	   	   	  
Lysis	  Buffer	  3	  	  
	  
10mM	  Tris-­‐HCL	  pH	  8.0,	  100mM	  NaCl,	  1mM	  EDTA,	  
0.5mM	  EGTA,	  0.1%	  SDS,	  0.5%	  N-­‐lauroylsarcosine	  	  
4°C	  
	  
	   	   	  RIPA	  buffer	  
	  
50mM	  HEPES-­‐KOH	  pH	  7.5,	  500mM	  LiCl,	  1mM	  
EDTA,	  1%	  Igepal	  CA-­‐630,	  0.7%	  SDS	  
4°C	  
	  
	   	   	  
Block	  solution	   0.5%	  BSA	  in	  PBS	  (phosphate	  buffered	  saline)	   4°C	  
	   	   	  
Elution	  buffer	  
	  
50mM	  Tri-­‐HCl	  pH	  8.0,	  10mM	  EDTA,	  1%	  SDS	  [1xPIC	  
added	  before	  use.	  Made	  fresh]	  
N/A	  
	  




All	   primer	   sequences	   were	   designed	   using	   PerlPrimer	   software	   (Sourceforge)	   and	  
synthesized	  by	  Sigma-­‐Aldrich.	  	  
All	  probes	  for	  mature	  miRNA	  detection	  were	  purchased	  from	  Applied	  Biosystems.	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Table	  6.	  Plasmid	  vectors	  
Plasmid	  name	   Insert	   Cat.	  number	   Company	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DMD-­‐pLightSwitch_3’UTR	  
















Table	  7.	  Primary	  antibodies	  
Antibody	   Dilution	  /	  amount	  
Company	  and	  
cat.number	   Dilution	  buffer	  
Rabbit	  monoclonal	  anti-­‐Phospho-­‐
p42/44	  MAPK	  (ERK1/2)	   1/250	   4370,	  Cell	  signaling	  
Blocking	  
solution	  
Mouse	  monoclonal	  anti-­‐ERK1/2	  
(MK1)	   1/400	  




Mouse	  monoclonal	  anti-­‐Giα-­‐2	   1/250	  




Rabbit	  monoclonal	  anti-­‐BNIP3L	   1/500	   ab109414,	  Abcam	  Plc.	   Blocking	  solution	  
Mouse	  monoclonal	  anti-­‐α-­‐Tubulin	   1/5000	   T5168,	  Sigma.	   5%	  BSA	  in	  TBST	  
Mouse	  monoclonal	  anti-­‐GAPDH	   1/500	   G8795,	  Sigma	   Blocking	  solution	  
Goat	  polyclonal	  anti-­‐GATA-­‐6	  (N-­‐18)	   10μg	   sc-­‐7245x,	  Santa	  Cruz	   Block	  solution	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1/1000	   Biotech	  Inc.	   (chIP)	  
Blocking	  
solution	  (W-­‐B)	  










Goat	  polyclonal	  anti-­‐GATA-­‐6	  (C-­‐20)	   10μg	   sc-­‐7244,	  Santa	  Cruz	  Biotech	  Inc.	  	  	  	   Block	  solution	  
	   	  
Table	  8.	  Secondary	  antibodies	  
Antibody	   Dilution	  	   Company	  and	  cat.number	   Dilution	  buffer	  
Polyclonal	  goat	  anti-­‐rabbit	  IgG/HRP	   1/2500	   D-­‐0487,	  Dako	   Blocking	  solution	  
Polyclonal	  goat	  anti-­‐mouse	  IgG/HRP	   1/2500	   Z-­‐0420,	  Dako	   Blocking	  solution	  
Anti-­‐goat	  IgG/HRP	   1/10000	   A-­‐5420,	  Sigma	   Blocking	  solution	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2.2 Methods	  
	  
2.2.1 Animal	  models	  
	  
All	   animal	   surgical	   procedures	   and	   perioperative	   management	   were	   carried	   out	   in	  
accordance	   with	   the	   United	   Kingdom	   Home	   Office	   Guide	   on	   the	   Operation	   of	   Animals	  
(Scientific	  Procedures)	  Act	  1986	  by	   licensed	  personnel.	   Standard	  measures	  were	   taken	   for	  
anaesthesia	  and	  analgesia	  in	  all	  recovery	  surgery	  procedures.	  	  
	  
2.2.1.1 	  Lapatinib-­‐loaded	  minipump	  pilot	  model	  
	  
For	  continuous	  LAP	  drug	  delivery,	  2mL	  minipumps	  (Alzet)	  were	   loaded	  with	  sufficient	  drug	  
solution	   to	   deliver	   10mg/kg/d	   and	   implanted	   in	   the	   scruff	   of	   male	   Sprague-­‐Dawley	   rats	  
(250–300g,	  n=3).	   LAP	  powder	   (Cell	   Signaling)	  was	  made	  up	  with	  pure	  DMSO	  as	   stock,	  and	  
diluted	   in	   PBS	   up	   to	   the	   2mL	   volume	   to	   load	   into	   the	  minipumps.	   No	   vehicle	  minipumps	  
were	  implanted	  for	  this	  pilot	  study,	  and	  an	  age-­‐matched	  control	  (AMC)	  animal	  was	  used	  as	  
control.	  Hearts	  were	  explanted	  for	  phenotype	  characterization	  7	  days	  after	  implantation.	  	  
	  
2.2.1.2 Doxorubicin-­‐induced	  heart	  failure	  model	  	  
	  
Adult	  male	  Sprague-­‐Dawley	   rats	   (250–300g)	  were	  administered	  a	   total	   cumulative	  dose	  of	  
15mg/kg	  of	  DOX	  delivered	  via	  six	  intraperitoneal	  (i.p.)	  injections	  over	  two	  weeks	  (n=5).	  Each	  
injection	  contained	  2.5mg/kg	  of	  DOX	   (Teva)	  diluted	   in	   saline	  up	   to	  a	  volume	  of	  2mL.	  AMC	  
rats	  (n=3)	  were	  used	  as	  controls.	  Animals	  were	  kept	  under	  constant	  monitoring	  for	  signs	  of	  
Materials	  and	  methods	  
	   75	  
heart	   failure	   and	   any	   other	   possible	   adverse	   effects.	   Three	  weeks	   after	   the	   last	   injection,	  
animals	  were	  sacrificed	  and	  hearts	  explanted,	  weighed,	  and	  prepared	  for	  cell	  isolation.	  	  
For	  the	  lower	  cumulative	  dose	  model	  tested	  (10mg/kg,	  n=6),	  five	  2mg/kg	  i.p.	  DOX	  injections	  
were	  spread	  over	  a	  fortnight.	  For	  the	  intermediate	  12.5mg/kg	  dose	  (n=6),	  animals	  received	  
five	  2mg/kg	   injections	  and	  a	  sixth	  2.5mg/kg	   i.p.	  DOX	   injection,	  also	  evenly	  spaced	  within	  a	  
two-­‐week	  period.	  	  
	  
2.2.1.3 	  Myocardial	  infarction	  induction	  
	  
Adult	  male	   Sprague-­‐Dawley	   rats	   (250–300g)	   underwent	   proximal	   left	   anterior	   descendent	  
(LAD)	   coronary	   artery	   ligation	   to	   induce	   chronic	   myocardial	   infarction	   (MI)	   as	   previously	  
described	   by	   our	   collaborators	   306.	   Two	   infarcted	   groups	   were	   generated.	   To	   model	  
pathologic	  post	  MI-­‐hypertrophy,	  animals	  were	  sacrificed	  4	  weeks	  after	  MI	   induction	   (n=5).	  
Late-­‐stage	   HF	   model	   hearts	   were	   explanted	   and	   prepared	   for	   cell	   isolation	   16-­‐20	   weeks	  
post-­‐MI	  surgery	  (n=5),	  when	  an	  advanced	  HF	  phenotype	  was	  established	  105,	  306.	  AMC	  were	  
used	  in	  both	  cases	  to	  preserve	  animal	  welfare.	  
	  
	   	  
Figure	   15.	   	   Transversal	   cuts	   of	   an	   infarcted	   heart.	   4w	   post-­‐MI	   induction	   by	   proximal	   LAD	   coronary	   artery	  
ligation,	  a	  white	  fibrotic	  scar	  can	  be	  distinguished	  in	  the	  myocardium.	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2.2.1.4 Adeno-­‐associated	  virus	  based	  gene	  therapy	  model	  
	  
AAV	  stocks	  (AAV9.LacZ	  and	  AAV9.miR30e)	  were	  diluted	  in	  H2O	  in	  order	  to	  reach	  the	  desired	  
dose	  in	  a	  total	  volume	  of	  250μL,	  which	  was	  loaded	  in	  precision	  glass	  syringe	  (Hamilton).	  The	  
tip	   of	   the	   needle	   was	   then	   bent	   in	   a	   90°	   angle	   for	   injection.	   Once	   animals	   were	  
anaesthetised	   and	   shaved,	   a	   1cm	   incision	   was	   made	   in	   a	   45°	   angle	   on	   top	   of	   the	   right	  
collarbone.	  Following	  dissection	  of	  fat	  and	  fascia,	  the	  AAV	  dose	  was	  slowly	  applied	  into	  the	  
jugular	   and	   bleeding	  was	   stopped	   by	   applying	   gentle	   pressure.	   Animals	  were	   kept	   single-­‐
caged	   after	   recovery	   until	   the	   wound	   was	   healed	   (~1w).	   Three	   weeks	   were	   allowed	   for	  
transgene	  expression.	  N=3	  animals	  were	  treated	  per	  group.	  	  
	  
2.2.2 Adult	  rat	  ventricular	  cardiomyocyte	  (ARVCM)	  isolation	  
	  
In	   brief,	   rats	  were	   injected	  with	   1000U/kg	   of	   heparin	   (Wockhardt)	   (i.p.)	   prior	   to	   killing,	   in	  
order	   to	   prevent	   thrombosis.	   Hearts	  were	   dissected	   out	   rapidly	   and	   immersed	   in	   ice-­‐cold	  
Krebs	  solution,	  previously	  bubbled	  with	  95%	  O2/5%	  CO2.	  The	  aorta	  was	  then	  cut	  below	  the	  
bifurcation	   point	   and	   cannulated	   into	   a	   Langendorff	   perfusion	   apparatus,	   maintained	   at	  
37˚C.	   Hearts	   were	   first	   perfused	  with	   Krebs	   solution	   for	   5	  minutes.	   Low	   calcium	  medium	  
gassed	   with	   100%	   O2	   was	   then	   perfused	   for	   further	   5	   minutes.	   Finally,	   the	   hearts	   were	  
perfused	  with	  an	  enzyme	  solution,	  gassed	  with	  100%	  O2,	  containing	  1mg/mL	  of	  collagenase	  
(Cooper	  Biomedical	  Inc.)	  and	  0.6mg/mL	  of	  hyaluronidase	  (Sigma-­‐Aldrich	  Ltd.)	  [C&H	  solution],	  
which	  was	   re-­‐circulated	   for	  10	  minutes.	  Hearts	  were	   then	  detached	   from	  the	  cannula	  and	  
the	  atria	  were	   removed.	  Ventricles	  were	  cut	   into	   strips	  and	   transferred	   into	  a	   falcon	   tube	  
with	  C&H	  solution.	  Tissue	  pieces	  were	  shaken	  and	  oxygenated	  for	  5	  minutes.	  After	  recovery	  
of	   isolated	   cells,	   this	   step	   was	   repeated	   on	   the	   remaining	   tissue.	   Cell	   suspensions	   were	  
centrifuged	   at	   low	   speed	   (40G)	   for	   1	  minute	   in	   order	   to	   pull	   down	   exclusively	   large	   cells	  
(cardiomyocytes),	   confirmed	   by	   microscopic	   visualization.	   Cell	   pellets	   were	   then	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resuspended	   and	   isolated	   cardiomyocytes	  were	   finally	   spun	   and	  washed	   three	   times	  with	  
DMEM	  before	  culturing.	  
	  




Breast	  cancer	  cell	   lines	  (BT-­‐474,	  MDA-­‐MB-­‐231)	  and	  H9c2	  cells	  were	  maintained	  in	  150	  cm2	  
flasks	  and	  plated	  in	  dishes	  (6-­‐well,	  24-­‐well,	  etc)	  when	  performing	  experiments.	  All	  cell	  lines	  
were	   kept	   in	   a	   humidified	   incubator	   with	   a	   5%	   CO2	   content	   and	   at	   37°C.	  When	   80-­‐90%	  
confluence	  was	   reached	   in	   the	   flasks,	   cells	  were	  passaged.	  Growth	  medium	  was	  aspirated	  
and	  one	  wash	  with	  warm	  PBS	  was	  performed.	  Cells	  were	  then	  detached	  using	  EDTA-­‐trypsin	  
for	   3-­‐4min	   at	   37°C.	   The	   same	   volume	   of	   EDTA-­‐trypsin	   was	   added	   of	   complete	   (FCS	  
containing)	   growth	   medium	   in	   order	   to	   inactivate	   such	   enzyme.	   Cells	   were	   harvested	   by	  
pipetting	   and	   transferred	   into	   a	   centrifuge	   tube.	   Following	   a	   4min	   spin	   at	   1200rpm,	   the	  
supernatant	  was	  aspirated	  and	  the	  cell	  pellet	  was	  resuspended	  in	  medium.	  The	  obtained	  cell	  
suspension	   was	   counted	   using	   a	   hemocytometer	   if	   necessary	   and	   re-­‐plated	   in	   fresh	  
flasks/dishes	   with	   additional	   growth	   medium.	   Cells	   were	   allowed	   to	   attach	   ON	   prior	   to	  
performing	  any	  experiments.	  In	  order	  to	  preserve	  a	  stock	  for	  each	  cell	  line,	  cell	  pellets	  from	  
low	   passages	   were	   routinely	   resuspended	   in	   freezing	   medium	   (FCS	   with	   10%	   DMSO	   –
dimethyl	  sulfoxide-­‐)	  and	  stored	  in	  cryovials	  in	  liquid	  N2.  
Primary	  isolated	  adult	  rat	  ventricular	  cardiomyocytes	  (ARVCM)	  are	  quiescent	  and	  were	  not	  
passaged.	  Primary	  isolated	  ARVCM	  were	  plated	  in	  laminin	  (Invitrogen)-­‐coated	  6-­‐well	  plates	  
and	  viable	  rod-­‐shaped	  cells	  were	  allowed	  to	  attach	  for	  an	  hour.	  Apoptotic	   floating	  ARVCM	  
were	  then	  discarded	  and	  medium	  was	  renewed	  for	  in	  vitro	  treatments.	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Figure	   16.	   Cultured	   ARVCM	   following	   isolation.	   The	   left	   picture	   shows	   cells	   directly	   after	   plating	   ,including	  
numerous	   floating	   apoptotic	   cardiomyocytes	   (‘popcorn	   cells’).	   On	   the	   right,	   the	  medium	   has	   been	   renewed	  
after	  1h	  of	  allowing	  the	  cells	  to	  attach	  to	  the	   laminin	  coating	  (‘panning	  step’).	  Mostly	  only	  viable	  rod-­‐shaped	  
ARVCM	  remain	  in	  the	  plate.	  	  
	  
2.2.3.2 In	  vitro	  treatments	  
	  
DOX	   (Teva)	   was	   then	   administered	   to	   cultured	   viable	   ARVCM.	   A	   clinically	   relevant	  
concentration	  of	  1µM	  was	  used	  throughout	  114.	  This	  dose	  was	  allowed	  to	  act	  in	  the	  cultures	  
for	  6h	  for	  miRNA	  expression	  level	  check.	  For	  evaluation	  of	  gene	  expression	  changes	  (mRNA	  
and	   protein),	   DOX	   treatments	  were	   conducted	   over	   18h.	   Control	  wells	  were	   treated	  with	  
identical	  volume	  of	  vehicle	  (saline).	  For	  LAP	  studies,	  cultured	  ARVCM	  and	  breast	  cancer	  cells	  
(BT-­‐474)	  were	   treated	   for	  6h	   for	  miRNA	  expression	  measurement	  by	  microarray.	   LAP	   (Cell	  
Signaling)	  was	  used	  at	  a	  5µM	  concentration	  307,	  308.	  	  
	  
2.2.4 Total	  RNA	  extraction	  
	  
For	  RNA	  extraction	   from	  cultured	   cells,	   growth	  medium	  was	  aspirated	   from	   the	  wells	   and	  
two	   PBS	   washes	   were	   performed.	   For	   RNA	   extraction	   from	   tissue,	   tissue	   pieces	   were	  
homogenized	  manually	  in	  1.5mL	  Eppendorf	  (epp)	  tubes.	  Cells/tissue	  were	  then	  lysed	  in	  1mL	  
of	   Trizol®	   reagent	   (Invitrogen)	   and	   incubating	   at	   RT	   for	   5min.	   200µL	   of	   chloroform	   were	  
added	   to	   each	   tube	   and	   vortexed	   vigorously.	   The	   tubes	   were	   then	   centrifuged	   at	   4˚C	   at	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12,000xg	   for	   15min.	   The	   aqueous	   phase	   formed	   at	   the	   top	   of	   the	   solution	   was	   in	   turn	  
transferred	  to	  a	  fresh	  tube	  and	  500µL	  of	  isopropanol	  were	  mixed	  in.	  After	  10min	  incubation	  
at	  RT,	  tubes	  were	  placed	  at	  -­‐80˚C	  for	  a	  minimum	  of	  30min	  and	  up	  to	  ON	  in	  order	  to	  enhance	  
small	   RNA	   precipitation.	   Once	   the	   solution	   thawed	   after	   the	   -­‐80˚C	   step,	   tubes	   were	  
centrifuged	   at	   4˚C	   at	   12,000xg	   for	   10min.	   A	  white	   RNA	  pellet	  was	   observed	   at	   this	   stage,	  
being	   the	   supernatant	   discarded.	   RNA	   pellets	   were	   then	   washed	   in	   1mL	   of	   75%	   ethanol.	  
Following	  a	  5min	  spin	  at	  7,500xg	  at	  4˚C,	  the	  ethanol	  was	  removed	  and	  pellets	  were	  allowed	  
to	  air	  dry	  at	  RT.	  Finally,	  RNA	  pellets	  were	  resuspended	  in	  an	  appropriate	  volume	  of	  RNAse-­‐
free	   water	   and	   quantified	   by	   NanoDrop	   (Wilmington).	   RNA	   integrity	   and	   NanoDrop	  
concentration	  estimation	  were	  checked	  by	  agarose	  gels.	  	  
	  
	  
Figure	  17.	  Example	  of	  RNA	  agarose	  gel	  for	  quality	  check.	  	  
	  
2.2.5 Transfections	  	  
	  
2.2.5.1 Cell	  lines	  
	  
For	   miRNA	   modulation	   or	   gene	   silencing	   using	   siRNA:	   H9c2	   cells	   were	   plated	   at	   40%	  
confluence	   and	   MDA-­‐mB-­‐231	   at	   50%	   in	   6-­‐well	   plates.	   On	   the	   following	   day,	   cells	   were	  
transfected	  with	  20nM	  of	  precursor	  miRNAs	  for	  overexpression	  (pre-­‐30e	  or	  pre-­‐NC;	  Applied	  
Biosystems)	  and	  100nM	  of	  miRCURY	  LNATM	  (LNA	  NC	  or	  LNA	  30,	  Exiqon)	  for	  family	  inhibition.	  
For	   GATA-­‐6	   gene	   silencing,	   a	   working	   concentration	   of	   25nM	   of	   Silencer®	   Select	   siRNA	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(S131118	   Ambion®,	   Life	   Technologies)	   was	   used.	   All	   transfections	   were	   performed	   using	  
HiPerFect	  transfection	  reagent	  (Qiagen)	  for	  72h.	  	  
For	   sponge	   vector	   transfections	   (pEGFP-­‐sp30	   or	   pEGFP-­‐C1	   parental	   control),	   we	   used	  
Lipofectamine	  2000	  (Life	  Technologies	  Ltd)	  on	  90%	  confluent	  cultures	  and	  allowed	  them	  to	  
get	  transfected	  over	  48h,	  in	  antibiotic-­‐free	  medium.	  
For	  3’UTR	   luciferase	  assays:	  H9c2	  cells	  were	  plated	  at	  a	  density	  of	  50.000	  cells/well	   in	  24-­‐
well	  plates	  and	  co-­‐transfected	  the	  following	  day	  with	  100nM	  of	  pre-­‐30e/pre-­‐NC	  and	  100ng	  
of	   the	   corresponding	   pLightSwitch_3’UTR	   GoClone	   plasmid	   for	   each	   target	   3’UTR,	   using	  
Lipofectamine	   2000	   (Life	   Technologies	   Ltd).	   In	   each	   independent	   replicate,	   3	   wells	   were	  
transfected	  per	  condition.	  
	  
2.2.5.2 Primary	  isolated	  ARVCM	  
	  
For	  contractility	  studies,	  primary	  isolated	  ARVCM	  were	  transfected	  in	  6-­‐well	  plates	  and	  kept	  
in	  solution	  (M199	  growth	  medium)	  for	  48h.	  We	  used	  Lipofectamine	  2000	  (Life	  Technologies	  
Ltd)	  and	  a	  molarity	  of	  100nM	  of	  the	  correspondent	  precursor,	  either	  pre-­‐30e	  or	  pre-­‐NC.	  	  
	  
2.2.6 Sponge	  plasmid	  construction	  
	  
The	   pEGFP-­‐sp30	   sponge	   vector	   was	   manufactured	   by	   annealing,	   purifying	   and	   cloning	  
primers	  coding	  for	  six	  bulged	  tandem	  repeats	  of	  mismatched	  miR-­‐30	  binding	  sites.	  The	  insert	  
was	   cloned	   into	   the	   pEGFP-­‐C1	   plasmid	   (Clontech)	   using	   the	   HindIII	   and	   BamHI	   restriction	  
sites,	   as	   3’UTR	   of	   the	   EGFP	   coding	   sequence.	   Double	   digestion	   of	   5μg	   of	   the	   pEGFP-­‐C1	  
parental	   plasmid	   was	   performed	   at	   37˚C	   ON.	   The	   six	   oligonucleotides	   designed	   for	   the	  
sponge	   insert	   were	   resuspended	   in	   annealing	   buffer	   up	   to	   a	   working	   concentration	   of	  
100μM.	   Equal	   volumes	   of	   complementary	   sequences	   (3	   primer	   couples)	   were	   mixed	   in	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microcentrifuge	  tubes	  and	  incubated	  at	  95˚C	  for	  5min.	  The	  heat	  block	  containing	  the	  tubes	  
was	  then	  allowed	  to	  cool	  down	  to	  RT	  gradually	  (~1h).	  Phosphorylation	  of	  the	  middle	  duplex	  
was	  carried	  out	  using	  2µl	  of	  the	  duplex	  solution	  and	  adding:	  0.2	  µl	  of	  100mM	  ATP,	  1	  µl	  of	  T4	  
PNK	  (polynucleotide	  kinase),	  2	  µl	  of	  10X	  PNK	  buffer	  (all	  from	  New	  England	  Biolabs)	  and	  H2O	  
up	  to	  a	  final	  volume	  of	  20	  µl.	  The	  mix	  was	  incubated	  at	  37˚C	  for	  45min.	  The	  digested	  pEGFP-­‐
C1	   and	   annealed	   primer	   couples	  were	   run	   in	   a	   1%	   agarose	   gel.	   The	   corresponding	   bands	  
were	  cut	  and	  eluted	  using	  the	  gel	  DNA	  extraction	  kit	  (Qiagen).	  The	  ligation	  reaction	  was	  set	  
up	  starting	  with	  150ng	  of	  double	  digested	  pEGFP-­‐C1	  plasmid	  and	  4ng	  of	  each	  duplex.	  1	  µl	  of	  
10X	  buffer,	  1µl	  of	  T4	  DNA	  ligase	  (New	  England	  Biolabs)	  and	  H2O	  up	  to	  10µl.	  The	  reaction	  was	  
allowed	   to	   take	   place	   ON	   at	   16˚C.	   Correct	   pEGFP-­‐sp30	   sponge	   vector	   generation	   was	  
confirmed	  by	  sequencing.	  	  
	  
2.2.7 miRNA	  profiling	  
	  
miRNA	  profiling	  was	   performed	  using	  Nanostring	   technology	   (nCounter	  miRNA	  Expression	  
Assay,	  both	  for	  human	  and	  rat)	  and	  required	  150ng	  of	  total	  RNA.	  To	  account	  for	  biological	  
and	   technical	   variability,	   RNA	   from	   three	   independent	   samples	   was	   included	   -­‐each	   in	  
triplicate-­‐	  in	  the	  platform.	  Background	  removal	  of	  the	  raw	  data	  was	  performed	  following	  the	  
producer’s	   instructions	  and	  according	  to	  the	  positive	  and	  negative	  controls	   included	   in	  the	  
profiling.	  Quantile	  normalization	  was	  carried	  out	  using	  Partek	  Genomic	  suite.	  The	  full	  list	  of	  
assayed	   miRNA	   sequences	   and	   complete	   raw	   data	   was	   deposited	   at	   GEO	   under	   the	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2.2.8 Quantitative	  Real	  Time	  PCR	  	  	  
	  
2.2.8.1 Reverse	  transcription	  (RT)	  
	  
The	  reverse	  transcription	  (RT)	  of	  mature	  miRNAs	  was	  performed	  using	  10ng	  of	  total	  RNA	  and	  
the	  TaqMan	  MicroRNA	  Reverse	  Transcription	  Kit	  (Applied	  Biosystems).	  1.5µL	  of	  the	  miRNA-­‐
specific	  TaqMan	  probe	  were	  combined	  with	  6µL	  of	  RNA	  plus	  master	  mix.	  	  
For	   gene	   expression	   quantification,	   the	   RT	   step	   was	   carried	   out	   using	   the	   Superscript	   III	  
Reverse	  Transcriptase	  (Invitrogen)	  and	  the	  reverse	  primer	  of	  the	  couple	  designed	  to	  expand	  
an	  exon-­‐exon	  region.	  0.5-­‐1µg	  of	  total	  RNA	  was	  firstly	  mixed	  with	  50nM	  of	  the	  reverse	  primer	  
and	   incubated	   at	   70°C	   to	   allow	   RNA	   denaturation	   and	   primer	   annealing.	  Master	  mix	   was	  
then	  added	  to	  each	  tube,	  reaching	  a	  volume	  of	  10µL.	  
Reactions	   were	   performed	   by	   incubating	   samples	   in	   a	   7900Ht	   Thermal	   Cycler	   (Applied	  
Biosystems),	   following	   the	   protocol	   specified	   by	   the	   provider	   in	   each	   case.	   Once	   cDNA	  
(complementary	  DNA)	  synthesis	  was	  completed,	  samples	  were	  placed	  on	   ice,	  resuspended	  
in	  an	  appropriate	  volume	  of	  H2O	  and	  prepared	  for	  quantitative	  PCR.	  	  	  
	  
2.2.8.2 Quantitative	  PCR	  (qPCR)	  
	  
For	  miRNA	  expression	   level	  determination,	  1ng	  of	   the	  obtained	  cDNA	  was	  mixed	  with	   the	  
appropriate	  volume	  of	  TaqMan	  Universal	  PCR	  Master	  Mix	  and	  20X	   real-­‐time	  probes	   (both	  
Applied	  Biosystems)	   in	   a	   Fast	  Optical	   96-­‐well	   plate.	   Each	   sample	  was	   assayed	   in	  duplicate	  
and	  the	  small	  nuclear	  (sn)RNA	  U6	  control	  was	  included	  throughout.	  
For	   gene	   expression	   (mRNA)	   levels,	   the	   transcripts	   of	   interest	   were	   amplified	   using	   SYBR	  
Green	  (Applied	  Biosystems)	  and	  the	  correspondent	  forward/reverse	  primers	  (Sigma).	  Three	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wells	   of	   a	   Fast	  Optical	   96-­‐well	   plate	  were	   included	   per	   sample	   as	   technical	   replicates.	   All	  
values	  were	  normalized	  to	  (sn)RNA	  U6.	  For	  both	  TaqMan	  and	  SYBR	  Green	  protocols,	  a	  final	  
volume	  of	  20µL/well	  was	  reached	  (5µL	  cDNA	  dilution	  plus	  15µL	  of	  qPCR	  master	  mix).	  Plates	  
were	   sealed	  with	  Optical	   Adhesive	   Covers	   (Applied	   Biosystems)	   and	   centrifuged	   briefly	   to	  
ensure	  that	  the	  entire	  volume	  was	  at	  the	  bottom	  of	  the	  wells.	  qPCR	  was	  performed	  on	  an	  
ABI	   Prism	   7900HT	   sequence	   detection	   system	   (Applied	   Biosystems)	   and	   40	   amplification	  
cycles	  were	  programed.	  Finally,	  data	  was	  analyzed	  using	  qBasePlus	  software	  (Biogazelle).	  	  
	  
2.2.9 3’UTR	  Luciferase	  reporter	  assays	  	  
	  
After	  24h	  of	  pre-­‐miR	  and	  3’UTR	  plasmid	  co-­‐transfection	  in	  24-­‐well	  tissue	  culture	  plates,	  cells	  
were	   lysed	   with	   50µL/well	   passive	   lysis	   buffer	   (Promega).	   Plates	   were	   then	   agitated	   at	  
medium	  speed	  during	  30min.	  Lysates	  were	  carefully	  transferred	  to	  96-­‐well	  Opti-­‐plates	  and 
50µL	  of	  LightSwitch	  Assay	  System	  reagent	  (Switchgear	  Genomics)	  were	  mixed	  into	  each	  well.	  
Following	  30min	  of	  incubation	  in	  the	  dark	  and	  at	  RT,	  luciferase	  activity	  was	  detected	  using	  a	  
GLOMAX	  96	  microplate	  luminometer	  (Promega).	  	  
	  
2.2.10 Protein	  studies	  -­‐	  Western	  Blotting	  	  
	  
2.2.10.1 Protein	  extraction	  and	  quantification	  
	  
Cell	  pellets	  obtained	  by	  scraping	  or	  trypsinising	  were	  lysed	  in	  an	  appropriate	  volume	  of	  NP-­‐
40	   lysis	   buffer	   (20-­‐60µL),	   containing	   Protease	   Inhibitor	   Cocktail	   (PIC,	   Roche).	   Tubes	  
containing	   the	   lysates	   were	   rotated	   for	   15min	   at	   4°C.	   Lysates	   were	   then	   centrifuged	   at	  
13,000rpm	   for	   further	   15min	   at	   4°C.	   Pellets	   were	   discarded	   and	   supernatants	   containing	  
proteins	  were	  transferred	   into	  a	   fresh	  tube	  for	  protein	  quantification.	  Protein	  content	  was	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quantified	  using	   the	  Bradford	  Reagent	  Kit	   (Bio-­‐Rad)	  and	   in	   relation	   to	  a	   standard	   curve	  of	  
serial	  dilutions	  of	  known	  concentration	  of	  bovine	  serum	  albumin	  (BSA,	  Sigma).	  Absorbance	  
was	   measured	   at	   a	   wavelength	   of	   595nm	   (Beckman	   DU®	   spectrophotometer,	   Harlow	  
Scientific).	  Once	  the	  concentration	  was	  determined,	  3μg/μL	  dilutions	  including	  SDS	  Loading	  
Buffer	  were	  prepared	  for	  Western	  Blotting.	  	  
A	   different	   method	   was	   used	   for	   protein	   extraction	   when	   wanting	   to	   preserve	  
phosphorylation.	  Medium	  was	   aspirated	   from	   the	  wells	   and	   the	   cells	   were	  washed	   twice	  
with	  cold	  PBS	  on	  ice.	  	  Cells	  were	  lysed	  by	  adding	  50μL	  per	  6-­‐well	  of	  boiling	  Laemmli’s	  buffer	  
with	   20%	   of	   1M	   Dithiothreitol	   (DTT).	   A	   viscous	   lysate	   was	   obtained	   by	   scraping	   the	   well	  
surface	  with	   a	   pipette	   tip,	  which	  was	   transferred	   to	   an	   epp	   tube	   and	   incubated	   in	   a	   heat	  
block	  at	  95°C	  for	  5min	  in	  order	  to	  denature	  all	  proteins	  –including	  proteases-­‐.	  Samples	  were	  
then	  sonicated	  (twice	  for	  2sec)	  on	  ice	  to	  reduce	  viscosity	  and	  snap	  frozen.	  	  
	  
2.2.10.2 SDS-­‐polyacrylamide	  electrophoretic	  gel	  
	  
Polyacrylamide	   resolving	   (usually	   10%)	   and	   stacking	   (4%)	   gels	   were	   freshly	   prepared	  
manually.	  Once	  polymerized,	  gels	  were	  disposed	  inside	  the	  electrophoresis	  kit	  (Bio-­‐Rad)	  and	  
the	  kit	  was	  filled	  with	  1xSDS/PAGE	  running	  buffer.	  Combs	  were	  removed	  from	  the	  gels	  and	  
10µL	   of	   the	   protein	   samples	  were	   loaded	   into	   the	  wells.	   10µL	   of	   rainbow	  protein	  marker	  
(Fermentas,	   Thermo	   Scientific)	   were	   also	   loaded	   at	   one	   or	   both	   marginal	   wells.	   SDS-­‐
polyacrylamide	  gel	  electrophoresis	  was	  run	  initially	  at	  80V	  and	  later	  at	  100V	  until	  the	  loading	  
dye	  could	  be	  visualised	  at	  the	  edge	  of	  the	  gel.	  	  
	  
2.2.10.3 Western	  blot	  
	  
Separated	  proteins	  were	  then	  transferred	  onto	  a	  Hybond	  C	  super	  nitrocellulose	  membrane	  
(GE	   Healthcare)	   for	   1h	   using	   a	   Mini-­‐PROTEAN®	   Tetra	   Cell	   kit	   (Bio-­‐Rad),	   at	   100V	   and	   in	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transfer	   buffer.	  Once	   the	   transfer	   step	   finished,	  membranes	  were	   stained	   for	   10min	  with	  
Ponceau	   S	   (Fluka,	   Sigma)	   on	   a	   shaker	   in	   order	   to	   confirm	   correct	   protein	   transfer.	  
Membranes	   were	   blocked	   in	   blocking	   buffer	   for	   1h	   at	   RT	   and	   then	   covered	   in	   primary	  
antibody	  solution.	  Primary	  antibodies	  were	  allowed	  to	  bind	  to	  the	  proteins	  ON	  on	  a	  shaker	  
at	   4°C.	   Three	   10min	   TBST	   washes	   were	   performed.	   Suitable	   secondary	   antibodies	   were	  
diluted	   in	   blocking	   solution	   and	   applied	   covering	   the	   washed	   membranes	   for	   1h	   at	   RT.	  
Following	  three	  additional	  TBST	  washes,	  protein	  bands	  were	  revealed	  using	  Amersham	  ECL	  
(GE	  Healthcare)	  and	  detected	  with	  Hyperfilm	  ECL	  (GE	  Healthcare)	  on	  an	  x-­‐ray	  developer	  or	  
on	   a	   Fusion	   Solo	   Chemi-­‐Imager	   (Vilber).	   Band	   intensity	   was	   quantified	   using	   Image	   J	  
software.	  	  
	  
2.2.11 cAMP	  accumulation	  	  
	  
Treated	  H9c2	  cells	  were	  lysed	  using	  0.1M	  HCl.	  The	  lysates	  were	  then	  assayed	  using	  the	  96-­‐
well	   strip	   cAMP	   EIA	   kit	   (Cayman	   chemical)	   and	   analysed	   according	   to	   manufacturer’s	  
instructions.	  The	  optional	  acetylation	  step	  was	  included	  in	  the	  protocol	  in	  order	  to	  increase	  
sensitivity	   at	   low	   concentrations	   of	   cAMP.	   Blank	   wells	   and	   a	   standard	   curve	   of	   known	  
concentrations	   (S1	   to	   S8,	   ranging	   from	   10pmol/mL	   to	   0.078pmol/L)	   were	   included	   in	  
duplicate.	   At	   least	   duplicate	   wells	   were	   also	   included	   for	   each	   sample	   to	   account	   for	  






Materials	  and	  methods	  
	   86	  
2.2.12 Apoptosis	  assays	  
	  
2.2.12.1 Caspase	  activity	  quantification	  
	  
Apoptosis	   in	   treated	  H9c2	   cultures	  was	  measured	  by	  quantifying	   caspase	  3	  and	   caspase	  7	  
activities,	   according	   to	   manufacturers’	   instructions	   (Caspase-­‐Glo	   3/7	   Assay,	   Promega).	  
Briefly,	   both	  medium	  and	   cells	  were	   collected	   from	  each	  well	   and	  50μl	   of	   cell	   suspension	  
were	   transferred	   to	   a	   96-­‐well	   plate	   in	   duplicate.	   100μl	   of	   Caspase-­‐Glo	   reagent	  were	   then	  
mixed	  into	  each	  well	  an	  incubated	  for	  1h	  at	  RT,	  before	  reading	  luminescence	  intensity	  using	  
a	   PHERAstarPlus	   machine	   (BMG	   Labtech).	   Luminescence	   value	   for	   caspase	   activity	   was	  
normalized	  to	  protein	  content.	  	  
	  
2.2.12.2 Annexin	  V	  apoptosis	  assay	  	  
	  
To	   assess	   the	   apoptotic	   rates	   in	   cardiac	   H9c2	   cultures	   following	   DOX	   treatment	   in	  
combination	  with	  miR-­‐30e	   overexpression,	   cells	  were	   transfected	   (pre-­‐30e	  mimics	   or	   pre-­‐
NC,	  as	  describeded	  in	  2.2.5.1)	  and	  treated	  with	  DOX	  (1μM,	  18h).	  Transfection	  with	  20nM	  of	  
a	  cell	  death	  siRNA	  pool	   (Qiagen)	  was	   included	  throughout	  as	  positive	  control	  of	  cell	  death	  
induction,	   also	   performed	  using	  HiPerfect	   reagent	   and	   during	   72h.	  Once	   treatments	  were	  
completed,	  detached	  cells	  floating	  in	  medium	  were	  recovered	  from	  the	  well	  and	  pooled	  with	  
the	   remaining	   adherent	   cells,	   which	   were	   recovered	   by	   trypsinisation.	   	   Cell	   pellets	   were	  
stained	   with	   the	   Annexin	   V/PE	   apoptosis	   detection	   kit	   (BD	   Biosciences)	   according	   to	   the	  
manufacturer’s	   protocol	   (double	   staining	   with	   annexin	   V/PE	   and	   propidium	   iodide),	   and	  
analysed	  using	  a	  FACSCanto	  II	  flow	  cytometer	  (BD	  Biosciences).	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2.2.13 Reactive	  oxygen	  species	  measurement	  
	  
Levels	   of	  ROS	  generation	   in	   the	   cultures	  were	  measured	  by	  using	   the	  MitoScience	  DCFDA	  
Cellular	  ROS	  Detection	  Assay	  Kit	   (Abcam	  Plc.,	  Cambridge,	  UK),	  according	  to	  manufacturer’s	  
instructions.	  Briefly,	  transfected	  and/or	  treated	  H9c2	  cells	  were	  harvested	  and	  25.000	  cells	  
were	  plated	  per	  96-­‐well,	   allowing	   them	   to	  attach	  ON.	  Culture	  medium	  was	   then	   removed	  
and	   wells	   were	   washed	   with	   the	   provided	   1xBuffer.	   100μl	   of	   2’,7’–dichlorofluorescein	  
diacetate	  (DCFDA)	  containing	  1xBuffer	  were	  added	  to	  the	  wells	  and	  incubated	  in	  the	  dark	  at	  
at	   37°C	   for	   45min.	  Wells	  were	   subsequently	  washed	  with	   1xBuffer.	   Fluorescence	   readings	  
were	  performed	  in	  96-­‐well	  microplates,	  using	  a	  PHERAstarPlus	  machine	  programmed	  with	  an	  
excitation	  wavelength	  of	  485nm	  and	  emission	  wavelength	  of	  535nm.	  
	  
2.2.14 Contractility	  of	  transfected	  ARVCM	  -­‐	  IonOptix	  
	  
Studying	   the	   contractility	   of	   isolated	   ARVCM	   using	   the	   IonOptix	   system	   provides	   several	  
advantages.	  First	  of	  all,	  this	  technique	  allows	  for	  animal	  work	  to	  be	  reduced,	  contributing	  to	  
animal	  welfare.	   In	  addition,	   recording	  contractile	   responses	  of	   treated/transfected	  ARVCM	  
in	   isolation	   enables	   researchers	   to	   investigate	  myocardial	   abnormalities	   at	   a	   cellular	   level	  
and	  obtain	  cell	   type-­‐specific	  data	   that	   is	   independent	  of	   the	  extracellular	  components	  and	  
signals	  that	  occur	  in	  the	  animal	  model.	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Figure	  18.	  IonOptix	  set	  up.	  	  
	  
Following	  48h	  of	  pre-­‐30e/NC	  transfection,	  ARVCM	  were	  recovered,	  resuspended	  in	  enzyme	  
solution	  buffer	  (no	  C&H	  added)	  and	  transferred	  into	  a	  Perspex	  bath	  using	  a	  glass	  coverslip	  as	  
base.	  Cells	  were	  maintained	  at	  37°C	  and	  superfused	  at	  a	  2mL/min	  rate	  with	  Krebs	  solution	  
containing	  1mM	  Ca2+,	  gassed	  with	  95%	  O2/5%	  CO2.	  After	  allowing	  10min	  for	  cells	  to	  sink	  and	  
mildly	   attach	   to	   the	   bottom	   of	   the	   bath,	   cardiomyocytes	   were	   electrically	   stimulated	   at	  
0.5Hz	  (1	  beat	  every	  2	  seconds)	  using	  two	  electrodes	  placed	  on	  each	  side	  of	  the	  Perspex	  bath.	  
An	   inverted	   microscope	   coupled	   to	   a	   video	   camera	   (MyoCam)	   was	   used	   for	   imaging,	  
measuring	  cell	  shortening	  with	  the	  IonOptix	  system	  (IonOptix	  Corp.).	  Of	  the	  ARVCM	  loaded	  
into	  the	  bath,	  a	  single	  rod-­‐shaped	  cell	  with	  clear	  striations	  was	  selected	  for	  analysis	  in	  order	  
to	   maximise	   survival	   through	   isoprenaline	   (ISO)	   dose-­‐response	   curves.	   Under	   baseline	  
conditions,	   3.5-­‐7%	   contractile	   amplitude	   is	   usually	   observed.	   Cells	   falling	   outside	   this	  
baseline	  contractility	  range	  were	  avoided.	  	  
A	  horizontal	  view	  of	  a	  single	  cell	  was	  used	  to	  optically	  track	  the	  contractile	  shortening	  of	  the	  
edges.	  Life	  images	  of	  contracting	  ARVCM	  were	  recorded	  and	  analysed	  using	  the	  Ion	  Wizard	  
software	   (IonOptix	   Corp.).	   Analysis	   parameters	   included	   time	   to	   peak	   contraction	   (Peak	   t)	  
and	   two	   values	   of	   time	   to	   baseline	   relaxation	   (50%,	   90%).	   Values	   were	   presented	   as	   %	  
contraction	  amplitude	  (%	  cell	  shortening),	  averaging	  at	  least	  10	  peaks	  per	  treatment	  per	  cell.	  
Baseline	  cell	  shortening	  was	  determined	  by	  superfused	  with	  drug-­‐free	  Krebs	  solution.	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ISO	  dose-­‐response	  curves	  were	  performed	  by	  adding	  the	  corresponding	  amount	  of	  the	  drug,	  
and	   1.7mM	   L-­‐Ascorbic	   acid	   (Sigma)	   to	   prevent	   its	   degradation	   309,	   to	   the	   gassed	   Krebs	  
solution.	  The	  starting	  ISO	  dose	  was	  1x10-­‐10M,	  gradually	  increasing	  until	  cells	  were	  arrhythmic	  
(~3x10-­‐8M).	  After	  each	  treatment,	  the	  bath	  was	  perfused	  with	  5%	  HCl	  and	  H2O	  to	  clean	  up	  
the	  pipes	  and	  the	  coverslip	  was	  replaced	  to	  load	  a	  new	  fraction	  of	  treated	  ARVCM.	  Pertussis	  
toxin	  (PTX,	  Sigma)	  treatment	  of	  ARVCM	  was	  performed	  at	  a	  1.5µL/mL	  concentration	  for	  3h	  
at	  37°C,	  as	  previously	  optimised	  by	  our	  collaborators	  310.	  Following	  the	  3h	  of	  PTX	  treatment	  
post-­‐transfection,	   contractile	   responses	   to	   stimulation	   with	   increasing	   doses	   of	   ISO	   were	  
performed.	  ARVCM	  from	  6	  different	  preparations	  were	  used	  for	  each	  treatment	  throughout.	  
	  
2.2.15 Chromatin	  immunoprecipitation	  (chIP)	  
	  
H9c2	  cells	  were	  expanded	  and	  seeded	  in	  150cm2	  tissue	  culture	  dishes	  at	  a	  density	  of	  5x106	  
each.	   50	   million	   cells	   were	   needed	   per	   condition	   (GATA-­‐6/IgG).	   Following	   ON	   adhesion,	  
cross-­‐linking	   of	   proteins	   to	  DNA	  was	   achieved	   by	   replacing	   the	  medium	  with	   30mL	   of	   1%	  
formaldehyde	   in	   Fixation	   Buffer	   and	   incubating	   at	   37°C	   for	   10min.	   125mM	  of	   glycine	  was	  
added	   to	   the	   plates	   and	   allowed	   to	   quench	   the	   reaction	   for	   5min	   at	   RT.	   Cells	   were	   then	  
washed	  twice	  with	  ice-­‐cold	  PBS	  and	  scraped	  into	  50mL	  collection	  tubes.	  Following	  a	  10min	  
spin	   at	   2,000rpm	  and	   4°C,	   the	   cell	   pellets	  were	   resuspended	   in	   1mL	   of	   Lysis	   Buffer	   1	   and	  
rotated	  for	  10min	  at	  4°C.	  After	  a	  centrifugation	  step	  performed	  exactly	  as	  the	  previous	  one,	  
pellets	   were	   resuspended	   in	   1mL	   of	   Lysis	   Buffer	   2	   and	   the	   rotation	   step	   was	   repeated.	  
Pellets	  were	   subsequently	   resuspended	   in	   1mL	  of	   Lysis	  Buffer	   3	   and	   the	   volume	  was	   split	  
into	  3	  epp	  tubes.	  Samples	  were	  subjected	  to	  three	  10sec	  rounds	  of	  sonication	  at	  output	  12,	  
on	   ice.	   Lysates	  were	   combined	  again	   and	   centrifuged	  at	   high	   speed	   for	   10min	  at	   4°C.	   The	  
supernatant	  was	   then	   transferred	   to	   a	   fresh	   tube	   and	   100μL	   of	   10%	  Triton	   X-­‐100	   (Sigma)	  
were	  mixed	   in.	  1mL	  of	   the	  volume	  was	  preserved	   for	  chIP,	  50μL	  were	  stored	  as	   Input	  and	  
10μL	  were	  run	  in	  a	  1%	  agarose	  gel	  to	  check	  DNA	  sonication.	  Prior	  to	  immunoprecipitation,	  
antibody	  was	  bound	  to	  the	  magnetic	  beads.	  100μL	  of	  Protein	  G	  or	  A	  (for	  rabbit	  antibodies)	  
Dynabeads®	   (Novex,	   life	   technologies)	   were	   used	   per	   sample.	   Beads	   were	   washed	   three	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times	  with	  1mL	  of	  Block	  Solution,	  collecting	   the	  beads	  using	  a	  magnetic	   stand	   (Invitrogen)	  
between	  washes.	   Beads	  were	   resuspended	   in	   Block	   Solution	   containing	   10μg	   of	   antibody	  
(final	   volume	   of	   250μL)	   and	   rotated	   ON	   at	   4°C.	   Unbound	   antibody	   was	   removed	   by	  
performing	   three	   washes	   in	   1mL	   of	   Block	   Solution.	   After	   the	   last	   wash,	   100μL	   of	   Block	  
Solution	  was	  added	  to	  the	  antibody-­‐beads	  complex	  and	  topped	  with	  1mL	  of	  the	  lysate.	  The	  
mix	   was	   rotated	   ON	   at	   4°C.	   Beads	   were	   collected	   with	   a	  magnetic	   stand	   and	   washed	   six	  
times	   with	   1mL	   of	   RIPA	   Buffer.	   One	   extra	   was	   performed	   with	   1mL	   TBS	   containing	   PIC	  
(Roche).	  Beads	  were	  collected	  again	  and	  DNA	  was	  eluted	  from	  the	  antibody-­‐bead	  complex	  
by	  adding	  200μL	  of	  freshly	  made	  Elution	  Buffer	  and	  shaking	  the	  tubes	  at	  RT	  for	  30min.	  Using	  
the	  magnetic	   stand,	   the	   supernatant	  was	   transferred	   into	   a	   fresh	   tube	   and	   reverse	   cross-­‐
linking	  was	   carried	   out	   on	   a	   heat	   block	   at	   65°C	   for	   6-­‐18h.	   150μL	   Elution	   Buffer	  were	   also	  
added	  to	  Input	  samples	  before	  proceeding	  to	  do	  the	  reverse	  cross-­‐linking.	  200μL	  of	  TE	  buffer	  
(Qiagen)	  and	  4μL	  of	  10mg/mL	  RNase	  A	  (Qiagen)	  were	  mixed	  into	  the	  samples	  and	  incubated	  
at	  37°C	  for	  30min.	  4μL	  of	  20mg/mL	  Proteinase	  K	  (New	  England	  Biolabs)	  were	  then	  added	  to	  
the	   samples	   and	   allowed	   to	   act	   at	   55°C	   for	   2h.	   400μL	   of	   [25%]phenol-­‐[24%]chloroform-­‐
[1%]isoamyl	  alcohol	  (Sigma)	  were	  added	  and	  tubes	  were	  centrifuged	  at	  high	  speed	  for	  5min.	  
The	  aqueous	  phase	  formed	  was	  transferred	  to	  a	  fresh	  tube	  and	  200mM	  NaCl	  and	  800μL	  of	  
absolute	  ethanol	  were	  added	  and	  vortexed	  vigorously.	  The	  mix	  was	  incubated	  at	  -­‐80°C	  for	  at	  
least	   30min.	   DNA	   was	   then	   pelleted	   and	   washed	   with	   1mL	   of	   80%	   ethanol,	   and	   then	  
centrifuged	  for	  further	  5min	  at	  high	  speed.	  Purified	  DNA	  pellets	  were	  allowed	  to	  air	  dry	  and	  
subsequently	  resuspended	  in	  30μL	  of	  10mM	  Tris-­‐HCl	  pH	  8.0	  (in	  150μL	  for	  Input	  samples).	  	  
	  
2.2.16 Cell	  proliferation	  assays	  
	  
Cell	  proliferation	  of	  MDA-­‐MB-­‐231	  cells	  was	  analyzed	   in	   response	   to	  modulation	  of	  miR-­‐30	  
levels	  by	  sulfoRHOdamine	  B	  colorimetric	  (SRB)	  assays.	  1.5x103	  cells/well	  were	  plated	  in	  96-­‐
well	   tissue	  culture	  plates.	  After	  allowing	  cells	   to	  attach	  ON,	   transfections	   (pre-­‐miR	  or	  LNA)	  
were	   performed	   over	   72h	   in	   quintuplicates.	   The	   day	   when	   the	   transfection	   period	   was	  
complete	  was	  considered	  Day	  0.	  One	  plate	  was	  assayed	  every	  other	  day	  up	  to	  day	  7	  (Day	  1,	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3,	   5	   and	   7).	   On	   each	   of	   these	   days,	   cells	   were	   fixed	   by	   adding	   100μL/well	   of	   cold	  
trichloroacetic	  acid	   (TCA)	  and	   incubating	  at	  4°C	   for	  1h.	  Wells	  were	  then	  washed	  five	  times	  
with	   tap	  water,	   removing	  excess	  water	  by	   tapping	   firmly	  after	   the	   last	  wash.	   Staining	  was	  
carried	   out	   by	   adding	   100μL/well	   of	   0.4%	   (w/v)	   SRB	   buffer	   (Sigma)	   in	   1%	   acetic	   acid.	  
Following	  30min	  at	  RT,	  plates	  were	  washed	  with	  1%	  acetic	  acid	  five	  times	  and	  plates	  were	  
allowed	   to	   air-­‐dry	   upside	   down	   ON.	   All	   plates	   were	   read	   on	   Day	   7,	   being	   the	   SRB	   stain	  
solubilized	   in	   each	   well	   with	   100μL	   of	   10mM	   Tris-­‐base	   solution.	   Plates	   were	   places	   in	   a	  
rocking	   shaker	   for	   10min	   prior	   to	   absorbance	   reading	   at	   492nm	   using	   an	   InfiniteTM	   200	  
quad-­‐4	  spectrophotometer	  (Tecan	  UK	  Ltd.). 
	  
2.2.17 Transwell	  migration	  assays	  
	  
Highly	  motile	  MDA-­‐MB-­‐231	  cells	  were	  used	  for	  transwell	  assays.	  Transfection	  of	  precursors	  
(pre-­‐30e	   and	   pre-­‐NC,	   20nM)	   and	   of	   the	   sponge	   vector	   (pEGFP-­‐sp30	   or	   pEGFP-­‐C1	   control)	  
was	  performed	   in	   6-­‐well	   plates,	   for	   72h	   and	  48h	   respectively.	   Cells	  were	   trypsinized	   after	  
transfection	   and	   counted	   using	   a	   Scepter™	   handheld	   cell	   counter	   (Millipore)	   to	   ensure	  
accurate	   values.	   50,000	   cells	   were	   plated	   in	   triplicate	   on	   each	   8μm	   pore	   Transwell®	  
Polycarbonate	  Membrane	   insert	   (BD	  Biosciences),	   fitted	   into	  24-­‐well	  plates.	  Medium	  used	  
for	   plating	   was	   serum-­‐free,	   and	   cells	   were	   allowed	   to	   migrate	   towards	   complete	   growth	  
medium	  placed	  at	  the	  bottom	  of	  the	  well	  through	  the	  porous	  membranes.	  After	  9h,	  medium	  
was	  removed	  and	  membranes	  were	  fixed	  with	  4%	  (w/v)	  paraformaldehyde	  (PFA)	  at	  37°C	  for	  
30min.	   Cells	   on	  both	   sides	  of	   the	   insert	  membranes	  were	   stained	  with	   0.2%	   crystal	   violet	  
diluted	   in	  20%	  methanol	   for	  a	   further	  30min	  at	  37°C.	  Following	  staining,	  membranes	  were	  
thoroughly	  washed	  in	  PBS	  until	  no	  blue	  solution	  was	  left	   in	  the	  chamber	  (5	  times	  at	   least).	  
Cells	  on	  the	  upper	  surface	  of	  the	  membrane	  	  (non-­‐migrated)	  were	  removed	  using	  a	  cotton	  
swab.	  Inserts	  were	  then	  cut	  using	  a	  scalpel	  and	  sealed	  on	  glass	  slides,	  with	  the	  bottom	  side	  
(containing	   migrated	   cells)	   facing	   upwards	   for	   imaging.	   Cells	   were	   visualised	   on	   an	   ACIS	  
ChromaVision	   microscope	   (ChromaVision	  Medical	   Systems	   Inc.),	   under	   the	   10x	   objective.	  
Five	   fields	   were	   imaged	   per	   insert,	   and	   three	   inserts	   were	   assayed	   per	   sample.	   Three	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independent	   experiments	   were	   included	   throughout.	   Migrating	   cells	   per	   field	   were	  
quantified	  manually	  using	  ImageJ	  software.	  
	  
2.2.18 Generation	  of	  AAV	  vectors	  
	  
The	  AAV9.LacZ	  and	  AAV.miR30e	  viruses	  used	  in	  this	  research	  were	  kindly	  manufactured	  by	  
Prof.	   Giacca’s	   team	   at	   the	   AAV	   Vector	   Unit	   of	   the	   International	   Centre	   for	   Genetic	  
Engineering	   and	   Biotechnology	   Trieste,	   as	   described	   previously	   311. For	   the	   AAV9.miR30e	  
vector,	   the	   precursor	   sequence	   of	   the	   human	  miR-­‐30e	   (pre-­‐miR-­‐30e)	  was	   cloned	   into	   the	  
multiclonning	   site	  of	   an	  engineered	   the	  pAAV-­‐MCS	   (Agilent	  Technologies)	  plasmid.	  Briefly,	  
rAAV	   particles	   were	   generated	   in	   HEK293T	   cultures	   by	   cross-­‐packaging	   of	   the	   transgene-­‐
containing	   genome	   into	   serotype	  9	  AAV	   capsids	   312.	   rAAV	   titers	   in	   dialyzed	   fractions	  were	  
determined	   by	   copy	   number	   measurement	   via	   PCR	   313;	   stocks	   typically	   ranging	   between	  
1x1012	  and	  1x1013	  viral	  genomes	  (vg)	  per	  mL	  of	  solution.	  	  
	  
	  
Figure	  19.	  Map	  of	  the	  pAAV-­‐MCS	  used	  to	  create	  AAV9.miR30e.	  The	  sequence	  coding	  for	  the	  human	  pre-­‐miR-­‐
30e	  was	  cloned	  into	  the	  MCS	  of	  the	  pAAV-­‐MCS	  plasmid	  in	  order	  to	  generate	  the	  genome	  of	  the	  rAAV	  for	  miR-­‐
30e	  overexpression.	  Cross-­‐encapsidation	  was	  performed	  with	  the	  serotype	  9	  AAV	  capsid.	  	  
	  
!"#$%&'$()#**
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2.2.19 LacZ	  reporter	  detection	  
	  
2.2.19.1 LacZ	  tissue	  staining	  
	  
The	  base	  of	  harvested	  hearts	  was	  minced	  in	  cold	  PBS/MgCl2	  solution	  for	  tissue	  homogenate	  
staining,	   using	   the	   LacZ	   tissue	   staining	   kit	   (InvivoGen).	  Minced	   tissue	  was	   fixed	   in	   Fixative	  
Solution	  for	  1h	  on	  ice.	  Tissue	  pieces	  were	  then	  washed	  several	  times	  with	  PBS	  and	  incubated	  
in	  Staining	  Solution	  for	  4h	  at	  37ᵒC.	  The	  Staining	  Solution	  was	  then	  discarded	  and	  the	  tissue	  
was	  washed	  in	  PBS	  repeatedly	  until	  clear.	  Minced	  tissue	  was	  then	  left	  in	  PBS	  at	  RT	  ON	  for	  the	  
blue	  LacZ	  precipitates	  to	  develop	  and	  colour	  was	  assessed	  the	  following	  day.	  	  	  
	  
2.2.19.2 LacZ	  histochemistry	  
	  
Fresh	   hearts	  were	   rinsed	   in	   cold	   PBS,	   embedded	   in	   Tissue-­‐Tek®	  O.C.T	   compound	   (Sakura)	  
and	   flash	   frozen	   for	   histochemistry	   in	   iso-­‐pentane	   placed	   on	   top	   of	   a	   liquid	   nitrogen	  
container.	   10μM	   sections	  were	   cut	   using	   a	   cryostat,	   spaced	  by	   intervals	   of	   300μM.	   10μM	  
sections	  were	  also	  obtained	   from	   liver	  and	  skeletal	  muscle	  of	  studied	  animals.	  Slides	  were	  
next	  fixed	  for	  15min	  in	  PBS/2mM	  MgCl2/0.1%	  glutaraldehyde/1.5%	  formaldehyde,	  and	  then	  
washed	  3	  times	  in	  PBS/0.02%	  NP-­‐40,	  for	  10min	  each	  time.	  The	  slides	  were	  incubated	  in	  LacZ	  
staining	   solution	   [PBS	   containing	   1mg/ml	   X-­‐Gal	   (Thermo	   Scientific),	   5mM	   K-­‐ferrOcyanide,	  
5mM	  K-­‐ferrIcyanide,	  2mM	  MgCl2,	  0.01%	  Na	  deoxycholate,	  0.02%	  Igepal	  (all	  from	  Sigma)]	  at	  
37ᵒC	  ON.	  Slides	  were	  subsequently	  rinsed	  with	  PBS	  and	  miliQ	  H2O	  and	  counterstained	  with	  
Hematoxilin	   and	   Eosin	   as	   follows:	   slides	   were	   submerged	   in	   Hematoxilin	   solution	   (Merck	  
Millipore)	   for	   30s	   and	   washed	   with	   tap	   water	   prior	   to	   staining	   with	   Eosin	   solution	   (0.5%	  
aqueous,	  Merck	  Millipore)	  during	  another	  30s.	  After	  a	   last	  wash	   in	  miliQ	  H2O,	   slides	  were	  
dehydrated	   in	   an	   ethanol	   (etOH)-­‐xylene	   gradient.	   Slides	   were	   sequentially	   submerged	   in	  
each	  of	  these	  etOH	  dilutions	  for	  5min:	  50%,	  70%,	  90%	  and	  100%.	  Finally,	  they	  were	  placed	  in	  
Materials	  and	  methods	  
	   94	  
pure	  xylene	  for	  10min	  before	  allowing	  them	  to	  air-­‐dry.	  Glass	  coverslips	  were	  then	  added	  to	  
the	  slides	  and	  nail	  varnish	  was	  used	  around	  the	  edges	  for	  mounting.	  Pictures	  of	  the	  stained	  
tissue	  slices	  were	  obtained	  using	  an	  Olympus	  DP70	  microscope.	  	  
	  
2.2.20 Statistical	  analysis	  	  
	  
Unless	   differently	   stated,	   data	   are	   presented	   as	   mean	   ±	   SEM	   calculated	   using	   Prism	   5	  
(GraphPad	   Software	   Inc.,	   CA,	   USA).	   Student’s	   t	   test	   was	   used	   for	   value	   comparison,	  
considering	  p<0.05	  as	  significance	  threshold.	  To	  analyse	  the	  contractile	  responses	  of	  isolated	  
ARVCM	  to	  increasing	  concentrations	  of	  isoproterenol,	  F	  tests	  were	  performed.	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Part	  I	  –	  Investigation	  of	  cardiac	  microRNA	  alteration	  by	  
anticancer	  agents	  lapatinib	  and	  doxorubicin	  
	  
3.1 Evaluation	  of	  cardiac	  microRNA	  expression	  upon	  HER2	  blockade	  
	  
Targeted	  therapies	  aim	  to	  target	  tumour	  cells	  more	  specifically.	  However,	  in	  spite	  of	  careful	  
target	  selection,	  some	  of	  the	  molecules	  are	  essential	  in	  other	  tissues.	  Examples	  of	  this	  that	  
affect	  the	  cardiovascular	  system	  include	  antiangiogenic	  therapies	  using	  VEGF	  inhibitors	  and	  
HER2	  blockers	  204,	  314.	  The	  sharing	  of	  central	  pathways	  by	  tumour	  cells	  and	  cardiomyocytes	  is	  
a	  drawback	  for	  the	  safety	  of	  these	  drugs,	  as	  it	  became	  apparent	  during	  the	  TRZ	  trials	  179.	  TRZ	  
is	  a	  humanized	  antibody	  that	  recognizes	  an	  extracellular	  epitope	  of	  the	  human	  HER2,	  while	  
LAP	   is	  a	   small	   inhibitor	  able	   to	  block	  both	  EGFR	  and	  HER2	  by	  binding	   to	   their	   intracellular	  
domain	  178,	  315.	  Although	  the	  associated	  risk	  of	  congestive	  HF	  observed	   in	  clinical	   trials	  was	  
greater	   for	   TRZ	   than	   for	   LAP	   179,	  192,	  316,	  we	   used	   LAP	   in	   our	   studies	   as	  we	   treated	   rats	   as	  
model	  of	  study	  and	  TRZ	  activity	  is	  limited	  to	  human	  cells.	  	  
At	  present,	  alterations	  of	  miRNA	  expression	  levels	  in	  response	  to	  LAP	  (in	  tumours	  and	  in	  the	  
heart)	  are	  yet	  to	  be	  described.	  We	  thus	  wished	  to	  explore	  this	  unknown	  aspect,	  aiming	  to	  
contribute	   to	   the	   limited	   knowledge	   about	   the	   molecular	   mechanisms	   implicated	   in	   the	  
cellular	   effects	   of	   LAP	   downstream	   of	   EGFR/HER2	   inhibition.	   Unveiling	   aberrant	   miRNA	  
expression	  associated	  with	  the	  cardiotoxicity	  deriving	  from	  HER2	  blockade	  could	  importantly	  
provide	  prognostic	  and	  diagnostic	  biomarkers	  as	  well	  as	  potential	  therapeutic	  targets.	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3.1.1 In	   vivo	   lapatinib	   treatment	   using	   osmotic	   minipumps	   –	   a	   pilot	  
study	  
	  
In	  collaboration	  with	  Dr.	  Alexander	  Lyon,	  we	  attempted	  to	  establish	  an	  in	  vivo	  model	  of	  LAP-­‐
induced	  cardiac	  injury.	  For	  this	  purpose,	  we	  designed	  a	  pilot	  study	  on	  small	  n	  numbers	  and	  
using	   age-­‐matched	   animals	   as	   control.	   The	   objective	   of	   this	   experiment	   was	   mainly	   to	  
evaluate	  whether	  LAP	  was	  able	  to	  block	  the	  EGFR/HER2	  pathway	  in	  the	  heart.	  We	  decided	  to	  
use	   osmotic	   minipumps	   as	   method	   for	   continuous	   drug	   diffusion.	   We	   loaded	   2mL	  
minipumps	  with	  sufficient	  LAP	  solution	  to	  deliver	  a	  clinically	  relevant	  dose	  of	  10mg/kg/d	  176,	  
and	  implanted	  them	  in	  the	  scruff.	  After	  7	  days,	  hearts	  were	  harvested	  for	  characterisation.	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Quantification	   ERK1/2	   phosphorylation	   (p-­‐ERK1/2)	   -­‐leading	   to	   kinase	   activation-­‐	   has	   been	  
described	   as	   a	   valid	   downstream	   indication	   of	   HER2	   blockage	   by	   TKI	   315.	   Therefore,	   we	  
quantified	   p-­‐ERK1/2	   levels	   in	   treated	   hearts	   as	   indication	   of	   LAP	   inhibitory	   activity	   in	   our	  
tissue	   of	   interest	   post-­‐minipump	   implantation.	   However,	   no	   concluding	   results	   were	  





Figure	  21.	  P-­‐ERK1/2	  levels	  in	  animals	  implanted	  with	  LAP-­‐loaded	  minipumps	  for	  1	  week.	  Left	  panel:	  Western	  
Blot	   protein	   bands	   for	   p-­‐ERK1/2,	   ERK1/2	   and	   GAPDH.	   Total	   protein	   staining	   with	   Ponceau	   also	   included	   as	  
normalizer.	  Right	  panel:	  densitometric	  quantification	  of	  the	  bands	  performed	  by	  ImageJ	  analysis,	  expressed	  as	  
ratio	   of	   p-­‐ERK1/2	   levels	   to	   the	   three	   normalizers	   (total	   ERK1/2,	  GAPDH	  and	  ponceau).	   Control	   hearts	   (CON)	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3.1.2 Acute	   lapatinib	   treatment	   does	   not	   trigger	   biologically	   relevant	  
changes	  in	  myocardial	  microRNA	  expression	  
	  
A	   circumstantial	   factor	   that	   greatly	   limited	   the	  progress	  of	   the	   in	   vivo	   experiments	   at	   this	  
stage	   was	   the	   closure	   of	   the	   Central	   Biomedical	   Services	   (CBS)	   at	   the	   Royal	   Brompton	  
Hospital,	  were	  our	  studies	  were	  being	  carried	  out.	  Meanwhile,	  we	  decided	  to	  investigate	  the	  
miRNA	  expression	  patterns	  deriving	  from	  LAP	  treatment	  in	  vitro,	  performed	  both	  on	  breast	  
cancer	  cells	  (BCC)	  -­‐to	  replicate	  the	  clinical	  use	  of	  LAP	  on	  HER2+	  BC	  patients-­‐	  and	  on	  cultured	  
adult	  rat	  ventricular	  cardiomyocytes	  (ARVCM).	  	  
BCC	  are	  classified,	  apart	  from	  other	  molecular	  parameters,	  according	  to	  their	  level	  of	  HER2	  
receptor	   expression.	   Examples	   of	   HER2-­‐overexpressing	   BCC	   are	   SKBR3,	   BT474,	   and	   ZR-­‐75;	  
while	  MDA-­‐MB-­‐231,	  MCF-­‐7	  and	  T47D	  are	  some	  of	   the	  BCC	  classified	  as	  HER2-­‐negative	   128.	  
Only	  BCC	  presenting	  high	  HER2	  expression	  are	  predicted	  to	  be	  responsive	  to	  TRZ	  and	  LAP,	  
due	  to	  their	   targeted	  mechanism	  of	  action.	  Out	  of	   the	  HER2-­‐overexpressing	  BCC	  available,	  
we	   chose	   BT474	   because	   it	   has	   been	   described	   as	   the	   most	   susceptible	   line	   to	   HER2	  
blockage	  317.	  
In	  order	  to	  determine	  whether	  optimization	  of	  the	  initial	  in	  vivo	  model	  of	  LAP	  administration	  
was	  worthy	  for	  the	  study	  of	  potential	  miRNA-­‐mediated	  mechanisms,	  we	  performed	  a	  miRNA	  
profiling	   of	   acute	   in	   vitro	   LAP	   treatments.	   LAP	   was	   administered	   to	   BT474	   and	   ARVCM	  
cultures	   for	  6h	   in	  order	   to	  allow	   for	   any	   transcriptional	   changes	   leading	   to	  altered	  miRNA	  
levels	   to	   occur	   318.	   Once	   again,	   p-­‐ERK1/2	   levels	   were	   used	   as	   an	   indication	   of	   LAP	   HER2-­‐
blocking	  activity	  and	  were	  measured	  prior	  to	  considering	  the	  in	  vitro	  LAP-­‐treated	  samples	  for	  
miRNA	   profiling	   by	   microarray.	   Even	   tough	   no	   consistent	   reductions	   in	   p-­‐ERK1/2	   were	  
observed	  in	  the	  hearts	  of	  LAP	  minipump-­‐implanted	  animals	  (Figure	  21),	  decreased	  p-­‐ERK1/2	  
was	  detected	  in	  LAP-­‐treated	  ARVCM	  and	  BT474	  BCC	  in	  vitro	  (Figure	  22).	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Figure	  22.	  LAP	  represses	  downstream	  ERK1/2	  phosphorylation.	  Western	  Blots	  showing	  p-­‐ERK1/2	  expression	  
following	  acute	  LAP	  treatment	  (5μM,	  6h)	  on	  A.	  2	  BCC:	  BT474	  (HER2+)	  and	  MDA-­‐MB-­‐231	  (HER2-­‐),	  normalising	  to	  
tubulin	  protein	  levels.	  B.	  ARVCM,	  normalising	  to	  both	  total	  ERK1/2	  levels	  and	  tubulin	  	  (**	  p<0.01).	  
	  
Therefore,	  we	  proceeded	  to	  identify	  the	  miRNA	  signatures	  of	  LAP-­‐treated	  BT474	  BCC	  as	  well	  
as	  primary	  isolated	  ARVCM.	  For	  this	  purpose,	  two	  different	  platforms	  were	  used:	  NanoString	  
nCounter®	   v2	   Human	   microRNA	   assay	   was	   used	   for	   BT474	   samples	   and	   NanoString	  
nCounter®	   Rat	   microRNA	   expression	   assay	   kit	   was	   used	   for	   ARVCM	   (See	   2.2.7).	   The	  
stringency	   criteria	   applied	   in	   the	   posterior	   miRNA	   profiling	   analyses	   comprised	   a	   p	   value	  
<0.05	   for	  statistical	   significance,	  an	  expression	  change	  of	  at	   least	  ±1.5	   folds	   relative	   to	   the	  
control,	  and	  a	  minimum	  of	  50	  copies	  counted	  per	  sample.	  
As	   represented	   in	  Figure	   23A,	   LAP	  was	   able	   to	   substantially	   up/down-­‐regulate	   the	  miRNA	  
expression	  of	  HER2-­‐overexpressing	  BT474	  BCC.	  One	  of	  our	  initial	  hypotheses	  with	  regard	  to	  
the	  possible	  contribution	  of	  miRNA-­‐mediated	  mechanisms	  to	  the	  cytotoxicity	  of	  LAP	  was	  the	  
identification	  of	  a	  shared	  miRNA	  signature	  by	  LAP-­‐treated	  cancer	  cells	  and	  cardiomyocytes.	  
However,	  ARVCM	  did	  not	  show	  a	  significantly	  altered	  miRNA	  signature	  upon	  acute	  exposure	  
to	   LAP	   in	   vitro.	   The	   bar	   graph	   in	   Figure	   23B	   illustrates	   the	   low	   expression	   levels	   of	   the	  
miRNAs	   that	   appeared	   to	   be	   dysregulated	   by	   LAP	   treatment.	   This	   was	   considered	   as	   a	  
potential	  reason	  for	  misinterpretation	  of	  the	  data;	  and	  any	  results	  involving	  miRNA	  scoring	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Figure	  23.	  Lapatinib-­‐induced	  miRNA	  alterations	  in	  BT474	  breast	  cancer	  cells	  and	  ARVCM.	  A.	  miRNA	  profiling	  
of	  BT474	  BCC	  treated	  with	  LAP	  (5μM,	  6h).	  36	  miRNAs	  presented	  with	  statistically	  significant	  altered	   (p<0.05)	  
expression	  levels	  by	  ≥1.5	  folds.	  B.	  miRNA	  profiling	  of	  primary	  isolated	  ARVCM	  treated	  with	  LAP	  (5μM,	  6h).	  Only	  
8	   miRNAs	   presented	   significantly	   (p<0.05)	   dysregulated	   levels.	   The	   expression	   of	   6	   out	   of	   these	   8	   miRNAs	  
changed	  by	  ≥1.5	  folds,	  although	  the	  minimum	  count	  of	  50	  copies	  considered	  as	  background	  threshold	  was	  not	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These	   findings	   led	   to	   an	   important	   change	   of	   direction	   in	   the	   project.	   In	   the	   light	   of	   the	  
miRNA	  profiling	  results	  from	  LAP-­‐treated	  ARVCM,	  we	  determined	  that	  our	  efforts	  to	  unravel	  
the	   importance	   of	   miRNA	   in	   cardiotoxicity	   associated	   with	   anticancer	   therapy	   should	   be	  
focused	   in	   other	   types	   of	   anti-­‐cancer	   agents	   than	   TKI.	   Consequently,	   we	   proceeded	   to	  
explore	   the	   myocardial	   effects	   of	   doxorubicin,	   maintaining	   miRNA	   regulation	   as	   central	  
focus.	  	  
	  
3.2 Doxorubicin	  induces	  changes	  in	  myocardial	  microRNA	  levels	  upon	  
both	  acute	  and	  sustained	  administration	  	  
	  
3.2.1 MicroRNA	  alteration	  profiling	  in	  doxorubicin	  cardiotoxicity	  
	  
At	  the	  start	  of	  this	  thesis,	  only	  one	  publication	  reported	  altered	  cardiac	  miRNA	  expression	  in	  
response	  to	  DOX.	  In	  it,	  Horie	  et.	  al	  described	  the	  up-­‐regulation	  of	  a	  miR-­‐146a	  upon	   in	  vitro	  
DOX	   treatment	   of	   neonatal	   cardiomyocytes	   200.	   Since	   then,	   another	   article	   has	   shown	  
evidence	   for	   substantially	   altered	  miRNA	   signature	   in	   DOX-­‐treated	   hearts	   319.	   However,	   a	  
global	   cardiomyocyte-­‐specific	  miRNA	   profiling	   is	   still	   lacking.	  We	   found	   this	   limiting	   given	  
that	   DOX-­‐induced	   cardiotoxicity	   usually	   displays	   in	   the	   form	   of	   cardiomyopathy	   and	  
therefore	  affects	  mainly	  cardiac	  myocytes	  141,	  159,	  and	  we	  wished	  to	  investigate	  the	  changes	  
in	  miRNA	  expression	  occurring	  particularly	  in	  this	  cell	  type.	  	  
For	  this	  purpose,	  we	  set	  up	  several	  models	  of	  study.	  Firstly,	  we	  established	  a	  model	  of	  DOX-­‐
induced	   HF	   in	   vivo.	   Although	   DOX	   has	   also	   been	   delivered	   in	   vivo	   via	   the	   use	   of	   osmotic	  
minipumps	   129,	   320,	   we	   decided	   to	   minimise	   surgical	   procedures	   and	   followed	   the	   well-­‐
described	   model	   of	   DOX-­‐induced	   heart	   failure	   by	   performing	   serial	   intra-­‐peritoneal	   (i.p.)	  
injections	   of	   the	   drug	   at	   a	   clinically	   relevant	   dose	   (15mg/kg	   cumulative	   dose)	   159,	   321.	   In	  
parallel,	   in	  order	  to	  evaluate	  acute	  alterations	   in	  miRNA	  induced	  by	  DOX,	  we	  administered	  
DOX	   to	   cultured	   ARVCM	   for	   6h.	   Most	   patients	   receiving	   DOX	   treatment	   exhibit	   a	   drug	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concentration	   in	   plasma	   raging	   between	   1	   and	   2µM.	  We	   thus	   chose	   1µM	   for	   all	   in	   vitro	  
treatments	  116.	  A	  third	  model	  of	  cardiac	  injury	  was	  included	  in	  the	  miRNA	  profiling:	  a	  post-­‐
myocardial	   infarction	   (MI)	   model,	   which	   served	   as	   positive	   control	   of	   severe	   myocardial	  
damage.	  Induced	  by	  proximal	  coronary	  artery	  ligation,	  MI	  leads	  to	  pathological	  hypertrophic	  
remodelling	  of	  the	  ventricles	  at	  4	  weeks	  post-­‐induction	  (4w	  post-­‐MI)	  	  322,	  323	  (Figure	  24).	  	  
	  
	  
Figure	  24.	  Experimental	  design	  for	  miRNA	  profiling.	  Three	  relevant	  models	  of	  cardiac	  toxicity	  were	  included	  in	  
the	  miRNA	  profiling:	  4w	  post-­‐MI,	  DOX	  in	  vivo	  and	  DOX	  in	  vitro	  (1μM,	  6h).	  MI	  was	  induced	  by	  proximal	  coronary	  
ligation.	   DOX-­‐induced	   cardiac	   dysfunction	   was	   achieved	   by	   i.p.	   administration	   of	   DOX	   (15mg/kg	   cumulative	  
dose)	  in	  6	  injections	  of	  2.5mg/kg	  spread	  over	  a	  fortnight.	  For	  both	  in	  vivo	  models,	  ARVCM	  were	  isolated	  prior	  
to	   RNA	   extraction.	   Cardiomyocyte-­‐specific	  miRNA	   profiling	  was	   performed	   on	   the	   rat	  Nanostring	   nCounter®	  
miRNA	  platform,	  using	  150ng	  of	  high-­‐quality	  total	  RNA.	  A	  minimum	  of	  3	  independent	  biological	  replicates	  and	  
3	  technical	  replicates	  were	  included	  in	  the	  microarray	  to	  account	  for	  variability.	  
	  
Raw	  data	  obtained	  from	  the	  miRNA	  profiling	  were	  first	  normalised	  for	  several	  housekeeping	  
genes	   included	   in	   the	   platform,	   the	   background	   was	   then	   removed	   and	   quantile	  
normalization	  was	  performed	   following	   the	  producers’	   instructions.	  Partek®	  Genome	  Suite	  
software	   was	   used	   for	   identification	   of	   differentially	   expressed	   miRNAs.	   Graphs	   showing	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fold	  changes	  were	  generated	  for	  each	  of	  the	  profiled	  models	  (DOX	  in	  vitro,	  DOX	  in	  vivo,	  4w	  
post-­‐MI)	  (Figure	  25).	  The	  aberrant	  expression	  levels	  detected	  for	  a	  group	  of	  miRNAs	  in	  the	  
different	   models	   assayed	   ranged	   mostly	   between	   1.5	   and	   3.5	   folds	   in	   relation	   to	   the	  
respective	  controls	  (Figure	  25B,	  D	  and	  F).	  	  
The	  signatures	  of	  differential	  miRNA	  expression	  detected	  in	  our	  experiment	  partially	  overlap	  
with	  published	  data	  (Table	  9),	  confirming	  the	  validity	  of	  our	  methods.	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Figure	  25.	  Graphic	  representation	  of	  the	  miRNA	  profiling	  results.	  A.	  miRNAs	  presenting	  altered	  expression	  in	  
cardiomyocytes	  after	  DOX	  treatment	  in	  vitro	  (6h,	  1μM).	  C.	  Differentially	  expressed	  miRNAs	  in	  our	  DOX-­‐induced	  
HF	  in	  vivo	  model	  (15mg/kg).	  E.	  Deregulated	  miRNA	  expression	  detected	  for	  ARVCM	  4w	  post-­‐MI.	  All	  values	  are	  
represented	  as	  averaged	  ratio	  (fold	  change)	  to	  the	  respective	  controls.	  Red	  circles	   indicate	  up-­‐regulation	  and	  
blue	  circles	  down-­‐regulation.	  +/-­‐	  1.5	  fold	  change	  threshold	  shown	  as	  a	  yellow	  line.	  B,	  D,	  F.	  Histogram	  showing	  
frequency	  distribution	  for	  fold	  change	  values.	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Up-­‐regulated	   	  	  
	   	   	   	   	   	   	  
miRNA	  
	  
DOX	  (in	  vitro)	   DOX	  (in	  vivo)	   4w	  post-­‐MI	   Existing	  evidence	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Table	  9.	  Altered	  miRNAs	  overlapping	  across	  models	  and	  existing	  evidence	  of	  implication	  in	  heart	  disease.	  List	  
of	  the	  miRNAs	  detected	  to	  have	  aberrant	  expression	   levels	   in	  more	  than	  one	  of	  the	  experimental	  models	  (+)	  
included	  in	  the	  microarray	  profiling.	  The	  referenced	  existing	  evidence	  relates	  to	  miRNA	  dyregulation	  previously	  
described	  in	  models	  of	  heart	  disease	  including:	  hypertrophy	  (Hyp),	  heart	  failure	  (HF),	  human	  cardiomyopathy	  
(CM),	  ischemia	  and	  myocardial	  infarction	  (MI).	  
	  
3.2.2 miR-­‐30	   is	   down-­‐regulated	   by	   doxorubicin	   treatment	   and	  
myocardial	  infarction	  
	  
Both	   specific	   and	   shared	   miRNA	   signatures	   were	   identified	   in	   the	   profiling	   for	   our	   three	  
models	  of	  study	  (Figure	  26).	  Interestingly,	  two	  members	  of	  the	  miR-­‐30	  family	  (miR-­‐30d,	  miR-­‐
30e)	  displayed	  reduced	  expression	  levels	  after	  acute	  and	  sustained	  DOX	  exposures	  as	  well	  as	  
after	  MI	  injury.	  A	  third	  miR-­‐30	  family	  member	  (miR-­‐30a)	  was	  down-­‐regulated	  upon	  both	   in	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Figure	  26.	  A	  miRNA	  signature	  overlaps	   in	  more	   than	  one	  model	  of	   study.	  The	  three	  models	  included	  in	  the	  
miRNA	  profiling	  were:	  DOX	  treatment	  in	  vitro	  performed	  on	  cultured	  primary	  isolated	  rat	  cardiomyocytes	  (6h,	  
1μM),	   DOX	   in	   vivo	  model	   (i.p.,	   15m/kg	   cumulative	   dose)	   and	   4w	   post-­‐MI	  model.	  A.	   Venn	   diagram	   showing	  
dysregulated	  miRNAs	  detected	  in	  each	  of	  the	  3	  models	  studied	  in	  accordance	  to	  the	  stringency	  criteria	  applied	  
(at	   least	  50	  copies	  counted	  per	   sample,	  p<0.05,	   fold	  chance	  >±1.5).	  B.	  Down-­‐regulated	  miRNAs	  shared	  by	  at	  
least	  2	  of	  the	  profiled	  models.	  C.	  miRNAs	  presenting	  up-­‐regulated	  expression	  levels	  in	  at	  least	  2	  models.	  Values	  
expressed	   as	   averaged	   fold	   changes	   in	   relation	   to	   the	   controls.	   Down-­‐regulation	   of	  miR-­‐30	   family	  members	  
highlighted	  with	  yellow	  boxes.	  	  
	  
Interestingly,	   miR-­‐30	   reduction	   mainly	   ranked	   within	   the	   20	   most	   significantly	   altered	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Table	   10.	   20	   most	   significantly	   dysregulated	   miRNAs	   as	   detected	   by	   profiling.	   P	   values	   and	   fold	   changes	  
detected	  for	  miR-­‐30	  in	  all	  three	  models	  highlighted	  in	  yellow.	  Primary	  isolated	  rat	  cardiomyocytes	  were	  treated	  
with	  DOX	  in	  vitro	  for	  6h	  at	  1μM.	  For	  in	  vitro	  treatments,	  rats	  were	  injected	  with	  a	  cumulative	  dose	  of	  15mg/kg	  
and	  sacrificed	  3w	  after	   the	   last	   injection.	  MI	  was	   induced	  by	  proximal	  coronary	  artery	   ligation;	  animals	  were	  
sacrificed	  4w	  post-­‐surgery.	  
	  
3.3 RT-­‐qPCR	  data	  validate	  the	  results	  obtained	  by	  microarray	  
	  
In	  order	  to	  confirm	  the	  reliability	  of	  the	  data	  obtained	  by	  high-­‐throughput	  miRNA	  profiling,	  
we	  wished	  to	  validate	  some	  of	  the	  results	  by	  RT-­‐qPCR.	  We	  selected	  3	  miRNAs	  that	  presented	  
aberrant	   expression	   in	   all	   3	   models	   in	   order	   to	   thoroughly	   confirm	   the	   detected	  
dysregulation	   in	   all	   conditions.	   Besides,	   we	   were	   interested	   in	   these	   3	  miRNAs	   (miR-­‐29c,	  
miR-­‐210	  and	  miR-­‐30e)	  since	  they	  had	  already	  been	  linked	  to	  some	  form	  of	  heart	  disease	  at	  
this	  point	  of	  the	  project	  although	  their	  exact	  role	  in	  cardiac	  pathology	  had	  not	  been	  defined	  
261,	  262,	  268.	  miR-­‐17-­‐5p	  proved	  to	  be	  comparably	  unchanged	  between	  all	  sample	  groups	  in	  the	  
profiling	  [p	  values	  =	  0.972723,	  0.761929,	  0.940185]	  and	  therefore	  we	  considered	  it	  as	  a	  good	  
negative	   control	   for	   the	   subsequent	   RT-­‐qPCR	   validation.	   As	   expected,	   no	   changes	   were	  
observed	   in	   miR-­‐17-­‐5p	   expression	   across	   samples.	   However,	   consistently	   with	   the	  
microarray	  results,	  reduced	  expression	  of	  miR-­‐29c,	  miR-­‐210	  and	  miR-­‐30e	  was	  quantified	  for	  
all	   three	   models	   (DOX	   in	   vitro,	   DOX	   in	   vivo,	   4w	   post-­‐MI)	   in	   relation	   to	   the	   appropriate	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Figure	  27.	  RT-­‐qPCR	  results	  validate	  the	  miRNA	  profiling	  data.	  Experimental	  validation	  of	  the	  miRNA	  profiling	  
was	  performed	  by	  Taqman®	  RT-­‐qPCR	  on	  the	  same	  samples	  used	  for	  microarray.	  A.	  No	  changes	   in	  miR-­‐17-­‐5p	  
expression	   were	   detected	   across	   samples.	   B.	   miR-­‐29c,	   miR-­‐210	   (C)	   and	   miR-­‐30e	   (D)	   presented	   reduced	  
expression	  levels	  in	  all	  models	  included	  in	  the	  profiling:	  DOX	  treatment	   in	  vitro	  (6h,	  1μM),	  DOX	  in	  vivo	  model	  
and	  4w	  post-­‐MI	  model.	  All	  values	  were	  normalized	  to	  U6	  expression	  and	  expressed	  as	  averaged	  ratios	  (±SEM)	  
relative	  to	  levels	  recorded	  in	  the	  control.	  (*p<0.05,	  **p<0.005,	  ***p<0.001;	  n.s.	  non-­‐significant).	  
	  
3.3.1 MicroRNA	   expression	   changes	   are	   maintained	   in	   a	   model	   of	  
chronic	  heart	  failure	  
	  
On	  account	  of	  practical	  and	  temporal	  restrictions,	  an	  early	  post-­‐MI	  model	  (4w	  post-­‐MI)	  was	  
included	   in	   the	   microarray.	   At	   4w	   post-­‐MI,	   there	   were	   signs	   of	   cardiac	   dysfunction	   as	  









































































































































































































Results	  –	  Part	  I	  
	   111	  
model	   where	   animals	   were	   not	   sacrificed	   until	   at	   least	   16w	   post-­‐MI	   became	   available	  
hereinafter.	  This	  model	  of	   late	  stage	  HF	  had	  previously	  been	  established	  and	  characterised	  
by	  our	  collaborators,	  and	  exhibits	   failure	  due	  to	  decompensated	  more	  severe	  hypertrophy	  
longer	  (16w	  instead	  of	  4w)	  after	  chronic	  MI	  induction	  306.	  We	  assessed	  the	  levels	  of	  miR-­‐29c,	  
miR-­‐30e	  and	  miR-­‐210	  expression	  in	  this	  model	  of	  late	  stage	  post-­‐MI	  induction.	  Importantly,	  
all	   3	   miRNAs	   showed	   sustained	   deregulated	   levels	   in	   the	   same	   direction	   as	   observed	   by	  
microarray	  (down-­‐regulation)	  (Figure	  28).	  This	  result	  indicates	  the	  biological	  relevance	  of	  the	  




Figure	  28.	  Changes	  in	  miRNA	  expression	  are	  maintained	  in	  a	  model	  of	   late	  stage	  HF.	  RT-­‐qPCR	  data	  showing	  
reduced	  miR-­‐29c,	  miR-­‐210	  and	  miR-­‐30e	  expression	  levels	  in	  the	  16w	  post-­‐MI	  late	  stage	  HF	  model	  in	  relation	  to	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3.4 Acute	   microRNA	   alteration	   caused	   by	   doxorubicin	   in	   ARVCM	   is	  
reproducible	  in	  the	  H9c2	  cardiac	  cell	  line	  
	  
Adult	  cardiomyocytes	  are	  non-­‐proliferating	  and	  renowned	  for	  being	  challenging	  to	  maintain	  
in	   culture,	   surviving	   for	   very	   short	   periods	   in	   vitro.	   Even	   though	   primary	   isolated	  
cardiomyocytes	  from	  animal	  models	  have	  enabled	  a	  vast	  amount	  of	  research,	  the	  molecular	  
experimenting	   on	   them	   is	   heavily	   limited	   by	   their	   instability	   in	   vitro	   327.	   For	   this	   reason,	  
establishing	  models	  more	  resilient	  to	  culture	  conditions	  was	  necessary	  328.	  A	  clonal	  cell	  line	  
called	   H9c2	   was	   derived	   from	   embryonic	   rat	   heart	   around	   forty	   years	   ago	   by	   Kimes	   and	  
Brandt	  329.	  Despite	  being	  fairly	  de-­‐differentiated	  and	  reflecting	  a	  ‘myoblast’	  stage,	  H9c2	  cells	  
retain	  numerous	  features	  of	  mature	  cardiomyocytes	  and	  can	  be	  used	  for	  biochemical	  studies	  
327.	  	  
To	  judge	  reproducibility,	  we	  assessed	  the	  effects	  of	  DOX	  on	  the	  miR-­‐29c,	  miR-­‐210	  and	  miR-­‐
30e	  expression	  of	  H9c2	  cultures.	  We	  recreated	  the	  same	  conditions	  used	  for	  the	  acute	  DOX	  
exposure	  in	  vitro	  on	  primary	  ARVCM.	  Although	  the	  expression	  of	  these	  3	  assayed	  miRNAs	  in	  
H9c2	  cells	  was	  remarkably	  lower	  than	  in	  ARVCM	  (Figure	  29A),	  a	  short	  exposure	  to	  DOX	  also	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Figure	  29.	  DOX	  down-­‐regulates	   the	  expression	  of	  miR-­‐29c,	  miR-­‐210	  and	  miR-­‐30e	   in	  H9c2	   cells.	  A.	  RT-­‐qPCR	  
data	   showing	   miRNA	   expression	   (miR-­‐29c,	   miR-­‐210,	   miR-­‐30e)	   relative	   to	   U6	   levels	   for	   untreated	   primary	  
isolated	  ARVCM	  and	  H9c2	  cardiac	  cell	   line.	  All	  values	  expressed	  as	  ratios	  to	  U6	  expression.	  B.	  Effects	  of	  DOX	  
treatment	  (6h,	  1μM)	  in	  the	  expression	  of	  the	  miRNA	  chosen	  for	  microarray	  validation	  (miR-­‐29c,	  miR-­‐210,	  miR-­‐
30e)	   on	   H9c2	   cells	   as	   quantified	   by	   RT-­‐qPCR.	   Values	   of	   independent	   triplicates	   are	   normalized	   to	   U6	   and	  
expressed	  as	  ratio	  to	  control	  [VEH(S):	  saline].	  (*p<0.05,	  **p<0.005).	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3.5 DISCUSSION	  –	  Part	  I	  
	  
3.5.1 Acute	   exposure	   to	   lapatinib	   does	   not	   trigger	   aberrant	  microRNA	  
expression	  in	  cardiomyocytes	  
	  
In	  the	  oncology	  clinic,	  molecular	  targeted	  therapies	  are	  being	  developed	  to	  increase	  specific	  
targeting	   of	   cancerous	   cells	   while	   reducing	   damage	   to	   their	   healthy	   neighbours.	  
Nonetheless,	   severe	   side	   effects	   have	   still	   been	   described	   to	   occur.	   In	   particular,	   HER2	  
blockade	   has	   been	   associated	   with	   increased	   risk	   of	   cardiac	   dysfunction.	   This	   was	  
unexpected	  and	  arose	  as	  the	  first	  adverse	  effect	  of	  a	  TKI,	  during	  the	  TRZ	  clinical	  trials	  179.	  We	  
wished	  to	  investigate	  whether	  cardiac	  miRNA	  dysregulation	  was	  induced	  by	  TRZ	  treatment,	  
reasoning	  that	  it	  could	  result	  in	  altered	  expression	  of	  multiple	  genes	  downstream	  and	  cause	  
part	  of	  the	  observed	  toxicity.	  	  
Due	  to	  the	  rat	  origin	  of	  the	  models	  available	  for	  this	  research,	  LAP	  was	  the	  HER2	  inhibitor	  of	  
choice	   over	   TRZ.	   Although	   LAP	   has	   a	   lower	   rate	   of	   associated	   cardiotoxicity,	   typically	  
characterized	  by	  mild	  reversible	  decreases	  in	  LVEF	  181,	  it	  blocks	  the	  same	  pathway	  as	  TRZ	  and	  
thus	  should	  trigger	  analogous	  changes	  in	  gene	  expression	  if	  they	  were	  to	  take	  place.	  	  	  
The	  intended	  experiment	  involved	  analysing	  the	  miRNA	  signature	  of	  cardiomyocytes	  isolated	  
from	  animals	   implanted	  with	   LAP-­‐loaded	  minipumps.	   Prior	   to	   proceeding	  with	   the	  miRNA	  
profiling,	  we	  checked	  p-­‐ERK1/2	  levels	  as	  an	  indicator	  of	  the	  degree	  of	  LAP	  inhibitory	  activity	  
taking	   place	   in	   the	   heart.	   This	   produced	   inconclusive	   results,	   where	   the	   proteins	   used	   to	  
normalise	   (ERK1/2,	   GAPDH)	   presented	   with	   unexpectedly	   variable	   levels	   across	   samples	  
(Figure	   21).	   Similar	   results	   were	   obtained	   upon	   repetition	   of	   Western	   blots.	   We	  
hypothesized	   a	   potential	   interference	   of	   DMSO	   with	   gene	   expression,	   given	   that	   total	  
protein	  staining	  with	  Ponceau	  was	  consistent.	  In	  fact,	  while	  Ponceau	  staining	  showed	  equal	  
protein	   loading,	   we	   observed	   a	   reduction	   in	   p-­‐ERK1/2	   for	   2	   of	   the	   LAP-­‐treated	   animals.	  
DMSO	  was	  used	  as	  solvent	  due	  to	  the	  lipophilic	  nature	  of	  LAP,	  but	  it	  is	  not	  innocuous	  to	  the	  
cells	  and	  has	  been	  described	  to	  alter	  gene	  expression	  levels	  133.	  Another	  potential	  issue	  with	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this	   pilot	   study	   was	   the	   administered	   dose.	   Patients	   undergoing	   LAP	   treatment	   usually	  
receive	  a	  dose	  ranging	  between	  10	  and	  20mg/kg/d	  176.	  Given	  that	  the	  dose	  used	  in	  our	  pilot	  
in	  vivo	  study	  was	  at	  the	  bottom	  of	  the	  range	  (10mg/kg/d),	  a	  higher	  dose	  might	  have	  resulted	  
in	  efficient	   inhibition	  of	  HER2.	  Moreover,	  drug	  precipitation	  or	  diffusion	  problems	  deriving	  
from	  minipump	  use	  may	  have	  prevented	  adequate	  delivery.	  With	  regard	  to	  time	  span,	  one	  
week	   post-­‐minipump	   implantation	   might	   not	   be	   long	   enough	   for	   cardiac	   dysfunction	   to	  
develop.	  However,	  we	  did	  not	  aim	  to	  study	  functional	  consequences	  of	  LAP	  treatment	  in	  the	  
heart	  but	   the	  molecular	   landscape.	  Hence,	  we	  believe	   that	  7	  days	   is	  a	   sufficient	  period	   to	  
achieve	  HER2	  blockage	  and	  assess	  the	  molecular	  consequences.	  Unfortunately,	  no	  published	  
literature	  described	   relevant	   in	  vivo	  models	  of	  HER2	   inhibition	   that	  could	  have	  guided	  our	  
chosen	  parameters.	  TRZ	  and	  LAP	  have	  both	  been	  administered	  to	  xenograft-­‐bearing	  mice	  in	  
order	   to	  prove	  antineoplasic	  efficacy	  on	  human	  cancer	  cell	   lines	   307,	  330,	  331;	  however,	   there	  
has	  been	  no	  evaluation	  of	  the	  cardiac	  implications	  in	  vivo.	  	  
These	  unconvincing	  findings	  led	  us	  to	  perform	   in	  vitro	  LAP	  treatments	  on	  ARVCM	  as	  proof-­‐
of-­‐concept	   and	   in	   order	   to	   preclude	   a	   faulty	   drug	   stock.	   LAP	   treatment	  was	   able	   to	   block	  
HER2	   pathway	   on	   ARVCM	   as	   well	   as	   on	   HER2	   overexpressing	   BCC	   (BT474)	   in	   vitro,	   as	  
confirmed	   by	   a	   reduction	   in	   p-­‐ERK1/2	   (Figure	   22).	   Although	   the	   expression	   of	   46	  miRNAs	  
was	   altered	   in	   BT-­‐474	   cells	   according	   to	   the	   stringent	   criteria	   applied,	   we	   detected	   no	  
significant	   changes	   in	  miRNA	   levels	   in	   treated	   ARVCM	   (Figure	   23).	   This	   suggests	   that	   LAP	  
does	  not	  exert	  a	   sufficiently	  powerful	  effect	  on	  cardiomyocytes	   to	   substantially	  alter	   their	  
miRNA	  signature.	  In	  keeping	  with	  the	  unchanged	  miRNA	  signature	  observed,	  mild	  molecular	  
events	  have	  been	   reported	   to	  occur	   in	   the	  cells	   following	  LAP	   treatment	   191.	  These	   results	  
are	   also	   in	   concordance	   with	   the	   low	   and	   reversible	   cardiotoxicity	   reported	   on	   patients	  
under	  LAP-­‐based	  regimes	  176.	  	  
We	  appreciated	  that	  the	  pilot	   in	  vivo	  LAP	  study	  produced	  inconclusive	  results.	  However,	   in	  
light	   of	   the	   microarray	   results	   revealing	   unchanged	   miRNA	   expression	   following	   acute	  
exposure	  to	  LAP,	  we	  decided	  not	  to	  pursue	  any	  further	  optimisation	  of	  the	  model.	  Instead,	  
we	  focused	  on	  studying	  the	  miRNA	  component	  of	  DOX	  cardiotoxicity,	  as	  ANTs	  are	  known	  to	  
cause	  irreversible	  and	  more	  severe	  cardiotoxicity	  than	  TKIs	  314.	   	  At	  this	  stage	  of	  the	  project	  
one	  published	  study	  had	  already	  revealed	  cardiac	  miRNA	  (miR-­‐146a)	  to	  be	  dysregulated	   in	  
response	  to	  DOX	  treatment	  200.	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3.5.2 Doxorubicin	   treatment	   and	   myocardial	   infarction	   induce	  
cardiomyocyte	  microRNA	  dysregulation	  
	  
Despite	   DOX	   cardiotoxicity	   being	   an	   extensively	   investigated	   subject,	   no	   comprehensive	  
analysis	  of	  the	  resulting	  cardiac	  miRNA	  signature	  was	  available	  at	  the	  start	  of	  this	  research.	  
We	   thus	   decided	   to	   explore	   the	   extent	   of	   DOX-­‐induced	   miRNA	   expression	   changes	   that	  
occur	  in	  the	  myocardium.	  In	  contrast	  to	  the	  published	  studies	  linking	  miRNA	  expression	  and	  
heart	   disease,	   which	   have	   broadly	   failed	   to	   profile	   specific	   cell	   types,	   we	   wished	   to	  
exclusively	   study	   the	   cardiomyocyte	   population.	   The	   rationale	   for	   this	   was	   that	   the	  
contractile	  ventricle	  -­‐made	  up	  mostly	  of	  cardiomyocytes,	  which	  are	  the	  contractile	  units-­‐	  is	  
most	   affected	   in	   both	   cardiomyopathy	   and	   HF.	   We	   believe	   this	   cell-­‐type	   specificity	   can	  
provide	   more	   relevant	   insights	   into	   the	   molecular	   events	   associated	   with	   myocardial	  
disease.	  	  
The	   assessment	   of	   global	   miRNA	   expression	   by	   microarray	   revealed	   42	   significantly	  
dysregulated	   miRNAs	   in	   DOX-­‐treated	   ARVCM,	   21	   in	   ARVCM	   obtained	   from	   DOX-­‐treated	  
hearts	  and	  51	  in	  ARVCM	  isolated	  from	  infarcted	  hearts.	  A	  set	  of	  7	  miRNAs	  (miR-­‐133b,	  miR-­‐
143,	   miR-­‐210,	   miR-­‐29c,	   miR-­‐30d,	   miR-­‐30e,	   miR-­‐345-­‐5p)	   were	   identified	   to	   be	   down-­‐
regulated	  in	  a	  similar	  fashion	  after	  cardiac	  injury	  in	  vivo	  following	  MI	  or	  DOX	  administration,	  
and	  also	  promptly	  after	  acute	  exposure	  to	  DOX	  in	  vitro	  (Figure	  26).	  On	  one	  hand,	  the	  altered	  
expression	   of	   the	   same	   miRNAs	   detected	   across	   models	   of	   DOX	   toxicity	   and	   post-­‐MI	  
dysfunction	  reflects	  important	  consistencies	  in	  the	  cardiomyocyte	  response	  to	  injury.	  On	  the	  
other	   hand,	   the	   fact	   that	   some	  miRNAs	  were	   only	   differentially	   expressed	   in	   response	   to	  
acute	  and/or	  sustained	  DOX	  treatments	  -­‐	  but	  not	  in	  the	  assayed	  post-­‐MI	  samples-­‐	  suggests	  
the	   existence	   of	  molecular	  mechanisms	   unique	   to	   this	   type	   of	   cardiac	   injury.	   Accordingly,	  
other	  miRNAs	  were	  found	  to	  be	  aberrantly	  expressed	  only	  post-­‐MI.	  	  
The	   aberrant	  miRNA	   expression	   detected	   for	   certain	  miRNAs	   was	  mostly	  mild	   relative	   to	  
controls	   (Figure	   25B,	   D	   and	   F).	   In	   agreement	  with	   this,	   changes	   in	  miRNA	   expression	   are	  
often	  reported	  to	  be	  modest	  while	  still	  producing	  relevant	  biological	  consequences	  210,	  332.	  In	  
addition,	   a	  number	  of	   the	  miRNAs	  we	   found	   to	  be	  altered	  have	  previously	  been	   linked	   to	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heart	  disease,	  independently	  validating	  our	  profiling	  (Table	  9)	  262,	  268,	  274,	  325,	  333.	  Van	  Rooij	  et	  
al	   introduced	   the	   concept	   “MImiRs”	   for	   a	   subgroup	   of	  miRNAs	   that	   are	   implicated	   in	   the	  
pathologic	   cardiac	   remodelling	   that	   occurs	   post-­‐MI,	   and	   leads	   to	   heart	   failure	   333.	  
Dysregulated	   expression	   of	  members	   of	   this	  MImiR	   group	   (miR-­‐29	   and	  miR-­‐199)	  was	   also	  
found	  in	  our	  experiment.	  	  
Experimental	   validation	  of	  a	   subset	  of	  miRNAs	  by	  RT-­‐qPCR	  supported	   the	   reliability	  of	   the	  
profiling	  results	  (Figure	  27).	  Assaying	  the	  post-­‐MI	  cohort,	  a	   later	  stage	  of	  the	  model	  (>16w	  
instead	  of	  4w	  post-­‐MI)	  showed	  miRNA	  dysregulation	  to	  be	  sustained	   in	  chronic	  HF	   (Figure	  
28).	   These	   long-­‐lasting	   effects	   on	   miRNA	   expression	   (maintained	   after	   both	   acute	   and	  
chronic	  DOX	  exposure	  and	  early/late	  post-­‐MI)	  point	   to	  prolonged	  cellular	  consequences	  of	  
these	  events.	   Indeed,	   the	  miRNA	   signature	   identified	  after	   a	   short	  DOX	   treatment	   in	   vitro	  
and	   retained	  over	   time	   is	  of	   translational	   relevance,	   indicating	   the	  potential	  of	  miRNAs	  as	  
early	  predictive	  biomarkers.	  	  
The	  rapid	  miRNA	  alteration	  observed	  in	  response	  to	  DOX	  suggested	  role	  for	  these	  miRNAs	  in	  
the	   development	   of	   subsequent	   pathophysiological	   changes.	   In	   fact,	   miRNAs	   have	   been	  
shown	  to	  be	  causal	  factors	  in	  developing	  heart	  disease	  149,	  255,	  334.	  Moreover,	  modulation	  of	  
individual	  miRNAs	  has	  been	  shown	  as	  sufficient	   to	  entirely	   revert	  pathological	  phenotypes	  
106,	   131,	   264,	   273,	   335.	   Taken	   together,	   this	   evidence	   suggests	   the	   therapeutic	   relevance	   of	  
maintaining	  physiological	  miRNA	  expression	  in	  the	  heart.	  	  
Even	   though	  we	   focused	  on	  cardiomyocytes,	   altered	  miRNA	   levels	   in	  non-­‐myocyte	   cardiac	  
cells	  also	  play	  described	  roles	  in	  heart	  disease.	  Others	  have	  investigated	  this	  and	  identified	  
that,	  for	  instance,	  dysregulated	  miR-­‐21	  and	  miR-­‐29	  levels	  in	  cardiac	  fibroblasts	  are	  crucial	  in	  
the	  development	  of	  HF	  264,	  265.	  The	  evaluation	  of	  DOX-­‐induced	  changes	  in	  miRNA	  expression	  
of	   cardiac	   fibroblasts	   could	   shed	   new	   light	   into	   the	   mechanisms	   of	   cardiotoxicity,	  
supplementing	  the	  data	  obtained	  for	  the	  myocyte	  population.	  miRNAs	  have	  been	  shown	  to	  
be	  transferred	  between	  cells	   in	  a	  paracrine	  manner,	  with	  growing	  evidence	   indicating	  that	  
active	  or	  passive	  miRNA	  secretion	  can	  direct	  gene	  expression	  changes	   in	  recipient	  cells	   336,	  
337.	  In	  the	  context	  of	  the	  heart,	  a	  possible	  miRNA-­‐mediated	  intercellular	  communication	  may	  
be	   taking	   place	   between	   cardiac	   cells	   (both	   myocytes	   and	   non-­‐myocytes).	   Indeed,	  
preliminary	   evidence	   is	   suggestive	   that	   cross	   talk	   occurs	   between	   fibroblasts	   and	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cardiomyocytes	   338.	   This	   could	   prove	   important	   in	   the	   development	   of	   HF,	   given	   the	   key	  
implication	  of	  fibrosis	  in	  the	  maladaptive	  myocardial	  remodelling	  that	  leads	  to	  HF	  38.	  	  
	  
3.5.3 miR-­‐30	   down-­‐regulation	   overlaps	   in	   both	   doxorubicin	   and	   post-­‐
myocardial	  infarction	  injury	  models	  
	  
The	   miR-­‐30	   family	   is	   highly	   expressed	   in	   the	   heart,	   with	   this	   abundance	   itself	   a	   possible	  
indication	  of	  the	  functionality	  of	  its	  members	  149.	  Since	  the	  start	  of	  this	  thesis,	  other	  authors	  
have	  associated	  reduced	  cardiac	  levels	  of	  miR-­‐30	  with	  myocardial	  matrix	  remodelling	  as	  well	  
as	  with	  angiotensin	  II-­‐induced	  hypertrophy	  in	  animal	  models	  266,	  339.	  Decreased	  miR-­‐30e	  was	  
also	   detected	   in	   myocardial	   tissue	   from	   patients	   with	   dilated	   cardiomyopathy	   and	   aortic	  
stenosis	  261.	  Furthermore,	  circulating	  miR-­‐30e	  levels	  appeared	  dramatically	  down-­‐regulated	  
in	  the	  HF	  group	  versus	  healthy	  individuals	  in	  a	  recent	  study	  299.	  	  
In	   spite	   of	   the	   mentioned	   evidence	   pointing	   to	   an	   important	   role	   of	   miR-­‐30	   in	   the	  
myocardium,	   its	   aberrant	   expression	   following	   exposure	   to	   DOX	   has	   not	   been	   previously	  
shown.	  Moreover,	  the	  mechanisms	  that	  link	  miR-­‐30	  to	  heart	  disease	  are	  not	  well	  understood	  
seeing	  as	  only	  two	  target	  genes	  (connective	  tissue	  growth	  factor	  -­‐CTGF-­‐	  and	  beclin-­‐1)	  have	  
been	  experimentally	  validated	  in	  relevant	  models	  to	  date	  266,	  339.	  
Our	   profiling	   revealed	   cardiomyocyte-­‐specific	   down-­‐regulation	   of	   three	   members	   of	   the	  
miR-­‐30	  family	  (a,	  b	  and	  e)	  upon	  DOX	  treatment,	  in	  both	  the	  acute	  in	  vitro	  and	  chronic	  in	  vivo	  
contexts.	   The	   expression	   of	  miR-­‐30d	   and	  miR-­‐30e	  was	   also	   found	   to	   be	   repressed	   in	   our	  
post-­‐MI	  model	   (Figure	  28).	  Further,	   the	  changes	   in	  miR-­‐30	   levels	  ranked	  mostly	  within	  the	  
20	   most	   significantly	   altered	   miRNAs	   for	   all	   three	   models	   assayed	   (Table	   10).	   Because	  
members	   of	   a	   miRNA	   family	   share	   the	   same	   seed	   region	   and	   therefore	   are	   predicted	   to	  
target	  the	  same	  genes	  209,	  more	  powerful	  effects	  will	  expectedly	  be	  observed	  in	  those	  genes	  
if	  multiple	  family	  members	  are	  dysregulated	  in	  the	  same	  direction	  (up/down-­‐regulated).	  We	  
reasoned	   that	   this	   amplifying	   effect	   against	   the	   same	   targets	   is	   more	   likely	   to	   cause	  
biologically	  relevant	  consequences	  and	  impact	  the	  cells’	  phenotypes.	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Importantly,	  miR-­‐30e	   down-­‐regulation	  was	  maintained	   in	   our	   late	   stage	  HF	  model	   (Figure	  
28).	  We	  considered	  the	  fact	  that	  altered	  miR-­‐30	  expression	  was	  not	  transitory	  in	  either	  DOX	  
or	  MI-­‐induced	   cardiac	   injury	   to	   be	   an	   important	   indication	   of	   the	  miR-­‐30	   involvement	   in	  
pathology	  progression.	  Additionally,	  the	  decreased	  miR-­‐30	  expression	  detected	  shortly	  after	  
DOX	  treatment	  indicates	  a	  possible	  causal	  role	  in	  the	  deriving	  cardiac	  dysfunction,	  and	  could	  
potentially	  be	  used	  as	  an	  early	  indicator	  of	  threatening	  changes	  in	  the	  heart	  319.	  Since	  altered	  
miR-­‐30	   expression	   has	   been	   previously	   linked	   to	   heart	   disease	   266,	   339,	   that	   its	   lowered	  
expression	  was	  detectable	  within	  hours	  of	  DOX	  treatment	  and	  sustained	  in	  a	  chronic	  in	  vivo	  
model	  encouraged	  us	  to	  believe	  that	  DOX	  could	  be	  causing	  unintended,	  fast	  acting	  and	  long	  
lasting	  effects	  through	  miR-­‐30	  in	  the	  myocardium.	  This	  led	  us	  to	  extend	  our	  investigation	  on	  
miR-­‐30.	   In	  particular,	  we	  selected	  miR-­‐30e	   for	   further	  experimental	  evaluation	  owing	   to	   it	  
presenting	   the	   greatest	   fold	   change	   in	   all	   three	   profiled	   models	   comparing	   to	   the	   other	  
altered	  members	  of	  the	  family.	  
	  
3.5.4 H9c2	  cells	  are	  an	  appropriate	  model	  to	  study	  doxorubicin-­‐induced	  
microRNA	  dysregulation	  in	  ARVCM	  
	  
In	  order	   to	  overcome	  the	  difficulties	  of	   culturing	  adult	   cardiomyocytes	   for	   in	  vitro	   studies,	  
we	  assessed	  the	  suitability	  of	  the	  rat	  cardiac	  H9c2	  cell	  line	  as	  a	  complementary	  model.	  H9c2	  
cells	   have	   been	   thoroughly	   characterized	   by	   Hescheler	   et	   al.,	   who	   described	   them	   as	  
immature	   embryonic	   cardiomyocytes.	   Even	   though	   several	   morphological	   traits	   of	  
cardiomyocytes	  are	  not	   conserved	   in	   this	   cell	   line,	  H9c2	   retain	  expression	  of	   functional	  β-­‐
adrenoceptors	   and	   G-­‐proteins.	   In	   addition,	   Ca2+	   handling	   and	   responsiveness	   to	   external	  
stimuli	   are	   present.	   H9c2	   cells	   are	   thus	   considered	   a	   suitable	   platform	   to	   study	  
transmembrane	   signal	   transduction	   and	   the	   molecular	   pathways	   also	   active	   in	   mature	  
cardiomyocytes	  327.	  	  
Like	  primary	  cardiomyocytes,	  H9c2	  have	  been	  shown	  to	  be	  susceptible	  to	  DOX	  injury,	  which	  
causes	   ROS	   stress	   and	   cell	   death	   340.	   H9c2	   cells	   are	   considered	   a	   relevant	  model	   for	   the	  
research	  of	  ANT	  cardiotoxicity,	  as	  they	  are	  damaged	  by	  DOX	  and	  allow	  stable	  expression	  of	  
Discussion	  –	  Part	  I	  
	   120	  
transgenes.	  Candidates	  for	  proposed	  gene-­‐based	  therapies	  can	  thus	  be	  effectively	  tested	  on	  
H9c2	  cultures	  341.	  	  
Even	  though	  our	  primary	  objective	  was	  to	  utilise	  H9c2	  cultures	  as	  platforms	  in	  which	  to	  test	  
the	   effects	   of	   miRNA	   expression	   modulation,	   we	   also	   wished	   to	   examine	   whether	   the	  
reductions	   observed	   in	   levels	   of	   certain	   miRNAs	   upon	   DOX	   administration	   to	   primary	  
isolated	  cardiomyocytes	  were	  reproducible.	  When	  compared,	  the	  baseline	   levels	  of	  miRNA	  
(miR-­‐29c,	  miR-­‐210,	  miR-­‐30e)	  expression	  quantified	  in	  H9c2	  cells	  was	  substantially	  lower	  than	  
in	  ARVCM.	  Regardless,	  DOX	  treatment	  still	  produced	  a	  significant	  reduction	  in	  the	  expression	  
levels	  of	  these	  miRNAs	  (Figure	  29).	  This	   finding	  suggests	  that,	  DOX-­‐induced	  changes	   in	  the	  
expression	  of	  certain	  miRNAs	  are	  mechanistically	  similar	  in	  H9c2	  and	  ARVCM.	  Consequently,	  
we	   incorporated	   the	   use	   of	   H9c2	   cultures	   to	   the	   study	   in	   order	   to	   enable	   a	   range	   of	  
molecular	  biology	  experiments	  to	  be	  routinely	  performed.	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Part	  II	  –	  Implications	  of	  miR-­‐30	  in	  doxorubicin-­‐
induced	  cardiac	  toxicity	  
	  
In	  the	  previous	  chapter	  of	  this	  thesis	  we	  discovered	  the	  down-­‐regulation	  of	  several	  members	  
of	  the	  miR-­‐30	  family	  (miR-­‐30a,	  miR-­‐30d	  and	  miR-­‐30e)	  in	  ARVCM	  by	  acute	  DOX	  treatment	  in	  
vitro	  and	  also	  following	  chronic	  exposure	  in	  vivo.	  Moreover,	  the	  4w	  post-­‐MI	  model	  included	  
in	   the	   profiling	   shared	   the	   reduced	   levels	   observed	   for	   both	   miR-­‐30d	   and	   miR-­‐30e.	   We	  
interpreted	   this	   overlapping	   as	   robust	   evidence	   of	   biological	   importance.	   Therefore,	   we	  
decided	   to	   investigate	   the	   downstream	   consequences	   of	   such	  miR-­‐30	   down-­‐regulation	   in	  
relevant	  cardiac	  pathways.	  	  
	  
3.6 Bioinformatic	  miR-­‐30	  target	  prediction	  	  
	  
Central	   to	   miRNA	   research	   is	   the	   identification	   of	   target	   genes,	   as	   it	   enables	   better	  
understanding	  of	  the	  effects	  that	  altered	  expression	  levels	  of	  a	  particular	  miRNA	  will	  have	  in	  
the	   cell.	  We	  used	   a	   publicly	   available	   online	   algorithm	   called	   TargetScan	   to	   predict	   target	  
genes	   based	   on	   seed-­‐3’UTR	   base-­‐pairing	   277.	  We	   retrieved	   a	   list	   of	   1357	   phylogenetically	  
conserved	  putative	   target	  genes	   for	   the	  miR-­‐30	   family,	  which	  we	  used	  as	   input	   for	  DAVID	  
database	   (Database	   for	   Annotation,	   Visualisation	   and	   Integrated	   Discovery)	   for	   gene	  
ontology	   (GOterms)	   and	   pathways	   enriched	   analysis	   342,	   343.	   Using	   DAVID,	   we	   wished	   to	  
detect	   relevant	   biological	   themes	   within	   the	   predicted	   miR-­‐30	   target	   list.	   Figure	   30	  
illustrates	   the	   results	  obtained	  by	  pathway	  enrichment	   analysis.	  Notably,	   genes	   related	   to	  
three	  types	  of	  cardiomyopathy	  were	  within	  the	  top	  10	  most	  significantly	  enriched	  pathways	  
identified	   in	   the	   target	   list	   for	  miR-­‐30.	   Again,	   this	   suggested	   the	   importance	   of	   adequate	  
miR-­‐30	  levels	  in	  preserving	  a	  healthy	  heart.	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Figure	  30.	  Pathway	  enrichment	  analysis	  for	  the	  miR-­‐30	  targets	  predicted	  by	  TargetScan.	  Top	  10	  significantly	  
enriched	  pathways	  for	  the	  predicted	  subset	  of	  miR-­‐30	  target	  genes	  as	  identified	  by	  DAVID	  database.	  	  
	  
Subsequently,	  we	   fed	   the	   initial	   list	   of	   conserved	   genes	   retrieved	   from	   TargetScan	   to	   the	  
Cytoscape	  software.	  Cytoscape	  performs	  analyses	  and	  provides	  graphic	  visualisation	  of	  gene	  
interacting	   networks,	   comparing	   the	   gene	   submitted	   subset	   to	   interactome	  databases	   344.	  
We	  performed	  this	  analysis	  because	  it	   is	  known	  that	  miRNAs	  tend	  to	  target	  multiple	  genes	  
belonging	   to	   the	   same	   pathway	   345,	   being	   predicted	   target	   genes	   that	   compose	   an	  
interaction	   network	   more	   likely	   to	   be	   endogenous	   functional	   miRNA	   targets.	   Within	   the	  
predicted	  miR-­‐30	  target	  list,	  Cytoscape	  identified	  56	  genes	  that	  form	  a	  complex	  interacting	  
network,	  which	  deserved	  further	  investigation	  (Figure	  31).	  	  
Taken	  together,	  the	  information	  obtained	  from	  DAVID	  and	  Cytoscape	  provided	  better	  insight	  
into	  which	  genes	  are	  susceptible	  to	  post-­‐transcriptional	  regulation	  by	  miR-­‐30.	  	  Of	  these,	  we	  
identified	  several	  genes	   that	  are	  key	   for	  an	  adequate	  cardiac	   function:	  ATP2A2	   (SERCA2a),	  
ADRB1	  (β1AR),	  ADRB2	  (β2AR),	  BNIP3L,	  DMD	  (dystrophin),	  DTNA	  (dystrobrevin-­‐alpha),	  GNAI2	  
(Giα-­‐2)	  and	  TRDN	  (triadin).	  We	  selected	  the	  four	  genes	  thought	  to	  potentially	  have	  the	  most	  
intriguing	   implications	   in	  cardiac	  disease	  [ADRB1	  (β1AR),	  ADRB2	  (β2AR),	  BNIP3L,	  and	  GNAI2	  
(Giα-­‐2)]	  for	  further	  investigation	  (Figure	  31,	  in	  yellow).	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Figure	  31.	  Gene	  interaction	  network	  for	  the	  predicted	  miR-­‐30	  targets	  by	  TargetScan.	  Graphic	  view	  of	  genetic	  
interactions	  generated	  using	  Cytoscape.	  Nodes	  highlighted	  in	  yellow	  (ADRB1,	  ADRB2,	  BNIP3L	  and	  GNAI2)	  were	  
selected	  for	  further	  investigation.	  Nodes	  in	  green	  (ATP2A2,	  DMD,	  DTNA,	  TRDN)	  are	  also	  relevant	  genes	  in	  heart	  
biology	  but	  were	  not	  studied	  in	  this	  thesis.	  	  
	  
We	   could	   confirm	   the	   TargetScan	   target	   prediction	   for	   each	   of	   the	   four	   genes	   selected,	  
ensuring	   miR-­‐30	   seed-­‐binding	   sequences	   were	   conserved	   in	   3’UTRs	   across	   species	   and	  
particularly	  between	  human	  and	  rat,	  given	  that	  our	  models	  for	  this	  research	  are	  of	  rat	  origin	  
(Figure	  32).	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Figure	  32.	  TargetScan	  seed	  pairing	  
(miR-­‐30-­‐mRNA)	  prediction.	  
Predicted	  interaction	  sites	  of	  miRNA	  
with	  3’UTR	  of	  the	  putative	  target	  
genes.	  Red	  circles	  highlight	  the	  
conservation	  of	  seed	  
complementary	  sequences	  in	  the	  
human	  (Homo	  sapiens,	  Hsa)	  and	  rat	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Since	   miR-­‐30e	   presented	   the	   greatest	   down-­‐regulation	   fold	   change	   in	   the	   profiling	   in	  
comparison	   to	   the	   other	   altered	   family	  members	   (miR-­‐30a,	  miR-­‐30d)	   (Figure	   33A),	   it	  was	  
chosen	  for	  the	  ectopic	  overexpression	  performed	  as	  part	  of	  the	  experimental	  validation	  of	  
our	   findings.	   As	   first	   validation	   of	   the	   predicted	   miRNA-­‐3’UTR	   interaction	   with	   the	   four	  
shortlisted	   targets	   (β1AR,	   β2AR,	   BNIP3L	   and	   Giα-­‐2;	   Figure	   33B),	   we	   performed	   luciferase	  
assays	  using	  H9c2	  cells	  as	  container	  platform.	  The	  objective	  of	  these	  luciferase	  assays	  was	  to	  
to	  evaluate	  whether	  miR-­‐30	   is	  able	   to	  directly	   target	   those	  genes	  by	   interacting	  with	   their	  
3’UTRs.	   We	   used	   plasmids	   containing	   the	   firefly	   luciferase	   reporter	   gene	   fused	   with	   the	  
3’UTR	   of	   the	   selected	   genes,	   under	   the	   control	   of	   a	   strong	   promoter	   (Cytomegalovirus	  
promoter,	  CMV).	  If	  co-­‐expression	  of	  those	  plasmids	  with	  miR-­‐30e	  mimics	  (pre-­‐30e)	  results	  in	  
reduced	  luciferase	  levels,	  it	  indicates	  that	  miR-­‐30	  directly	  represses	  the	  tested	  target	  genes.	  
Notably,	  there	  was	  a	  reduction	  in	  luciferase	  activity	  when	  co-­‐transfecting	  the	  cultures	  with	  
the	  vector	  containing	  the	  3’UTRs	  and	  the	  miR-­‐30e	  precursor	  for	  ectopic	  overexpression.	  As	  
expected,	  no	  changes	  in	  luciferase	  activity	  were	  detected	  for	  a	  non-­‐target	  gene	  (programed	  
cell	  death	  protein	  4,	  PDCD4)	   that	  was	   included	  as	  negative	  control	   (Figure	   33C).	   This	  data	  
confirms	  a	  direct	  modulation	  of	   the	  3’UTR	  regions	  of	  β1AR,	  β2AR,	  BNIP3L	  and	  Giα-­‐2	  by	  miR-­‐
30e.	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Figure	   33.	   miR-­‐30	   targets	   β1AR,	   β2AR,	   BNIP3L	   and	   Giα-­‐2.	   A.	   Representation	   of	   the	   down-­‐regulation	   fold	  
changes	  detected	  for	  the	  three	  altered	  miR-­‐30	  family	  members	  by	  microarray	  profiling.	  B.	  Predicted	  base-­‐pair	  
annealing	  between	  the	  human	  3’UTR	  target	  mRNAs	  and	  the	  miRNA	  sequence	  (seed	  in	  red).	  C.	  Luciferase	  assays	  
performed	  on	  H9c2	  cultures,	  by	  co-­‐transfecting	  the	  corresponding	  3’UTR-­‐containing	  vector	  for	  each	  target	  and	  
the	  miR-­‐30e	  mimic	  (pre-­‐30e,	  100nM)	  for	  24h.	  The	  3’UTR	  of	  the	  non-­‐target	  PDCD4	  gene	  was	  used	  as	  negative	  
control.	   Averaged	   values	   of	   three	   independent	   experiments	   (±SEM)	   expressed	   as	   ratios	   to	   3’UTR+pre-­‐NC	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3.7 Experimental	  target	  validation	  
	  
Following	  the	  encouraging	  results	  obtained	  from	  3’UTR	  luciferase	  assays,	  we	  continued	  with	  
additional	  experimental	  validation	   in	  order	  to	   fully	  confirm	  β1AR,	  β2AR,	  BNIP3L	  and	  Giα-­‐2	  as	  
real	   miR-­‐30	   target	   genes.	   In	   an	   effort	   to	   minimize	   false	   positives	   in	   our	   results,	   we	  
performed	  a	  combination	  of	  both	  gain	  and	  loss-­‐of-­‐function	  approaches.	  	  
	  
3.7.1 Gain-­‐of-­‐function	  studies	  
	  
Ectopic	  miR-­‐30	  overexpression	  was	  achieved	  by	  transfecting	  H9c2	  cultures	  with	  pre-­‐30e	  as	  
mimic	   (Figure	   34A).	   Target	   gene	   expression	   in	   response	   to	   increased	  miR-­‐30e	   levels	   was	  
assessed	  at	  both	  mRNA	  and	  protein	  level.	  However,	  given	  the	  reported	  lack	  of	  commercially	  
available	  specific	  antibodies	  for	  βAR	  346,	  347	  and	  the	  unsuccessful	  previous	  experience	  in	  our	  
collaborators’	  group	  (Prof.	  Harding	  /	  Dr.	  Lyon),	  solely	  messenger	   levels	  were	  measured	  for	  
β1AR	   and	   β2AR.	   Reduced	   target	   gene	   expression	  was	   detected	   for	   all	   4	   studied	   targets	   in	  
response	   to	   artificially	   increased	   miR-­‐30	   levels	   (Figure	   34B	   and	   C).	   This	   evidence	   was	  
consistent	  with	  the	  data	  obtained	  by	  luciferase	  assays	  (Figure	  33C).	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Figure	  34.	  miR-­‐30	  overexpression	  results	  in	  reduced	  target	  expression.	  A.	  RT-­‐qPCR	  data	  for	  the	  quantification	  
of	  miR-­‐30e	  overexpression	   achieved	   (FC,	   fold	   change).	   Raw	  values	  normalized	   to	  U6	  expression.	   B.	  RT-­‐qPCR	  
data	  shows	  relative	  target	  mRNA	  levels	  when	  overexpressing	  miR-­‐30.	  All	  values	  are	  normalized	  to	  U6	  levels	  and	  
presented	   as	   ratios	   to	   the	   pre-­‐NC	   transfected	   controls.	   C.	   Relative	   protein	   levels	   of	   BNIP3L	   and	   Giα-­‐2	  were	  
measured	   by	   Western	   Blot;	   band	   densitometry	   was	   quantified	   by	   ImageJ	   and	   normalized	   to	   tubulin.	  
Transfections	  were	  performed	  on	  H9c2	  cardiac	  cultures	  using	  HiPerfect	  for	  72h,	  comparing	  pre-­‐30e	  (miR-­‐30e	  
mimic)	  against	  pre-­‐NC	  transfected	  controls	  (20nM	  both).	  Three	  biological	  replicates	  were	  included,	  expressed	  
as	  averaged	  ratios	  to	  control	  ±SEM.	  (*p<0.05;	  **p<0.01;	  ***p<0.001).	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3.7.2 Loss-­‐of-­‐function	  studies	  
	  
As	   a	   complementary	   form	   of	   experimental	   validation,	   we	   adopted	   a	   loss-­‐of-­‐function	  
strategy.	   The	   reason	  behind	   this	   additional	   target	   authentication	  was	   to	  exclude	  potential	  
artefacts	  deriving	   from	  the	   introduction	  of	  synthetic	  miRNA	  mimics	   into	  cultured	  cells.	  For	  
this	  purpose,	  we	  designed	  and	  generated	  a	  sponge	  vector	  for	  miR-­‐30	  family	  inhibition.	  The	  
basis	  of	  our	  sponge	  vector	  consisted	  in	  cloning	  6	  bulged	  repeats	  of	  the	  miRNA-­‐binding	  site	  
(complementary	   to	   the	  miR-­‐30	   sequence)	   in	   tandem.	   These	  miR-­‐30	   binding	   repeats	  were	  
located	   within	   the	   3’UTR	   sequence	   of	   an	   EGFP	   (Enhanced	   Green	   Fluorescent	   Protein)	  
reporter	   gene	   that	   was	   present	   in	   the	   parental	   plasmid	   used	   (pEGFP-­‐C1,	   Clontech	  
Laboratories	  Inc.)	  (Figure	  35A).	  The	  introduction	  of	  mismatches	  (‘bulges’)	  within	  the	  miR-­‐30	  
repeats	   in	   the	   sponge	   vector	   design	   mimics	   the	   imperfect	   miRNA-­‐mRNA	   annealing	   that	  
mostly	   occurs	   during	   gene	   expression	   regulation,	   and	  prevents	   cleavage	  by	  AGO2	  by	  RNA	  
interference	  mechanism	  that	  would	  take	  place	  in	  case	  of	  perfect	  complementarily	  between	  
the	  two	  molecules.	  Indeed,	  AGO2	  cleavage	  would	  reduce	  the	  power	  of	  the	  sponge	  activity	  of	  
the	   plasmid.	  With	   the	   bulged	   design,	   our	   sponge	   vector	   can	   thus	   escape	   degradation	   by	  
AGO2	  and	  continue	   to	  effectively	   sequester	  up	   to	  6	  endogenous	  miR-­‐30	  molecules	   348.	  An	  
advantage	  that	  reporter-­‐containing	  sponges	  hold	  over	  other	  methods	  of	  miRNA	  inhibition	  is	  
the	  possibility	  of	  using	  said	   reporter	  expression	   to	  select	  construct-­‐expressing	  cells.	  Figure	  
35B	   illustrates	   the	   EGFP	   detected	   in	   transfected	   H9c2	   cells,	   indicative	   of	   an	   efficient	  
transfection.	   Transitory	   transfection	   of	   H9c2	   cultures	  with	   our	   pEGFP-­‐sp30	   sponge	   vector	  
resulted	  in	  reduced	  levels	  of	  mature	  miR-­‐30,	  as	  indicated	  by	  miR-­‐30e	  quantification	  (Figure	  
35C).	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Figure	  35.	  Homemade	  miR-­‐30	   sponge	  vector	   for	  miR-­‐30	   family	   inhibition.	  A.	  Schematic	  view	  of	  the	  sponge	  
plasmid	   components	   and	   sequence	   repeated	   for	   bulged	   miR-­‐30	   annealing	   through	   the	   seed	   region.	   B.	  
Transfected	   H9c2	   cultures	   (using	   Lipofectamine	   2000,	   for	   48h).	   Signal	   observed	   in	   the	   GFP	   channel	   shows	  
sponge	  vector-­‐containing	  cells	  (EGFP+).	  C.	  RT-­‐qPCR	  showing	  mature	  miR-­‐30e	  quantification	  as	  averaged	  ratio	  of	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Equally	   to	  miR-­‐30	   overexpression	   experiments,	   target	   levels	   were	   evaluated	   after	  miR-­‐30	  
repression.	  Contrary	   to	   the	  results	  obtained	  from	  the	  gain-­‐of-­‐function	  studies,	  significantly	  
increased	   expression	  was	   detected	   for	   all	   β1AR,	   β2AR,	   BNIP3L	   and	   Giα-­‐2	   upon	   pEGFP-­‐sp30	  
mediated	  miR-­‐30	  inhibition	  (Figure	  36).	  
	  
	  
Figure	  36.	  miR-­‐30	   inhibition	   increases	  target	  expression	   levels.	  A.	  RT-­‐qPCR	  data	  shows	  relative	  target	  mRNA	  
levels	  when	  inhibiting	  miR-­‐30	  family	  using	  our	  homemade	  sponge	  vector	  pEGFP-­‐sp30.	  All	  values	  are	  normalized	  
to	  U6	  levels	  and	  presented	  as	  ratios	  to	  the	  pEGFP-­‐C1	  transfected	  controls.	  B.	  Relative	  protein	  levels	  of	  BNIP3L	  
and	  Giα-­‐2	  were	  measured	   by	  Western	   Blot;	   band	   densitometry	  was	   quantified	  was	   quantified	   by	   ImageJ	   and	  
normalized	  to	  tubulin.	  Transfections	  were	  performed	  on	  H9c2	  cardiac	  cultures	  using	  Lipofectamine	  2000	  over	  
48h.	   Three	   biological	   replicates	   were	   included,	   expressed	   as	   averaged	   ratios	   to	   control	   ±SEM.	   (*p<0.05;	  
**p<0.01;	  ***p<0.001).	  
	  
To	   further	   demonstrate	   our	   findings,	  we	   corroborated	   the	   effects	   of	  miR-­‐30	   repression	   in	  
target	  expression	  seen	  with	  our	  pEGFP-­‐sp30	  by	  using	  a	  commercial	  miR-­‐30	  family	  inhibitor.	  
The	  molecule	  of	  choice	  was	  a	  Locked	  Nucleic	  Acid	  (LNA)	  conceived	  for	  whole	  miRNA	  family	  
repression.	  Activity	  of	   the	  commercial	   LNA30	  was	  confirmed	  by	   the	   reduction	  observed	   in	  
miR-­‐30e	  (Figure	  37A).	  In	  keeping	  with	  the	  sponge	  vector	  results,	  moderately	  greater	  target	  
expression	  became	  apparent	  upon	  LNA30	  treatment	  (Figure	  37B	  and	  C).	  The	  magnitude	  of	  
the	   variations	   in	  mRNA	   and	   protein	   target	   levels	   achieved	  with	   LNA	   oligonucleotides	  was	  
comparable	  to	  the	  effects	  caused	  by	  pEGFP-­‐sp30.	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Figure	  37.	  miR-­‐30	   family	   inhibition	  by	   LNA.	  A.	  RT-­‐qPCR	  showing	  mature	  miR-­‐30e	  quantification	  as	  averaged	  
ratio	   of	   three	   independent	   transfections.	   All	   Ct	   values	   were	   normalised	   to	   U6	   expression.	  B.	   RT-­‐qPCR	   data	  
shows	  relative	  target	  mRNA	  levels	  when	  inhibiting	  the	  whole	  miR-­‐30	  family	  with	  specific	  LNA	  oligonucleotides	  
(LNA30).	  All	  values	  are	  normalized	  to	  U6	  levels	  and	  presented	  as	  ratios	  to	  the	  pre-­‐NC	  transfected	  controls.	  C.	  
Relative	  protein	  levels	  of	  BNIP3L	  and	  Giα-­‐2	  were	  measured	  by	  Western	  Blot;	  band	  densitometry	  was	  quantified	  
was	  quantified	  by	   ImageJ	  and	  normalized	  to	  tubulin.	  Transfections	  were	  performed	  on	  H9c2	  cardiac	  cultures	  
using	  HiPerfect	  and	  100nM	  of	  LNA	  over	  72h.	  Three	  biological	  replicates	  were	  included,	  expressed	  as	  averaged	  
ratios	  to	  control	  ±SEM.	  (*p<0.05;	  **p<0.01).	  
	  
3.7.3 Doxorubicin	  induces	  target	  gene	  expression	  through	  miR-­‐30	  down-­‐
regulation	  
	  
Once	   the	   experimental	   validation	   of	   β1AR,	   β2AR,	   BNIP3L	   and	   Giα-­‐2	   as	   miR-­‐30	   targets	   was	  
completed,	  we	  proceeded	   to	   investigate	   the	   effects	   that	   exposure	   to	  DOX	  has	   directly	   on	  
such	   target	   genes.	   Since	  miR-­‐30	   family	  members	   are	  down-­‐regulated	   in	   the	  heart	  by	  DOX	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DOX	  would	  up-­‐regulate	  their	  targets.	  To	  test	  this	  hypothesis,	  we	  treated	  H9c2	  cells	  with	  DOX	  
alone	  or	  in	  combination	  with	  miR-­‐30e	  overexpression.	  Accordingly,	  target	  mRNA	  levels	  were	  
increased	  in	  response	  to	  DOX.	  Strikingly,	  counteraction	  of	  miR-­‐30	  reduction	  by	  DOX	  through	  
ectopic	  overexpression	  was	   sufficient	   to	   rescue	   target	   expression	   levels	  back	   to	   the	   range	  
observed	  for	  the	  vehicle	  treatment	  (Figure	  38).	  This	  evidence	  supports	  our	  theory	  that	  the	  
effects	  that	  DOX	  has	  on	  the	  expression	  of	  β1AR,	  β2AR,	  BNIP3L	  and	  Giα-­‐2	  are,	  at	  least	  partially,	  




Figure	   38.	   DOX	   affects	   β1AR,	   β2AR,	   BNIP3L	   and	   Giα-­‐2	   expression	   via	   miR-­‐30.	   RT-­‐qPCR	   data	   showing	  mRNA	  
levels	  for	  the	  selected	  target	  genes	  (β1AR,	  β2AR,	  BNIP3L	  and	  Giα-­‐2).	  Pre-­‐30e	  and	  pre-­‐NC	  oligonucleotides	  (20nM)	  
were	  allowed	  to	  transfect	  H9c2	  cultures	  during	  72h.	  DOX	  treatment	  was	  performed	  over	  18h	  and	  saline	  (S)	  was	  
used	  as	  vehicle.	  Values	  of	  at	   least	  three	   independent	  replicates	  are	  expressed	  as	  mean	  ±SEM,	  and	  plotted	  as	  
ratios	  the	  respective	  VEH(S)	  sample.	  (*p<0.05;	  **p<0.01;	  ***	  p<0.001).	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3.8 miR-­‐30	   fine-­‐tuning	   of	   the	   β-­‐adrenergic	   pathway	   suggests	   a	   β-­‐
blocker	  like	  activity	  
	  
A	   relevant	   aspect	   contributing	   to	  miRNAs	   being	  master	   regulators	   of	   cellular	   processes	   is	  
their	  intrinsic	  ability	  to	  target	  a	  broad	  subset	  of	  genes.	  Often,	  several	  members	  implicated	  in	  
the	  same	  molecular	  pathway	  are	  targeted	  by	  the	  same	  miRNA.	  This	  allows	  miRNAs	  to	  fine-­‐
tune	  complex	  cascades,	  maintaining	  a	  tight	  equilibrium	  of	  components.	  Importantly,	  the	  net	  
cellular	  phenotype	  will	  ultimately	  be	  determined	  by	  the	  overall	  modulation	  of	  targets	  with	  
complementary	  and/or	  opposing	  functions	  211.	  	  
cAMP	   is	   considered	   the	   direct	   downstream	   effector	   of	   βAR	   and	   its	   levels	   mirror	   	   βAR	  
activation,	   whilst	   inversely	   correlating	   with	   Gi	   activity	   (Figure	   39A).	   While	   cAMP	  
accumulation	  regulates	  contractile	  responses	  (positive	  inotropic	  effect)	  11,	  high	  cAMP	  levels	  
have	  been	   linked	  to	  apoptotic	  cell	  death	  349,	  350.	  We	  observed	  significantly	   increased	  cAMP	  
accumulation	   upon	   acute	   DOX	   treatment,	   as	   well	   as	   when	   exogenously	   inhibiting	  miR-­‐30	  
with	   our	   pEGFP-­‐sp30	   vector	   (or	   LNA30).	   On	   the	   other	   hand,	   lower	   cAMP	   levels	   were	  
detected	  when	  overexpressing	  miR-­‐30e	  in	  H9c2	  cultures	  (Figure	  39B).	  These	  results	  confirm	  
the	  regulation	  of	  functional	  β1AR	  and	  β2AR	  by	  miR-­‐30	  and	  hint	  that	  miR-­‐30	  exerts	  a	  greater	  
inhibitory	  effect	  on	  βAR	  than	  Giα-­‐2.	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Figure	  39.	  miR-­‐30	  effects	  on	  cAMP	  accumulation	  and	  contractility.	  A.	  Differential	  contribution	  of	  β1AR,	  β2AR	  
and	   Giα-­‐2	   to	   cAMP	   accumulation.	   B.	   cAMP	   accumulation	   expressed	   as	   %	   of	   the	   respective	   control	   samples.	  
Values	  are	  the	  mean	  ±SEM	  of	  three	  independent	  experiments	  (*p<0.05;	  **p<0.01;	  ***p<0.001).	  	  
	  
Three	  of	   the	  miR-­‐30	   targets	   chosen	   as	   focus	   for	   this	   thesis	   (β1AR,	   β2AR	   and	  Giα-­‐2)	   are	   key	  
constituents	  of	  the	  β-­‐adrenergic	  pathway	  that	  controls	  contraction	  in	  cardiomyocytes.	  Given	  
the	  central	  role	  of	  myocardial	  contraction	  in	  cardiac	  function,	  we	  wished	  to	  evaluate	  global	  
contractile	  responses	  of	  miR-­‐30e	  overexpressing	  ARVCM	  (Figure	  40B).	  We	  used	  the	  IonOptix	  
video	   edge	   set	   up	   for	   single	   cardiomyocyte	   contraction	   monitoring	   (Figure	   40A).	   No	  
significant	  differences	  in	  baseline	  contractility	  were	  observed	  on	  transfected	  ARVCM	  (Figure	  
40C).	   However,	  when	   stimulated	  with	   increasing	   concentrations	   of	   a	   β-­‐adrenergic	   agonist	  
(isoprenaline,	  ISO),	  the	  amplitude	  of	  paced	  contractile	  responses	  was	  decreased	  in	  miR-­‐30e	  
overexpressing	   cardiomyocytes	   (Figure	   40D).	   Importantly,	   this	   finding	   is	   supported	  by	   the	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Figure	   40.	   Contractile	   responses	   of	   miR-­‐30e	   overexpressing	   ARVCM	   at	   baseline	   and	   upong	   isoprenaline	  
stimulation.	   A.	   IonOptix	   optical	   mapping	   used	   to	   measure	   ARVCM	   contractility,	   analysed	   using	   IonWizard	  
software.	   B.	   RT-­‐qPCR	   showing	   mature	   miR-­‐30e	   quantification	   as	   averaged	   ratio	   of	   three	   independent	  
transfections	  on	  ARVCM.	  Transfections	  were	  performed	  using	  pre-­‐30e/NC	  mimics	  (100nM)	  and	  Lipofectamine	  
2000,	   over	   48h.	   All	   Ct	   values	   were	   normalised	   to	   U6	   expression	   (***p<0.001,	   FC~100)	   C.	   Baseline	   %	   of	  
contraction	   amplitude	   of	   paced	   ARVCM	   transfected	  with	   either	   pre-­‐30e	   or	   pre-­‐NC	   for	   48h,	  measured	   using	  
IonOptix	   (n=8-­‐10;	   t	   test;	   ns,	   non-­‐significant).	   D.	   Contractile	   response	   of	   isoprenaline-­‐stimulated	   ARVCM	  
previously	  transfected	  with	  either	  pre-­‐30e	  or	  pre-­‐NC	  for	  48h,	  recorded	  by	  IonOptix.	  Dashed	  trend	  line	  included	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We	   next	   investigated	   the	   role	   of	   Gi	   activity	   in	   the	   contractile	   responses	   of	   miR-­‐30e	  
overexpressing	  ARVCM	  by	  inhibiting	  Gi	  with	  Pertussis	  Toxin	  (PTX).	  PTX	  blocks	  the	  interaction	  
of	  Gi	  with	  G	  protein-­‐coupled	  receptors	  (GPCR),	  thus	  impairing	  the	  β2/Gi	  intracellular	  cascade	  
351.	  As	  observed	   in	  absence	  of	  PTX	  treatment,	  miR-­‐30e	  overexpressing	  PTX-­‐treated	  ARVCM	  
presented	   a	   dampened	   response	   to	   ISO	   in	   relation	   to	   control	   (pre-­‐NC	   transfected)	   cells	  
(Figure	   41A).	   In	   comparison	   to	   untreated	   preparations,	   Gi	   ablation	   by	   PTX	   resulted	   in	   a	  
significant	  increase	  in	  the	  contractile	  amplitude	  of	  ISO-­‐stimulated	  control	  ARVCM.	  However,	  
no	   statistically	   significant	   changes	  were	  observed	   for	  miR-­‐30e	  overexpressing	   cells	   (Figure	  
41B).	  Again,	  this	  finding	  is	  consistent	  with	  the	  previous	  results	  (Figure	  39	  and	  Figure	  40)	  and	  
supports	  a	  preferential	  βAR	  inhibition	  by	  miR-­‐30.	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Figure	   41.	   Contractile	   responses	   of	  miR-­‐30e	   overexpressing	   ARVCM	   to	   isoprenaline	   stimulation	   combined	  
with	   PTX	   treatment.	   A.	  %	   contraction	  amplitude	   induced	  by	   increasing	   concentrations	  of	   ISO	  on	  pre-­‐30e	  or	  
pre-­‐NC	   transfected	   ARVCM	   (100nM,	   Lipofectamine	   2000,	   48h),	   treated	   with	   PTX	   (1.5μg/mL)	   3h	   before	  
contractility	   measurement	   (*p<0.0001).	   B.	   Transfected	   ARVCM	   (as	   in	   A.)	   comparing	   PTX	   treatment	   to	   no	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3.9 Effects	  of	  miR-­‐30	  on	  doxorubicin-­‐induced	  cardiac	  cell	  toxicity	  	  
	  
Cardiomyocyte	  death	   is	   a	   crucial	   trait	   of	   cardiomyopathy	   and	  heart	   failure	   62.	   Evidence	  of	  
cytochrome	  c	  release	  and	  caspase	  activation	  in	  functionally	  impaired	  human	  hearts	  has	  been	  
reported,	   highlighting	   a	   direct	   importance	   of	   apoptosis	   in	  myocardial	   dysfunction	   352.	   The	  
implication	   of	   caspase-­‐dependent	   apoptosis	   has	   also	   been	   shown	   in	   DOX-­‐induced	  
cardiotoxicity,	   both	   in	   vivo	   168,	   353	   and	   in	   H9c2	   cultures	   166,	   340.	   We	   therefore	   measured	  
caspase	  activity	  in	  H9c2	  cultures,	  aiming	  to	  investigate	  whether	  miR-­‐30	  levels	  influence	  the	  
toxic	   effects	   of	   DOX	   on	   cardiac	   cells.	   Interestingly,	   we	   observed	   a	   reduction	   in	   caspase	  
activity	   when	   reverting	   miR-­‐30	   expression	   by	   exogenously	   mimicking	   miR-­‐30e	  
simultaneously	   to	  DOX	  administration	   (Figure	   42A).	  By	  contrast,	  a	  greater	  number	  of	   cells	  
seemed	   to	   have	   active	   apoptotic	   signalling	   following	   miR-­‐30	   inhibition	   with	   our	   sponge	  
vector	   (pEGFP-­‐sp30).	   Nevertheless,	   no	   further	   increase	   in	   caspase	   activity	   was	   detected	  
when	   repressing	  miR-­‐30	   expression	   both	   by	  DOX	   treatment	   and	   transfection	  with	   pEGFP-­‐
sp30	  (Figure	  42B).	  
To	  further	  evaluate	  the	  modulation	  of	  DOX-­‐induced	  cell	  death	  rate	  by	  miR-­‐30,	  we	  performed	  
Annexin	  V	   (AnnV)	  apoptotic	  assays.	  This	  method	  combines	   fluorophore	   (PE)-­‐coupled	  AnnV	  
for	   phosphatidylserine	   membrane	   translocation	   detection	   with	   Propidium	   Iodide	   (PI)	   to	  
assess	  membrane	   integrity.	   In	   conjunction,	   these	   two	   stainings	   allow	   the	   identification	   of	  
several	  stages	  of	  apoptotic	  death	  by	  flow	  cytometry	  analysis	  354.	  While	  the	  administration	  of	  
transfection	  reagent	  (Mock,	  HiPerfect)	  alone	  had	  a	  substantial	  impact	  on	  cell	  viability,	  H9c2	  
cardiac	   cultures	   overexpressing	   miR-­‐30e	   were	   moderately	   more	   resilient	   to	   DOX	   toxicity,	  
presenting	  a	  higher	  percentage	  of	  viable	  cells	  and	  lower	  percentage	  of	  early	  apoptotic	  cells	  
(Figure	   43).	   This	   result	   was	   consistent	   with	   the	   observed	   effects	   of	   miR-­‐30	   on	   caspase	  
activity	   (Figure	   42),	   although	   Annexin	   V	   staining	   suggested	   a	   less	   pronounced	   protective	  
effect	  exerted	  by	  miR-­‐30e	  overexpression	  against	  global	  DOX	  toxicity.	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Figure	   42.	   miR-­‐30	   expression	   inversely	   correlates	   with	   caspase	   activation	   in	   cardiac	   cultures.	   A.	   Caspase	  
activity	   measured	   on	   miR-­‐30e	   overexpressing	   cultures	   (pre-­‐30e/NC	   mimics,	   20nM,	   72h,	   HiPerfect),	   in	  
combination	   with	   DOX	   treatment	   (1μM,	   18h).	   B.	   Caspase	   activity	   measured	   in	   response	   to	   miR-­‐30	   family	  
inhibition	  using	  the	  pEGFP-­‐sp30	  sponge	  vector	  (48h,	  Lipofectamine),	  either	  alone	  (left	  graph)	  or	  in	  combination	  
with	  DOX	  treatment	  (1μM,	  18h;	  right	  graph).	  All	  transfections	  were	  performed	  on	  H9c2	  cultures	  and	  results	  are	  
presented	  as	   averaged	   triplicates	   relative	   to	   control	   values	   ±SEM.	  Vehicle	   treatments	  were	  performed	  using	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Figure	   43.	   miR-­‐30e	   overexpression	   partly	   counteracts	   DOX-­‐induced	   apoptosis	   in	   cardiac	   cells.	   Bar	   graphs	  
represent,	   for	  each	  condition,	   the	  percentage	  of	   cells	  belonging	   to	  each	  population:	   viable	   (PI-­‐	  AnnV-­‐),	  early	  
apoptosis	  (PI-­‐	  AnnV+)	  and	  late	  apoptosis	  and	  necrosis	  (PI+	  AnnV+,	  PI+	  AnnV-­‐);	  as	  detected	  by	  flow	  cytometry.	  A	  
total	  of	  10.000	  cells	  were	  studied	  per	  treatment.	  Untreated	  H9c2	  cells	  served	  as	  healthy	  control,	  while	  mock-­‐
transfected	   H9c2	   cultures	   indicated	   the	   toxicity	   of	   the	   transfection	   reagent	   (HiPerfect).	   H9c2	   cells	   were	  
transfected	   with	   pre-­‐30e	   mimic	   or	   pre-­‐NC	   (20nM,	   HiPerfect,	   72h)	   and	   treated	   with	   DOX	   (1μM,	   18h).	   The	  
settings	   for	   flow	   cytometry	   analysis	   were	   established	   for	   each	   replicate	   according	   to	   the	   profiles	   of	   cells	  
transfected	  with	  a	  cell	  death	  siRNA	  pool	  control	  –used	  as	  positive	  control	  of	  cell	  death-­‐	  (20nM,	  HiPerfect,	  72h),	  
stained	  for	  either	  of	  the	  markers	  or	  both.	  
	  
Oxidative	   stress	  has	  been	  described	   to	   lead	   to	   caspase	  activation	   in	  H9c2	  cardiac	   cells	   355.	  
More	   importantly,	   reactive	   oxygen	   species	   (ROS)	   stress	   has	   emerged	   as	   a	   key	   mediating	  
mechanism	  of	   the	   toxic	   effects	   of	   ANT	   in	   the	   heart	   119,	  155-­‐157,	  165.	   Considering	   our	   findings	  
showing	  myocardial	  miR-­‐30	  down-­‐regulation	  upon	  acute	  and	  chronic	  exposure	  to	  DOX	  and	  
the	   regulation	   of	   caspase	   activity	   by	   miR-­‐30	   (Figure	   26	   and	   Figure	   42),	   we	   wished	   to	  
determine	   whether	   alterations	   in	   miR-­‐30	   levels	   per	   se	   could	   translate	   in	   changes	   in	   ROS	  
generation.	   Indeed,	   cardiac	   cultures	   over-­‐expressing	   miR-­‐30e	   presented	   lower	   ROS	   levels	  
than	   controls.	   Moreover,	   the	   reverse	   phenotype	   was	   observed	   when	   inhibiting	   miR-­‐30	  
family	   with	   the	   pEGFP-­‐sp30	   sponge	   vector,	   mimicking	   the	   increased	   ROS	   levels	   resulting	  
from	  DOX	  treatment	  (Figure	  44).	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Figure	   44.	   miR-­‐30	   levels	   inversely	   correlate	   with	   reactive	   oxygen	   species	   (ROS)	   generation.	   Cellular	   ROS	  
content	  measured	  using	   a	  DCFDA	   kit.	   Results	   expressed	   as	   fluorescence	  measures	   relative	   to	   the	   respective	  
control	  condition.	  DOX	  treatment	  was	  performed	  at	  a	  concentration	  of	  1μM	  and	  over	  18;	  saline	  was	  used	  as	  
vehicle.	  For	  miR-­‐30e	  overexpression,	  pre-­‐30e/NC	  mimics	  (20nM)	  were	  transfected	  using	  HiPerfect	  during	  72h.	  
For	   miR-­‐30	   family	   inhibition,	   pEGFP-­‐sp30	   or	   pEGFP-­‐C1	   parental	   control	   vectors	   were	   transfected	   using	  
Lipofectamine	  2000	  for	  48h.	  All	  conditions	  were	  assayed	  on	  H9c2	  cultures	  and	  repeated	  three	  times.	  (*p<0.05,	  
**p<0.005)	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3.10 GATA-­‐6	  mediates	  miR-­‐30	  down-­‐regulation	  by	  doxorubicin	  
	  
Up	  to	  this	  point	  of	  the	  present	  research,	  we	  focused	  on	  investigating	  the	  downstream	  effects	  
that	  the	  DOX-­‐induced	  reduction	  in	  miR-­‐30	  had.	  However,	  the	  mechanistic	  link	  between	  DOX	  
treatment	   and	   cardiac	   miR-­‐30	   down-­‐regulation	   was	   still	   unknown.	   Given	   the	   tissue	  
specificity	  of	  DOX	  toxic	  effects,	  we	  hypothesized	  a	  potential	  involvement	  of	  cardiac-­‐specific	  
regulators	   in	  mediating	   the	   reduction	   in	  miR-­‐30	   expression.	   ‘Cardiac’	   transcription	   factors	  
(TFs)	  are	  considered	  to	  encompass	  3	  members	  of	  the	  GATA	  family	  (4,	  5	  and	  6),	  the	  myocyte	  
enhancer	   factor	   2	   (MEF2),	   the	   homeobox	   Csx/Nkx-­‐2.5	   and	   heart	   and	   neural	   derivatives	  
(HAND)	   394.	   In	   order	   to	   test	   our	   premise	   of	   TFs	   being	   involved	   in	  mediating	   the	   observed	  
changes	   in	   miR-­‐30	   levels,	   we	   evaluated	   whether	   the	   expression	   of	   cardiac	   TFs	   is	   altered	  
upon	  exposure	  to	  DOX	  in	  primary	  isolated	  ARVCM.	  
	  
3.10.1 Cardiac	  GATA-­‐6	  expression	  is	  affected	  by	  doxorubicin	  
	  
Time	  course	  DOX	  treatments	   revealed	  no	  consistent	  alterations	   in	   the	  expression	   levels	  of	  
GATA-­‐4,	   MEF2,	   Nkx-­‐2.5	   and	   HAND2	   in	   ARVCM	   (not	   shown).	   However,	   we	   identified	   a	  
reproducible	  early	  increase	  in	  GATA-­‐6	  levels	  (30min-­‐1h)	  (Figure	  45B).	  GATA-­‐6	  is	  a	  zing	  finger	  
TF	  highly	  expressed	   in	  the	  heart	   (Figure	  45A)	  and	  has	  been	  described	  to	  play	  a	  key	  role	   in	  
cardiac	   development	   356-­‐358.	   Therefore,	   we	   decided	   to	   further	   study	   the	   implications	   of	  
GATA-­‐6	  in	  DOX-­‐induced	  cardiac	  toxicity.	  Interestingly,	  	  
Interestingly,	  when	  assessing	  miR-­‐30e	  expression	  levels	  upon	  DOX	  time	  course	  treatment,	  a	  
sustained	   reduction	   was	   observed	   from	   the	   1h	   time	   point	   (Figure	   45B).	   Moreover,	   we	  
discovered	  evidence	  of	  GATA-­‐6	  binding	  to	  the	  promoter	  of	  miR-­‐30	  clusters	  in	  human	  by	  data	  
mining	   of	   deposited	   chromatin	   immunoprecipitation	   sequencing	   (ChIP-­‐seq)	   experiments,	  
using	  the	  publicly	  available	  ChIPBase	  database	  359	  (Figure	  45C).	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Figure	  45.	  GATA-­‐6	  expression	   is	   acutely	   induced	  by	  DOX.	  A.	  GATA-­‐6	  expression	   levels	  across	  tissues	  (Figure	  
exported	   from	  ChIPBase	  database).	  B.	  RT-­‐qPCR	  data	   showing	   relative	  GATA-­‐6	  mRNA	   levels	   (left)	  and	  mature	  
miR-­‐30e	   levels	   (right)	   in	   ARVCM	   after	   time	   course	   treatment	   with	   DOX	   (1μM).	   Average	   ±SEM	   of	   three	  
independent	   replicates	   are	   presented	   as	   ratio	   to	   vehicle	   treatment	   (VEH,	   saline)	   (*p<0.05,	   **p<0.005,	  
***p<0.0005)	  C.	  Venn	  diagram	   illustrating	   the	  TF	  biding	   sites	   identified	  by	  ChIPBbase	  analysis	   for	   all	  miR-­‐30	  
clusters.	  The	  table	  shows	  the	  miR-­‐30	  family	  cluster	  organization	  and	  the	  chromosomic	  location	  in	  both	  human	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3.10.2 GATA-­‐6	  is	  involved	  in	  regulating	  miR-­‐30	  transcription	  
	  
In	  order	  to	  unveil	  the	  nature	  of	  the	  regulatory	  effect	  exerted	  by	  GATA-­‐6,	  we	  repressed	  such	  
TF	   through	   RNA	   interference	   (RNAi)	   (Figure	   46A).	   GATA-­‐6	   inhibition	   resulted	   in	   increased	  
levels	  of	  two	  miR-­‐30	  family	  members	  encoded	  in	  different	  clusters	  (miR-­‐30d	  and	  miR-­‐30e),	  
at	   both	   the	   primary	   and	  mature	   stages	   of	   their	   bioprocessing	   (Figure	   46B).	   This	   evidence	  
suggests	   that	   GATA6	   regulates	   the	   transcription	   of	   miR-­‐30	   family	   members	   by	   directly	  
interacting	  with	  their	  promoters.	  	  
We	  next	  aimed	  to	  confirm	  the	  direct	   interaction	  of	  GATA-­‐6	  with	  the	  promoters	  controlling	  
different	  miR-­‐30	  clusters	  as	  observed	  by	  other	  authors	   in	  other	   cells	  by	  ChIP	   (as	   retrieved	  
from	  Deepbase).	  However,	   a	  number	  of	   technical	   challenges	  were	   faced	  when	  attempting	  
ChIP	  experiments,	  the	  main	  limitation	  being	  the	  lack	  of	  a	  sufficiently	  potent	  commercial	  anti-­‐
GATA-­‐6	  antibody	  for	  rat	  cells.	  We	  tested	  the	  three	  most	  recommended	  antibodies	  for	  GATA-­‐
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Figure	   46.	   GATA-­‐6	   represses	   miR-­‐30	   transcription.	   A.	   RT-­‐qPCR	   and	   western	   blotting	   data	   confirm	   GATA-­‐6	  
silencing	  achieved	  using	  a	  specific	  siRNA	  (25nM,	  72h),	  both	  at	  mRNA	  and	  protein	  level.	  B.	  Primary	  and	  mature	  
levels	  quantified	  by	  RT-­‐qPCR	  for	  both	  miR-­‐30d	  and	  miR-­‐30e,	   in	  response	  to	  GATA-­‐6	  knock	  down.	  (**p<0.001,	  
***p<0.0001)	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3.10.3 Inhibition	   of	   GATA-­‐6	   correlates	   with	   decreased	   miR-­‐30	   target	  
expression	  
	  
In	  an	  effort	  to	  further	  characterise	  the	  effects	  of	  GATA-­‐6	  in	  relation	  to	  miR-­‐30,	  we	  measured	  
gene	  expression	  levels	  of	  the	  hereby-­‐identified	  miR-­‐30	  targets	  (β1AR,	  β2AR,	  BNIP3L,	  and	  Giα-­‐
2)	  upon	  GATA-­‐6	  silencing.	  In	  accordance	  with	  the	  changes	  observed	  in	  miR-­‐30	  (Figure	  46B),	  
target	  mRNA	  levels	  were	  reduced	  in	  response	  to	  GATA-­‐6	  inhibition	  (Figure	  47A,	  solid	  bars).	  
Decreased	   target	   expression	   could	   be	   compensated	   by	   simultaneous	   miR-­‐30	   family	  
inhibition	   using	   LNA	   oligonucleotides	   (Figure	   47A,	   patterned	   bars),	   suggesting	   a	   direct	  
mediation	  of	  the	  GATA-­‐6	  effects	  on	  target	  gene	  expression	  by	  miR-­‐30.	  
Given	  the	  protective	  effect	  demonstrated	  for	  miR-­‐30e	  against	  caspase-­‐dependent	  apoptosis	  
(Figure	  42),	  we	  wished	  to	  determine	  the	  impact	  of	  GATA-­‐6	  –as	  negative	  miR-­‐30	  modulator-­‐	  
on	  cell	  toxicity	  in	  vitro.	  Treated	  H9c2	  cardiac	  cultures	  exhibited	  less	  caspase	  activation	  upon	  
GATA-­‐6	   repression.	   This	   effect	   was	   still	   significant	   in	   combination	   with	   DOX	   treatment	  
(Figure	  47B).	  Again,	  these	  results	  concur	  with	  previously	  obtained	  data	  regarding	  miR-­‐30	  and	  
target	  expression	  following	  GATA-­‐6	  silencing	  (Figure	  46B	  and	  Figure	  47A).	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Figure	  47.	  GATA-­‐6	  silencing	  results	  in	  decreased	  levels	  of	  miR-­‐30	  targets	  and	  reduced	  apoptosis.	  A.	  RT-­‐qPCR	  
results	   for	   miR-­‐30	   target	   mRNA	   levels	   in	   response	   to	   GATA-­‐6	   silencing,	   and	   after	   co-­‐transfection	   with	  
compensatory	   LNA	   family	   inhibitors.	   B.	   Relative	   caspase	   activity	   in	   response	   to	   GATA-­‐6	   silencing,	   plus	   and	  
minus	   DOX	   (18h)	   treatment.	   Values	   presented	   as	   averaged	   ratio	   of	   triplicates	   ±SEM	   (*p<0.05;	   **p<0.01,	  
***p<0.001;	  ns,	  non-­‐significant).	  All	  RT-­‐qPCR	   results	  were	  normalised	   to	   the	   correspondent	  U6	  Ct	   value	  and	  
expressed	  as	  ratio	  to	  the	  control	  samples.	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3.11 miR-­‐30	  and	  breast	  cancer	  
	  
The	  results	  obtained	  so	  far	  indicate	  a	  relevant	  role	  for	  miR-­‐30	  in	  the	  molecular	  events	  that	  
lead	  to	  DOX-­‐induced	  cardiotoxicity.	  Importantly,	  miR-­‐30	  expression	  seems	  to	  protect	  against	  
cardiomyocyte	   cell	   death	  and	   to	  have	  a	  β-­‐blocker	   like	  effect	  on	   the	  β-­‐adrenergic	  pathway	  
(Figure	  40,	  Figure	  41,	  Figure	  42	  and	  Figure	  43).	  This	  evidence	  incites	  the	  consideration	  of	  a	  
translational	  application.	  Given	  that	  the	  potential	  therapeutic	  use	  of	  this	  miRNA	  would	  be	  in	  
combination	  with	  DOX	  and	  administered	   to	   cancer	  patients,	   it	   is	   essential	   to	   evaluate	   the	  
effects	  that	  miR-­‐30	  may	  have	  in	  cancer	  cells.	  	  
Recent	  reports	  have	  shown	  a	  tumour-­‐suppressor	  effect	  for	  miR-­‐30	  360-­‐362.	  We	  gained	  initial	  
insight	   into	   the	   effects	   of	   miR-­‐30	   modulation	   in	   relation	   to	   breast	   cancer	   using	   a	  
combination	  of	  experimental	  techniques	  and	  bioinformatic	  analyses.	  	  
	  
3.11.1 Effects	  of	  miR-­‐30	  on	  the	  proliferation	  and	  migration	  of	  MDA-­‐MB-­‐
231	  breast	  cancer	  cell	  line	  
	  
Firstly,	  we	  wished	  to	  investigate	  whether	  transient	  miR-­‐30	  overexpression	  or	  inhibition	  was	  
sufficient	   to	   affect	   proliferation	   of	  MDA-­‐MB-­‐231	   BCC	   in	   vitro.	  We	   therefore	   performed	   a	  
Sulforhodamine	   B	   (SRB)	   assay	   363	   to	   measure	   cell	   density	   of	   transfected	   MDA-­‐MB-­‐231	  
cultures	  with	  miR-­‐30	  mimics	  (pre-­‐30e)	  or	  miR-­‐30	  family	  inhibitors	  (LNA	  30),	  in	  comparison	  to	  
the	   respective	   controls.	   Figure	   48	   shows	   how	   sole	   miR-­‐30	   modulation	   fails	   to	   alter	  
proliferation	  of	  MDA-­‐MB-­‐231	  cells	  in	  vitro.	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Figure	  48.	  Transient	  miR-­‐30	  modulations	  do	  not	  affect	  BCC	  proliferation.	  Growth	  curves	  expressed	  as	  optical	  
density	   (OD)	   for	  MDA-­‐MB-­‐231	  cultures	  evaluated	  using	  the	  SRB	  method.	  A.	  Cell	  growth	  evaluated	  after	  miR-­‐
30e	   overexpression	   (day	   0	   –	   day	   7).	   B.	   Cell	   growth	   evaluated	   upon	   miR-­‐30	   family	   inhibition	   using	   LNA	  
oligonucleotides	  (day	  0	  –	  day	  7).	  Optical	  density	  (OD)	  measured	  at	  492nm.	  Values	  presented	  as	  mean±SEM,	  F	  
test	  performed.	  
	  
We	  subsequently	  carried	  out	  transwell	  migration	  assays	  using	  the	  same	  BCC	  (MDA-­‐MB-­‐231).	  
Upon	  exogenous	  manipulation	  of	  miR-­‐30	  expression,	  differential	  migration	  was	  observed	  in	  
MDA-­‐MB-­‐231	   cultures.	   Increased	   miR-­‐30	   levels	   resulted	   in	   a	   reduced	   percentage	   of	  
migrating	  cells,	  while	  miR-­‐30	  repression	  had	  the	  opposite	  effect	  (Figure	  49A).	  	  
In	   an	   effort	   to	   assess	   miR-­‐30	   expression	   during	   metastatic	   progression,	   we	   quantified	  
mature	   miR-­‐30e	   levels	   in	   MDA-­‐MB-­‐231	   cell	   lines	   derived	   from	   an	   established	   xenograft	  
model	  (kindly	  provided	  by	  Prof.	  Harikrishna	  Nakshatri).	  Three	  different	  lines	  were	  available:	  
origin	   MDA-­‐MB-­‐231	   were	   the	   cells	   used	   for	   injection,	   T	   MDA-­‐MB-­‐231	   proceed	   from	   the	  
generated	   primary	   tumour	   and	   L	   MDA-­‐MB-­‐231	   were	   derived	   from	   lung	   metastases.	  
Interestingly,	   a	   mild	   but	   progressive	   reduction	   in	   endogenous	   miR-­‐30e	   expression	   was	  
observed	  between	  these	  three	  MDA-­‐MB-­‐231	  lines	  (Figure	  49B).	  This	  was	  in	  agreement	  with	  
the	   results	   obtained	   from	   the	   transwell	   migration	   assays	   (Figure	   49A).	   Moreover,	   these	  
results	   indicated	   that	  miR-­‐30	   delivery	   in	   patients	  with	   breast	   cancer	   could	   counteract	   the	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Figure	   49.	  miR-­‐30	   expression	   correlates	  with	   reduced	   breast	   cancer	   cell	  migration.	   A.	   Transwell	  migration	  
assays	  were	  performed	  on	  MDA-­‐MB-­‐231	  cells	  following	  72h	  of	  precursor	  transfection	  (20nM,	  pre-­‐30e/pre-­‐NC)	  
or	  48h	  of	  pEGFP-­‐30/pEGFP-­‐C1	  (1μg	  per	  well	  in	  6-­‐well	  plates).	  50.000	  cells	  were	  transferred	  in	  triplicate	  to	  24-­‐
wells	   containing	   the	   membrane	   inserts	   and	   cells	   were	   allowed	   to	   migrate	   towards	   the	   chemo	   attractant	  
medium	  (FCS	  containing)	  below	  the	   insert	  for	  9h.	   Inserts	  were	  then	  stained	  with	  crystal	  violet	  and	  5	  fields	  of	  
view	  were	  evaluated	  under	  the	  microscope.	  Quantification	  of	  migrating	  cells	  is	  expressed	  as	  the	  mean±SEM	  	  %	  
of	   the	   respective	   control	   condition	   (bar	   graph).	   Three	   independent	   replicates	   were	   performed,	   and	   3	  
membranes	  were	  quantified	  each	  time.	  (*p<0.05,	  *p<0.001).	  B.	  RT-­‐qPCR	  data	  indicating	  miR-­‐30e	  expression	  in	  
different	   MDA-­‐MB-­‐231	   cell	   lines	   derived	   from	   different	   tumour	   stages/locations	   [MDA-­‐MB-­‐231	   (origin),	   T	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3.11.2 Bioinformatic	   data	   mining	   reveals	   reduced	   miR-­‐30	   expression	   in	  
breast	  cancer	  patients	  
	  
To	  further	  evaluate	  the	  relevance	  of	  miR-­‐30	  expression	  in	  association	  with	  breast	  cancer,	  we	  
proceeded	   to	   bioinformatically	   analyse	   freely	   available	   patients	   data	   deposited	   on	   GEO	  
(Gene	  Expression	  Omnibus)	   364.	  The	  miRNA	  profiling	   study	   selected	  –GSE26659-­‐	   compared	  
77	   breast	   carcinoma	   biopsies	   to	   17	   relapse-­‐free	   mammoplasty	   controls.	   Analysis	   of	  
differentially	  expressed	  miRNAs	  between	  these	  two	  groups	  revealed	  reduced	  miR-­‐30	  family	  
expression	  in	  the	  breast	  carcinoma	  group,	  being	  miR-­‐30e	  and	  miR-­‐30a	  the	  only	  statistically	  
significant	   members	   (Figure	   50A).	   The	   distribution	   of	   normalized	   miR-­‐30e	   and	   miR-­‐30a	  
expression	  in	  both	  groups	  can	  be	  observed	  in	  the	  scatter	  plot	  in	  Figure	  50B.	  We	  confirmed	  
the	   down-­‐regulated	  miR-­‐30a	   and	  miR-­‐30e	   expression	   obtained	   from	  GEO	  dataset	   analysis	  
using	   a	   different	   database	   for	   miRNA	   expression	   analysis	   called	   SurvMicro.	   Using	  
multivariate	   survival	   analysis,	   SurvMicro	   examines	   miRNA	   signatures	   of	   more	   than	   40	  
cohorts	  and	  matches	  them	  to	  clinical	  outcome	  365,	  366.	  The	  selected	  database	  on	  SurvMicro	  
includes	  miRNA	  expression	  profiling	  of	  528	  samples	  of	  breast	  carcinoma,	  classified	  into	  low	  
and	  high	  risk.	  Figure	  50C	  shows	  clear	  differences	  between	  the	  two	  groups	  for	  miR-­‐30a	  and	  
miR-­‐30e	  expression	  levels.	  
Moreover,	  we	   investigated	   the	  prognostic	  value	  of	  miR-­‐30e	  and	  miR-­‐30a	  by	  using	  another	  
web-­‐based	  tool	  called	  PROGmiR.	  PROGmiR	  pools	  miRNA	  expression	  data	  deposited	  in	  both	  
GEO	  and	  The	  Cancer	  Genome	  Atlas	  (TCGA)	  367	  to	  elaborate	  predictions	  of	  miRNA	  expression	  
in	   relation	   to	   survival	   of	   cancer	  patients	   368.	  We	   retrieved	  Kaplan-­‐Meier	   survival	   curves	  of	  
breast	  cancer	  patients	  depending	  on	  the	  recorded	  expression	  levels	  of	  miR-­‐30e	  and	  miR-­‐30a.	  
Although	  miR-­‐30e	  expression	  did	  not	  significantly	  correlate	  with	  higher	  or	  lower	  survival	  (not	  
shown),	  patients	  presenting	  higher	  miR-­‐30a	   levels	   in	  their	  breast	  tumours	  had	  significantly	  
better	  prognosis	  (Figure	  50D).	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Figure	  50.	  Reduced	  miR-­‐30	  levels	  correlate	  with	  breast	  cancer.	  A.	  GEO2R	  analysis	  of	  GEO	  dataset GSE26659	  
revealed	  significant	  miR-­‐30e	  and	  miR-­‐30a	  down-­‐regulation	  in	  breast	  cancer	  patients	  compared	  to	  the	  control	  
cohort.	  B.	  Normalised	  miRNA	  levels	  (miR-­‐30e	  and	  miR-­‐30a)	  recorded	  for	  all	  patients	  of	  the	  breast	  cancer	  (BC)	  
and	  control	  groups.	  C.	  	  Box	  plots	  showing	  miR-­‐30a	  and	  miR-­‐30e	  expression	  levels	  in	  the	  low	  risk	  and	  high	  risk	  
groups	   of	   a	   528-­‐sample	   breast	   carcinoma	   cohort,	   as	   retrieved	   by	   SurvMicro	   (p	   values	   are	   indicated	   in	   the	  
graphs).	  D.	  PROGmiR	  Kaplan-­‐Meier	  survival	  curve	  in	  breast	  cancer	  patients	  with	  high	  (in	  red)	  and	  low	  (in	  green)	  
miR-­‐30a	  expression.	  (*p<0.05,	  **p<0.01,	  ***p<0.001).	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3.12 Establishment	  of	  a	  miR-­‐30	  gene	  therapy	  model	  
	  
Based	  on	  our	  previous	  results	   (See	  sections	  3.8	  and	  3.9),	  we	  postulated	  a	  cardioprotective	  
role	  for	  miR-­‐30	  against	  DOX	  insult.	  In	  order	  to	  prove	  such	  hypothesis,	  we	  wished	  to	  establish	  
an	  in	  vivo	  model	  of	  AAV-­‐mediated	  miR-­‐30	  gene	  transfer	  that	  could	  potentially	  be	  translated	  
into	  the	  clinic.	  	  
It	   is	   known	   that	   the	   administration	   route	   of	   viral	   vectors	   greatly	   influences	   cardiac	  
transduction	  efficiency.	  The	  most	  common	  routes	  used	  for	  recombinant	  AAV	  (rAAV)	  cardiac	  
injection	   include	   multiple	   intravascular	   (intra-­‐venous/arterial)	   and	   intramuscular	  
approaches.	   Some	   examples	   are	   illustrated	   in	   (Figure	   51A)	   369.	   Alternatively	   to	   delivery	  
methods	   requiring	   open-­‐chest	   surgery,	  we	   performed	   intra-­‐jugular	   injections	   according	   to	  
Dr.	  Lyon’s	  technical	  expertise	  (Figure	  51B).	  	  
	  
	  
Figure	  51.	  Delivery	   route	   selected	   for	  our	  AAV	  based	  gene	   therapy	   strategy.	  A.	  Local	  routes	  for	  rAVV	  gene	  
therapy	   delivery	   in	   the	   heart	   (a:	   systemic	   through	   vena	   cava,	   b:	   intra-­‐coronary	   artery,	   c:	   intra-­‐myocardial	  
injection).	  B.	  Schematic	  view	  of	  the	  main	  blood	  vessels	  in	  the	  rat.	  Intra-­‐jugular	  injection	  route	  used	  highlighted	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3.12.1 Viral	  dose	  optimization	  using	  a	  AAV9.LacZ	  reporter	  
	  
As	  for	  any	   in	  vivo	  model,	  the	  appropriate	  dose	  of	  rAAV	  had	  to	  be	  determined	  for	  our	  gene	  
transfer	  model.	  For	  this	  purpose,	  we	  used	  an	  AAV9	  vector	  coding	  for	  the	  LacZ	  reporter	  gene	  
(AAV9.LacZ).	  The	  reason	  for	  using	  the	  serotype	  9	  is	  to	  maximise	  cardiac	  transduction,	  given	  
that	  AAV9	   vectors	   are	   considered	   the	  most	   cardiotropic	   serotype	   312,	  370.	   According	   to	   the	  
expertise	   of	   our	   collaborators	   who	   kindly	   generated	   the	   viral	   vectors	   (Prof.	   Giacca’s	  
laboratory	   ICGEB,	   Trieste),	   3	  weeks	  were	   sufficient	   for	   transgene	   expression	   in	   the	   target	  
tissue.	  	  Four	  treatment	  arms	  were	  included	  in	  this	  initial	  experiment,	  assaying	  three	  doses	  in	  
the	  logarithmic	  scale	  and	  using	  saline	  injections	  as	  control:	  
	  
	  
Figure	  52.	  Experimental	  design	  for	  AAV9.LacZ	  dose	  response	  test.	  Three	  groups	  of	  animals	  (n=3	  each)	  received	  
intra-­‐jugular	   injections	   of	   different	   doses	   of	  AAV9.LacZ	   recombinant	   virus:	   Low	   (4.5x1011	   viral	   genomes/rat),	  
Half	   Log	   (1.45x1012	   vg/rat)	   and	   High	   (4.5x1012	   vg/rat).	   Three	  weeks	  were	   allowed	   for	   transgene	   expression.	  
Hearts	  were	   then	   explanted	   and	   x-­‐gal	   staining	  were	   performed	   both	   on	  minced	   tissue	   and	   on	   10μm	   frozen	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3.12.1.1 LacZ	  transgene	  expression	  detection	  
	  
LacZ	   reporter	   staining	   on	   pieces	   of	   treated	   myocardium	   revealed	   highest	   transduction	  
efficiency	  to	  cardiac	  muscle	  at	  the	  Half	  Log	  dose	  tested	  (Figure	  53).	  
	  
	  
Figure	   53.	   Tissue	   LacZ	   detection	   in	   pieces	   of	   treated	   hearts.	   A.	   Tissue	   LacZ	   staining	   performed	   on	  minced	  
treated	   hearts	   3	   weeks	   post-­‐injection	   of	   AAV9.LacZ.	   One	   image	   is	   shown	   per	   dose	   (Saline	   control,	   Low	   -­‐
4.5x1011vg/rat-­‐,	  Half	   Log	   -­‐1.45x1012vg/rat-­‐,	  High	   -­‐1.45x1012vg/rat-­‐)	   as	   representative	  of	  n=3	  animals.	  B.	   	  One	  
stained	   tissue	  piece	  per	  heart	  disposed	  according	   to	   the	  viral	  dose	   received.	  The	  Half	   Log	  dose	  provided	   the	  
highest	  transduction	  and	  is	  highlighted	  in	  red.	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In	   order	   to	   have	   more	   accurate	   information	   about	   the	   viral	   transduction	   achieved,	   we	  
performed	  histochemistry	  for	  LacZ	  reporter	  detection	  on	  sliced	  treated	  hearts.	  The	  relative	  
percentage	  of	   infected	  cells	  detected	  by	  histochemistry	  (Figure	  54)	  was	  comparable	  to	  the	  
results	   obtained	   via	   staining	   of	   minced	   tissue	   (Figure	   53),	   indicating	   that	   maximum	  
transduction	   is	   achieved	   at	   the	   Half	   Log	   Dose	   (1.42x1012vg/rat).	   Interestingly,	   substantial	  
infiltration	  of	  nuclei	  appearing	  to	  be	  inflammatory	  cells	  was	  detected	  by	  H&E	  staining	  in	  the	  
High	  Dose	  group	  (Figure	  54).	  	  
	  
	  
Figure	  54.	  LacZ	  reporter	  detection	  on	  heart	  slices	  of	  treated	  animals.	  Representative	  images	  of	  stained	  cardiac	  
tissue	   harvested	   from	   rats	   3	  weeks	   post	   AAV9.LacZ	   intra-­‐jugular	   injection.	   Tissues	  were	   embedded	   in	  O.C.T	  
compound	  and	  10μm	  thick	  sliced	  were	  cut	  using	  a	  cryostat,	  prior	  to	  LacZ	  staining.	  For	  the	  Low	  dose,	  rats	  (n=3)	  
received	  4.5x1011vg	  each.	  For	  the	  Half	  Log	  dose,	  n=3	  rats	  were	  administered	  1.42x1012vg	  each.	  Animals	  of	  the	  
High	  dose	  group	  (n=3)	  received	  4.5x1012vg.	  Control	  animals	  were	  injected	  with	  the	  same	  volume	  of	  saline	  (S).	  
Smaller	  panel	  at	  the	  bottom	  right	  shows	  a	  representative	  High	  Dose	  staining	  at	  higher	  magnitude	  (40x).	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We	   next	   evaluated	   LacZ	   expression	   in	   liver	   and	   skeletal	   muscle	   from	   treated	   animals	   to	  
monitor	  viral	  particle	  clearance	  in	  other	  tissues.	  As	  it	  can	  be	  observed	  in	  Figure	  55,	  no	  LacZ	  
signal	  was	  detected	  for	  neither	  of	  the	  non-­‐cardiac	  tissues	  assayed.	  	  	  
	  
	  
Figure	  55.	  LacZ	  histochemistry	  on	  liver	  and	  skeletal	  muscle	  of	  treated	  animals.	  Representative	  images	  of	  liver	  
and	   skeletal	  muscle	   tissue	   harvested	   from	   rats	   3	  weeks	   post	   AAV9.LacZ	   intra-­‐jugular	   injection.	   Tissues	  were	  
embedded	  in	  O.C.T	  compound	  and	  10μm	  thick	  sliced	  were	  cut	  using	  a	  cryostat,	  prior	  to	  LacZ	  staining.	  For	  the	  
Low	  dose,	  rats	  (n=3)	  received	  4.5x1011vg	  each.	  For	  the	  Half	  Log	  dose,	  n=3	  rats	  were	  administered	  1.42x1012vg	  
each.	  Animals	  of	  the	  High	  dose	  group	  (n=3)	  received	  4.5x1012vg.	  Control	  animals	  were	  injected	  with	  the	  same	  
volume	  of	  saline	  (S).	  	  
	  
3.12.2 	  AAV9.miR30e	   does	   not	   achieve	   detectable	   cardiac	   transgene	  
overexpression	  	  
	  
In	  addition	  to	  the	  trial	  performed	  using	  the	  reporter	  vector	  AAV9.LacZ,	  we	  wished	  to	  confirm	  
whether	   cardiac	  miR-­‐30e	   overexpression	  was	   achieved	  with	   the	   AAV9.miR30e	   vector.	   For	  
this	   purpose,	  we	   studied	   a	   cohort	  where	  AAV9.miR30e	  was	   injected	   following	   exactly	   the	  
same	  protocol	  as	  for	  the	  previous	  LacZ	  reporter	  experiment.	  The	  transgene	  (human	  pre-­‐miR-­‐
30e)	  was	  allowed	  to	  be	  expressed	  for	  3	  weeks.	  Animals	   injected	  with	  AAV9.LacZ	  served	  as	  
control.	   Two	   animal	   groups	  were	   treated	  with	   AAV9.miR30e,	   one	   receiving	  Half	   Log	   dose	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No	  significant	  differences	  in	  miR-­‐30e	  expression	  were	  observed	  across	  sample	  groups,	  both	  
in	   the	   liver	   and	   in	   the	   heart	   (Figure	   56).	   	   The	   RNA	   samples	   obtained	   from	   treated	   hearts	  
presented	   slightly	   variable	   U6	   levels.	   Therefore,	   the	   accuracy	   of	   RNA	   quantification	   was	  
confirmed	  visually	  by	  RNA	  gel	  and	  miR-­‐1,	  an	  abundant	  miRNA	  in	  the	  heart,	  was	  chosen	  as	  an	  
additional	  normalizer	  for	  RT-­‐qPCR.	  Nevertheless,	  miR-­‐30e	  expression	  remained	  steady	  using	  
both	  U6	  and	  miR-­‐1	  as	  controls	  (Figure	  56A	  and	  B).	  	  
	  
	  
Figure	  56.	  Evaluation	  of	  miR-­‐30e	  expression	  after	  AAV9.miR30e	  treatment.	  RT-­‐PCR	  data	  showing	  mature	  miR-­‐
30e	  quantified	  in	  tissues	  from	  treated	  animals	  3	  weeks	  post	  AAV9	  intra-­‐jugular	  injection.	  Tissues	  were	  manually	  
homogenized	   prior	   RNA	   extraction	   and	   preparation	   for	   Taqman	   RT-­‐PCR.	   Cardiac	   miR-­‐30e	   levels	   were	  
normalised	  to	  both	  U6	  (A)	  and	  miR-­‐1	   (B)	   levels.	   	   C.	   Liver	  miR-­‐30e	  were	  normalised	  to	  U6.	  N=3	  animals	  were	  
included	  per	  group:	  AAV9.LacZ	  (High	  dose,	  4.5x1012vg/rat),	  AAV9.miR30e	  at	  Half	  log	  (1.42x1012vg/rat)	  and	  High	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Given	  that	  AAV9.miR30e	  encodes	  for	  the	  precursor	  form	  of	  miR-­‐30e	  (pre-­‐miR-­‐30e)	  and	  that	  
no	   increase	   in	   mature	   miR-­‐30e	   expression	   was	   detected	   (Figure	   56),	   we	   reasoned	   that	  
measuring	   pre-­‐miR-­‐30e	   would	   provide	   valuable	   information	   about	   a	   potential	   block	   in	  
miRNA	   maturation.	   As	   for	   mature	   miR-­‐30e,	   no	   cardiac	   pre-­‐miR-­‐30e	   overexpression	   was	  
detected	  following	  AAV9.miR30e	  treatment	  (Figure	  57).	  	  
	   	  	  
	  
Figure	  57.	  Cardiac	  pre-­‐30e	   levels	   remain	  unaltered	   following	  AAV9.miR30e	  treatment.	  RT-­‐qPCR	  data	  shows	  
the	  precursor	  miR-­‐30e	  (pre-­‐30e)	  levels	  recorded	  in	  treated	  hearts	  3	  weeks	  after	  intra-­‐jugular	  rAAV	  injections.	  
N=3	   animals	   were	   included	   per	   group:	   AAV9.LacZ	   (High	   dose,	   4.5x1012vg/rat),	   AAV9.miR30e	   at	   Half	   log	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3.13 DISCUSSION	  –	  Part	  II	  
	  
3.13.1 miR-­‐30	  target	  prediction	  and	  experimental	  validation	  
	  
After	  detecting	  a	  cardiomyocyte-­‐specific	  down-­‐regulation	  of	  several	  miR-­‐30	  family	  members	  
upon	  both	  acute	  and	  chronic	  DOX	  exposure	   (recapitulated	   in	  our	  models	  of	  post-­‐MI	   injury	  
leading	   to	  HF)	   (Figure	   26,	   Table	   10	   and	  Figure	   28),	  we	  proceeded	   to	   investigate	  potential	  
targets	  of	  miR-­‐30.	  	  
The	   anticipated	   relevance	   of	   miR-­‐30	   in	   heart	   disease	   was	   supported	   by	   DAVID	   pathway	  
enrichment	   analysis	   of	   the	   predicted	   miR-­‐30	   gene	   target	   list	   retrieved	   from	   TargetScan,	  
which	   showed	   significant	   enrichment	   of	   predicted	   targets	   with	   involvement	   in	  
cardiomyopathy	   (Figure	   30).	   	  Moreover,	  we	  used	  Cytoscape	   software	   in	  order	   to	   visualize	  
gene	   interacting	   networks	   within	   the	   extensive	   list	   of	   putative	   miR-­‐30	   targets	   (a	   total	   of	  
1357	   phylogenetically	   conserved	   genes).	   We	   considered	   genes	   that	   also	   interacted	   with	  
other	  miR-­‐30	  targets	  as	  predictions	  with	  potentially	  higher	  relevance.	   Importantly,	  miRNAs	  
have	  been	  described	  to	  regulate	  complex	  biological	  processes	  by	  regulating	  multiple	  genes	  
of	  a	  signalling	  cascade.	  This	  phenomenon	  allows	  for	  modest	  changes	  in	  miRNA	  expression	  to	  
have	   biologically	   relevant	   downstream	   consequences	   that	   affect	   the	   global	   cellular	  
phenotype	  211,	  267,	  371.	  Of	  the	  56-­‐gene	  interacting	  network	  revealed	  by	  Cytoscape	  within	  the	  
predicted	   miR-­‐30	   target	   list,	   we	   identified	   a	   subset	   of	   genes	   that	   are	   fundamental	   in	  
cardiomyocyte	   biology:	   ATP2A2	   (SERCA2a),	   ADRB1	   (β1AR),	   ADRB2	   (β2AR),	   BNIP3L,	   DMD	  
(dystrophin),	   DTNA	   (dystrobrevin-­‐alpha),	   GNAI2	   (Giα-­‐2)	   and	   TRDN	   (triadin)	   (Figure	   31).	   A	  
direct	  association	  with	  cardiomyopathy	  and	  HF	  was	  more	  straightforward	  to	  hypothesise	  for	  
some	  of	  these	  than	  for	  others.	  β1AR,	  β2AR	  and	  Giα-­‐2	  are	  key	  components	  of	  the	  β-­‐adrenergic	  
pathway,	  which	   is	  often	  altered	   in	  the	  development	  of	  HF	  11,	  while	  BNIP3L	   is	  known	  to	  be	  
pro-­‐apoptotic	   in	   cardiomyocytes	   75.	   On	   the	   other	   hand,	   the	   targeting	   of	   Ca2+	   transporter	  
SERCA2a	   by	  miR-­‐30	   seems	   to	   be	   counterintuitive,	   since	   it	   is	   lower	   levels	   of	   SERCA2a	   that	  
have	  been	  found	  to	  worsen	  prognosis	  in	  patients	  105.	  DMD,	  DTNA	  and	  TRDN	  have	  structural	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roles	   in	   the	   myocardium	   that,	   although	   central	   to	   contraction,	   are	   part	   of	   a	   separate	  
compartment	   of	   myocyte	   biology	   372-­‐374.	   Therefore,	   we	   shortlisted	   four	   of	   the	   predicted	  
target	   genes	   identified	   as	   part	   of	   the	   interaction	   network	   to	   be	   the	   focus	   of	   this	   thesis	  
hereinafter:	   β1AR,	   β2AR,	   BNIP3L	   and	   Giα-­‐2.	   In	   any	   case,	   initial	   luciferase	   validation	   was	  
performed	  for	  the	  non-­‐selected	  genes	  too,	  since	  members	  of	  our	   laboratory	  might	  wish	  to	  
investigate	  them	  in	  the	  future	  (Figure	  62).	  	  
The	   strategy	   followed	   for	   experimental	   validation	   of	   the	   four	   selected	   miR-­‐30	   target	  
predictions	   consisted	   of	   initial	   3’UTR	   luciferase	   assays	   (Figure	   33C),	   followed	   by	   a	  
combination	  of	  gain	  and	   loss-­‐of-­‐function	  studies.	  Synthetic	  mimics	  coding	   for	   the	  pre-­‐miR-­‐
30e	   were	   used	   to	   exogenously	   increase	   miR-­‐30e	   expression.	   For	   miR-­‐30	   inhibition,	   we	  
generated	  a	  sponge	  vector	   (pEGFP-­‐sp30)	  able	   to	  sequester	  endogenous	  miR-­‐30	  molecules.	  
Successful	  transfection	  of	  H9c2	  cultures	  with	  said	  vector	  could	  be	  confirmed	  by	  visualization	  
of	   the	   fluorescence	   produced	   by	   EGFP-­‐positive	   cells.	   Lower	   EGFP	   signal	   was	   observed	   in	  
cultures	  transfected	  with	  pEGFP-­‐sp30	  compared	  to	  the	  parental	  plasmid	  lacking	  the	  tandem	  
repeats	  (pEGFP-­‐C1)	  (Figure	  35B),	  most	  likely	  a	  result	  of	  the	  post-­‐transcriptional	  repression	  of	  
the	   EGFP	   reporter	   exerted	   by	   endogenous	   miR-­‐30	   molecules,	   rather	   than	   a	   differential	  
transfection	  efficacy.	  	  
	  Experimental	   overexpression	   of	   miR-­‐30e	   correlated	   with	   decreased	   expression	   of	   the	  
predicted	  targets	  (Figure	  34).	  On	  the	  contrary,	  miR-­‐30	  family	  inhibition	  triggered	  an	  increase	  
in	   target	   levels	   both	  when	   using	   the	   homemade	   pEGFP-­‐sp30	   vector	   and	   commercial	   LNA	  
inhibitors	   for	   this	  purpose	   (Figure	   36	  and	  Figure	   37).	  Taken	   together,	   the	   results	  obtained	  
from	  miR-­‐30	  modulation	  in	  both	  directions	  validate	  the	  four	  predicted	  genes	  selected	  from	  
the	   initial	   bioinformatics	   prediction	   (β1AR,	   β2AR,	   BNIP3L	   and	  Giα-­‐2)	   as	  bone	   fide	   targets	   of	  
miR-­‐30.	   In	   keeping	   with	   these	   findings,	   increased	   β2AR	   cardiac	   expression	   upon	   DOX	  
treatment	  in	  vivo	  has	  recently	  been	  reported	  375.	  Moreover,	  the	  fact	  that	  DOX	  treatment	  was	  
able	  to	  up-­‐regulate	  expression	  of	  the	  miR-­‐30	  targets	  validated	  in	  this	  study	  agrees	  with	  the	  
observed	  DOX-­‐induced	  down-­‐regulation	  of	  miR-­‐30.	  This	   result	  hints	   the	   importance	  of	   the	  
identified	  miR-­‐30	  targets	   in	   the	  cardiac	  molecular	  events	   triggered	  by	  DOX.	  Notably,	   these	  
effects	   could	  be	  offset	  by	   the	  administration	  of	  miR-­‐30e	  mimics	   in	   combination	  with	  DOX	  
(Figure	   38).	   This	   balancing	   effect	   of	   miR-­‐30e	   supplementation	   suggests	   the	   DOX-­‐induced	  
increase	   in	  target	  expression	   levels	   to	  be	  a	  direct	  result	  of	   the	  down-­‐regulation	  of	  miR-­‐30.	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This	  finding	  entails	  that	  therapeutic	  addition	  of	  miR-­‐30	  could	  compensate	  for	  the	  effects	  of	  
DOX	   on	   the	   described	   target	   genes,	   maintaining	   their	   expression	   closer	   to	   physiological	  
levels.	  	  
	  
3.13.2 miR-­‐30	  targets	  have	  key	  implications	  in	  cardiac	  disease	  
	  
The	   association	   between	   reduced	   miR-­‐30	   levels	   and	   cardiac	   disease	   has	   been	   recently	  
reported	  in	  relevant	  animal	  models	  and	  also	  in	  patient	  samples	  261,	  266,	  339.	  Nevertheless,	  the	  
description	   of	   miR-­‐30	   target	   genes	   and	   their	   cellular	   functions	   has	   remained	   scarce.	   The	  
target	  subset	  discovered	  in	  this	  research	  makes	  up	  core	  components	  of	  cardiac	  cell	  signalling	  
and	  function.	  Therefore,	  we	  reasoned	  that	  the	  central	  downstream	  effects	  that	  would	  derive	  
from	   manipulating	   miR-­‐30	   in	   cardiac	   cells	   would	   partly	   reflect	   the	   mechanisms	   being	  
unleashed	  by	  DOX	  treatment	  in	  the	  myocardium.	  
	  
3.13.2.1 Beta-­‐adrenergic	  pathway	  modulation	  by	  miR-­‐30	  
	  
Three	  of	   the	  validated	  miR-­‐30	  targets	  during	   the	  course	  of	   this	   thesis	  are	  key	  members	  of	  
the	   β-­‐adrenergic	   pathway:	   β1AR,	   β2AR	   and	   Giα-­‐2.	   β-­‐adrenoceptors	   function	   to	   detect	  
catecholamine	   stimulation	   in	   the	   cell	   surface	   and	   translate	   it	   into	   cellular	   activities.	  
Subsequent	   to	   βAR	   activation	   is	   the	   synthesis	   of	   the	   intracellular	   mediator	   (or	   second	  
messenger)	   cAMP	   by	   AC	   19.	   We	   demonstrated	   that	   cAMP	   accumulation	   levels	   vary	   in	  
response	   to	   alterations	   in	   miR-­‐30	   levels,	   exhibiting	   an	   inverse	   correlation	   with	   miR-­‐30	  
abundance	   (Figure	   39).	   This	   is	   in	  keeping	  with	   the	  direct	  post-­‐transcriptional	   regulation	  of	  
β1AR	   and	   β2AR	   by	   miR-­‐30	   described	   in	   this	   thesis.	   DOX	   treatment	   triggered	   greater	  
accumulation	   of	   cAMP	   than	   specific	   miR-­‐30	   inhibition,	   which	   suggests	   that	   DOX	  may	   act	  
through	  additional	  pathways	  that	  also	  encourage	  cAMP	  build-­‐up.	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With	  regard	  to	  cardiomyocyte	  contractility,	  the	  βAR	  positive	  inotropic	  effect	  arises	  following	  
a	  rise	  in	  intracellular	  Ca2+	  mediated	  by	  AC-­‐cAMP-­‐PKA	  signalling	  19,	  20.	  Given	  that	  Giα-­‐2	  inhibits	  
AC	  activity	  and	  therefore	  has	  a	  negative	  inotropic	  effect	  (reduced	  contractility)	  376,	  the	  cAMP	  
accumulation	  we	  observed	  suggests	  miR-­‐30	  to	  be	  inhibiting	  βARs	  more	  deeply	  compared	  to	  
Giα-­‐2.	  Our	   suspicions	  about	   the	   regulation	  exerted	  by	  miR-­‐30	  on	   the	  β-­‐adrenergic	  pathway	  
were	   reaffirmed	   by	   the	   contractility	   studies	   performed	   on	   transfected	   ARVCM.	   Baseline	  
contraction	  amplitude	  of	  ARVCM	  with	  exogenously	   increased	  miR-­‐30e	   levels	  did	  not	  differ	  
from	   control	   cardiomyocytes	   (Figure	   40B),	   importantly	   implying	   that	   higher	   miR-­‐30	  
expression	   is	   not	   detrimental	   for	   basal	   contraction.	   However,	   ARVCM	   showed	   decreased	  
contractile	   response	   to	   ISO	   stimulation	   upon	  miR-­‐30e	   overexpression	   (Figure	   40C),	   which	  
might	  appear	  counterintuitive	  in	  relation	  to	  HF	  since	  it	  tends	  to	  be	  associated	  with	  reduced	  
CO.	   Yet,	   the	   observed	   reduction	   in	   contractile	   responses	   precisely	   mirrors	   the	   effects	  
achieved	  with	  β-­‐blocker	  agents,	  widely	  used	  to	  rescue	  cardiac	  function	  86.	  Moreover,	  it	  must	  
be	  considered	  that	  miR-­‐30	  expression	  achieved	  by	  exogenous	  overexpression	  is	  substantially	  
greater	  than	  physiological	  levels.	  	  
These	  overexpression	  experiments	  served	  to	  illustrate	  the	  overall	  impact	  of	  miR-­‐30	  on	  the	  β-­‐
adrenergic	  pathway,	  which	  results	  from	  the	  net	  effect	  of	  the	  simultaneous	  repression	  of	  βAR	  
and	   Giα-­‐2.	   ISO	   is	   a	   βAR	   agonist	   and,	   given	   that	   βARs	   enhance	   cardiomyocyte	   contractility	  
while	   Giα-­‐2	   inhibits	   it,	   the	   attenuated	   contractile	   response	   to	   ISO	   stimulation	   suggests	  
preferential	  repression	  of	  βAR	  by	  miR-­‐30	  alongside	  a	  compensatory	  inhibition	  of	  Giα-­‐2.	  In	  any	  
case,	   it	   is	  worth	  noting	   that	  alternate	  miR-­‐30	   target	  genes	   to	   the	  ones	   studied	  here	  could	  
also	   be	  modulating	   contractile	   responses	   of	   transfected	  ARVCM.	   The	  observed	   contractile	  
phenotype	   was	   copied	   by	   PTX-­‐mediated	   ablation	   of	   Gi	   combined	   with	   miR-­‐30	  
overexpression.	   PTX	   treatment	   resulted	   in	   more	   cell	   death	   and	   higher	   arrhythmia	   in	   the	  
studied	  ARVCM,	  which	   agrees	  with	   the	  described	   anti-­‐apoptotic	   and	   anti-­‐arrhythmic	   roles	  
for	  Giα-­‐2	   22,	  24,	  377.	  Even	  though	  cells	   survived	  to	  shorter	  dose	  response	  curves	   following	   the	  
challenges	   of	   transfection	   with	   miR-­‐30e	   mimics	   over	   48h	   and	   exposure	   to	   PTX,	   pre-­‐NC	  
transfected	  ARVCM	   treated	  with	   PTX	   showed	   significantly	   enhanced	   contractile	   amplitude	  
upon	   stimulation	   with	   ISO.	   Conversely,	   PTX-­‐treated	   miR-­‐30e	   overexpressing	   ARVCM	  
presented	  no	  significant	  alteration	  of	  their	  contractile	  response	  to	  ISO	  in	  relation	  to	  miR-­‐30	  
transfected	   ARVCM	   not	   unexposed	   to	   PTX	   (Figure	   41).	   These	   results	   indicate	   that,	   even	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when	   incorporating	   extra	  Giα-­‐2	   inhibition	   by	   PTX,	  miR-­‐30	   still	   has	   predominantly	   inhibitory	  
effects	  on	  βARs	  (β1AR,	  β2AR).	  	  
In	  summary,	  high	  miR-­‐30	  expression	  correlates	  with	  lower	  intracellular	  cAMP	  accumulation,	  
reduced	  contractile	  response	  to	  ISO	  stimulation	  but	  normal	  baseline	  contractility,	  and	  with	  
unaffected	  contraction	  amplitude	  upon	  PTX	  treatment.	  These	  data	  support	  a	  β-­‐blocker	  like	  
activity	   for	  miR-­‐30.	  Since	  we	  have	  shown	  here	   that	  miR-­‐30	   targets	  both	  β1AR	  and	  β2AR,	   it	  
would	  function	  as	  a	  non-­‐selective	  β-­‐blocker.	  Recent	  publications	  propose	  a	  preferred	  use	  of	  
β1-­‐selective	   blockers	   that	   are	   able	   to	   concomitantly	   maintain/stimulate	   β2AR	   signalling.	  
Certainly,	  β2AR-­‐specific	  agonists	  are	   thought	   to	  provide	  an	  attractive	   therapeutic	   target	   to	  
minimize	  myocyte	  apoptosis	  and	  arrhythmogenesis	  378.	  Nevertheless,	  it	  is	  important	  to	  note	  
that	   miRNAs	   are	   moderate	   regulators	   and	   miR-­‐30	   administration	   would	   therefore	   cause	  
modest	  changes	   in	  βAR	  expression.	   In	  addition,	  miR-­‐30	  repression	  of	  the	  β2AR-­‐Gi	  signalling	  
pathway,	  which	   is	  considered	  to	  be	  anti-­‐apoptotic	   in	  cardiomyocytes,	  would	  expectedly	  be	  
compensated	  by	   the	   simultaneous	   inhibition	  of	   the	  key	  pro-­‐apoptotic	   gene	  BNIP3L.	   In	   the	  
particular	   case	   of	   DOX-­‐induced	   cardiotoxicity,	   it	   should	   be	   noted	   that	   given	   the	   reported	  
increase	  in	  β2AR	  expression	  in	  injured	  hearts	  –in	  agreement	  with	  our	  data-­‐	  375,	  it	  is	  debatable	  
whether	  β2AR	  stimulation	  would	  be	  beneficial	   in	   this	  model.	  Besides,	   some	  degree	  of	  Giα-­‐2	  
inhibition	   by	   miR-­‐30	   is	   not	   predicted	   to	   be	   damaging,	   as	   Giα-­‐2	   expression	   is	   found	   up-­‐
regulated	  in	  end	  stage	  HF	  56.	  
Remarkably,	  the	  implications	  of	  the	  subset	  of	  miR-­‐30	  targets	  described	  here	  extend	  beyond	  
the	   DOX	   cardiotoxicity	   model	   on	   which	   this	   research	   has	   focused.	   A	   number	   of	   cardiac	  
conditions	  leading	  to	  failure	  have	  been	  attributed	  to	  an	  intense	  stimulation	  of	  βARs	  -­‐	  from	  
hypertrophy	   leading	   to	   failure	   52,	   to	  stress	   (Takotsubo)	  cardiomyopathy	  deriving	   from	  high	  
circulating	   adrenaline	   379.	   Chronic	   catecholamine	   stimulation	   causes	   negative	   inotropic	  
effects	  on	  myocytes,	  leading	  to	  global	  ventricular	  dysfunction	  18.	  Catecholamines	  have	  been	  
shown	  to	  induce	  dose-­‐dependent	  apoptosis	  in	  cardiomyocytes,	  which	  can	  be	  blunted	  by	  the	  
use	  of	  β-­‐blockers.	  This	   toxicity	  appears	   to	  be	  mediated	  by	   increased	  cAMP	   leading	   to	  Ca2+	  
overload	   380.	   In	   addition,	   metabolic	   products	   of	   catecholamines	   have	   been	   shown	   to	  
generate	  ROS	  381.	  Oxidative	  stress	  has	  been	  linked	  to	  the	  pathophysiology	  of	  HF	  in	  general	  382	  
and,	  more	  specifically,	  to	  anthracycline	  cardiomyopathy	  114,	  156.	  Therefore,	  the	  restoration	  of	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miR-­‐30	   expression	   in	   DOX-­‐treated	   hearts	   could	   also	   contribute	   to	   reduced	   ROS	   levels	   by	  
repressing	  β-­‐adrenergic	  expression.	  	  
To	   recapitulate,	   the	   down-­‐regulation	   of	   miR-­‐30	   caused	   by	   DOX	   could	   be	   enhancing	   β-­‐
adrenergic	  signalling	  (Figure	  38,	  Figure	  39,	  Figure	  41).	  This,	  in	  turn,	  would	  lead	  to	  increased	  
responsiveness	  to	  catecholamines	  and	  the	  associated	  risks	  of	  overstimulation.	  Importantly,	  a	  
potential	   link	   between	   DOX	   cardiotoxicity	   and	   the	   detrimental	   effects	   of	   the	  
catecholamine/βAR	  cascade	  can	  be	  drawn	  from	  a	  study	  where	  the	  administration	  of	  clinical	  
doses	   of	   DOX	   in	   dogs	   induced	   an	   increase	   in	   circulating	   catecholamines	   60.	   The	   potential	  
contribution	   of	   catecholamine-­‐mediated	   βAR	   stimulation	   to	   the	   mechanisms	   involved	   in	  
DOX	  cardiomyopathy	  would	  precisely	  support	  the	  discussed	  therapeutic	  use	  of	  miR-­‐30	  as	  a	  
β-­‐blocker	  agent.	  	  
	  
3.13.2.2 Apoptosis	  prevention	  
	  
Apoptosis	   is	   the	  predominant	   type	  of	  programmed	  cell	  death	   in	   the	  heart	  and	   it	  has	  been	  
elucidated	  as	  a	  causal	  factor	  in	  HF.	  In	  fact,	  the	  presence	  of	  even	  low	  numbers	  of	  apoptotic	  
cardiomyocytes	  is	  able	  to	  drive	  lethal	  dilated	  cardiomyopathy	  69.	  Apoptosis	  undermines	  the	  
contractile	   mass	   that	   forms	   the	   functional	   myocardium,	   contributing	   to	   pathological	  
remodelling	  of	  the	  remaining	  cardiomyocytes	  to	  maintain	  CO.	  During	  MI,	  cell	  death	  occurs	  
acutely	   but	   affecting	   to	   a	   great	   proportion	   of	   the	  myocardium,	  while	  more	  moderate	   but	  
sustained	   apoptosis	   features	   subsequently	   in	   HF.	   Any	   of	   the	  mechanisms	   involved	   in	   this	  
pathologic	  process	  are	  considered	  as	  therapeutic	  targets	  383.	  	  
Mitochondrial	   cell	   death	   is	   particularly	   important	   in	   the	   myocardium,	   as	   it	   has	   been	  
estimated	   that	   mitochondria	   correspond	   to	   approximately	   an	   impressive	   36%	   of	   the	  
cardiomyocyte	  content	  68.	  The	  pivotal	  role	  of	  this	  organelle	  in	  cardiac	  cell	  loss	  is	  mediated	  by	  
intrinsic	   death	   pathways	   through	   the	   release	   of	   apoptogenic	   proteins	   (cytochrome	   c)	   and	  
caspase	   activation	   67,	   384.	   Interestingly,	   the	   administration	   of	   caspase	   inhibitors	   is	   able	   to	  
prevent	   cardiac	   apoptosis	   in	   vivo	   and	   to	  dramatically	   reduce	   infarction	   size	   385-­‐387.	   Indeed,	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caspase-­‐dependent	   apoptosis	   affecting	   cardiomyocytes	   is	   now	   appreciated	   to	   be	   a	   crucial	  
event	  in	  the	  development	  of	  DOX-­‐associated	  injury	  167,	  168,	  353	  and	  of	  HF	  in	  general	  62,	  352.	  Our	  
results	  showed	  the	  ability	  of	  miR-­‐30	  to	  partly	  counteract	  the	  caspase	  activation	  induced	  by	  
DOX	   in	   cardiac	   cultures	   (Figure	   42).	   In	   keeping	  with	   this,	   Annexin	  V	   assays	   also	   showed	  a	  
modest	  protection	  against	  DOX-­‐induced	  apoptosis	   in	  general	  exerted	  by	  miR-­‐30	  expression	  
(Figure	  43).	  In	  aggregate,	  these	  results	  suggest	  a	  contribution	  of	  miR-­‐30	  down-­‐regulation	  to	  
the	  apoptosis	  induced	  by	  DOX	  in	  cardiac	  cells.	  	  
Given	   the	   biological	   implications	   of	   the	   miR-­‐30	   target	   genes	   validated	   here,	   it	   is	   not	  
surprising	  that	  their	  inhibition	  by	  said	  miRNA	  contributes	  to	  diminish	  caspase	  activation	  and	  
therefore	  apoptosis.	   The	  present	   findings	   suggest	  preferential	   repression	  of	   the	  AC-­‐cAMP-­‐
PKA	  arm	  rather	  than	  the	  β2AR-­‐Gi-­‐PI3K/Akt	  arm	  of	  the	  β-­‐adrenergic	  pathway	  by	  miR-­‐30.	  Since	  
the	   former	   cascade	   is	   associated	   with	   pro-­‐apoptotic	   effects	   while	   the	   latter	   has	   been	  
described	  as	  anti-­‐apoptotic,	  the	  fine-­‐tuning	  exerted	  by	  miR-­‐30	  is	  expected	  to	  be	  protective	  
for	  cardiomyocytes.	  miR-­‐30	  indeed	  prevents	  cAMP	  accumulation	  (Figure	  39),	  which	  seems	  to	  
mediate	   myocyte	   death	   associated	   with	   βAR	   overstimulation	   350,	   388.	   Furthermore,	   the	  
moderate	  Gi	   targeting	  by	  miR-­‐30	   in	   relation	   to	  βAR	   inferred	   from	  our	   results	   (Figure	   40C,	  
Figure	  41)	  is	  most	  likely	  to	  be	  advantageous,	  as	  retention	  of	  Gi	  activity	  serves	  to	  reduce	  cell	  
death	  in	  cardiomyocytes	  22,	  24.	  	  
On	   the	   other	   hand,	   probably	   complementing	   the	  mentioned	   beneficial	   effects	   exerted	   by	  
modulating	   the	   β-­‐adrenergic	   pathway,	   miR-­‐30	   is	   able	   to	   target	   the	   pro-­‐apoptotic	   gene	  
BNIP3L.	  Interestingly,	  BNIP3L	  has	  been	  linked	  to	  cardiomyopathy	  through	  mitochondrial	  cell	  
death	  72,	  74,	  75.	  Mitochondria	  are	  an	  important	  source	  of	  ROS,	  which	  seems	  to	  be	  increased	  by	  
the	  metabolism	  of	  ANT	  (DOX)	  and	  also	  of	  catecholamines	  168,	  381,	  389.	  Mitochondria	  of	  failing	  
hearts	   produce	   more	   ROS	   than	   in	   healthy	   hearts,	   eventually	   surpassing	   the	   scavenging	  
capacity	  of	  endogenous	  anti-­‐oxidants	   382.	  Oxidative	  stress	  has	  been	  associated	  with	  matrix	  
remodelling	  and	  fibrosis,	  leading	  to	  pathological	  hypertrophy	  or	  dilated	  cardiomyopathy	  and	  
ultimately	   to	   failure	   390-­‐392.	   Also,	   ROS	   can	   cause	   altered	   Ca2+	   homeostasis	   and	   therefore	  
affect	  contraction	  393.	  Our	  investigation	  of	  the	  consequences	  of	  miR-­‐30	  manipulation	  in	  ROS	  
levels	  supports	  the	  benefit	  of	  maintaining	  high	  miR-­‐30	  expression	  also	  in	  this	  regard	  (Figure	  
44).	  In	  comparison	  with	  caspase	  activity	  and	  Annexin	  V	  assays	  where	  the	  protective	  effects	  
caused	   by	   miR-­‐30	   overexpression	   counteract	   only	   part	   of	   the	   cell	   death	   caused	   by	   DOX	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(Figure	  42	  and	  Figure	  43),	  miR-­‐30	  modulation	  seems	  to	  result	  in	  ROS	  changes	  closer	  to	  DOX	  
treatment	   itself.	   This	  may	   indicate	   that	   the	   observed	   protective	   effects	   of	  miR-­‐30	   against	  
DOX	   toxicity	   are	   in	   great	   part	   a	   consequence	   of	   such	   reduced	   ROS	   generation,	   which	   is	  
known	  to	  be	  highly	  detrimental	  for	  the	  cells	  –especially	  for	  cardiomyocytes	  due	  to	  their	  high	  
mitochondrial	  content-­‐	  158.	  	  	  
	  
3.13.3 GATA-­‐6	  negatively	  regulates	  miR-­‐30	  transcription	  
	  
TFs	  are	  known	  to	  regulate	  miRNA	  expression.	   In	  fact,	  a	   large	  number	  of	  TF	  (e.g.	  p53,	  Myc)	  
have	  been	  shown	  to	  be	  the	  underlying	  cause	  of	  aberrant	  miRNA	  expression.	   In	  contrast	  to	  
the	  other	   types	  of	  miRNA	  expression	  regulation,	  TFs	  can	  determine	  relevant	  cell	  or	   tissue-­‐
specific	  patterns	  225.	  Several	  TFs	  are	  considered	  as	  cardiac-­‐specific:	  GATA-­‐4,	  GATA-­‐5,	  GATA-­‐6,	  
MEF2,	  Csx/Nkx-­‐2.5	  and	  HAND	  394.	  
Even	   though	   a	   protective	   role	   has	   been	   reported	   for	   GATA-­‐4	   against	   DOX	   injury	   in	  
cardiomyocytes	  148,	  395,	  there	  is	  no	  published	  evidence	  linking	  GATA-­‐6	  to	  DOX	  cardiotoxicity.	  
Interestingly,	  we	  could	  detect	  a	  significant	  early	  (30min-­‐1h)	  increase	  in	  GATA-­‐6	  expression	  in	  
response	   to	   DOX	   treatment	   on	   cultured	   ARVCM	   (Figure	   45B).	   Although	   we	   had	   already	  
described	  the	  down-­‐regulation	  of	  miR-­‐30e	  at	  6h	  of	  DOX	  exposure	  (Figure	  26	  and	  Figure	  27),	  
we	   could	   also	   confirm	   a	   significant	   reduction	   of	   miR-­‐30e	   levels	   from	   the	   1h	   time	   point	  
(Figure	  45B).	  Even	  though	  it	  is	  known	  that	  changes	  in	  the	  expression	  of	  a	  certain	  TF	  and	  of	  
the	   gene	   being	   regulated	   do	   not	   necessarily	   need	   to	   be	   contemporaneous	   in	   order	   to	   be	  
biologically	   relevant	   396,	  397,	   the	   fact	   that	  miR-­‐30	   down-­‐regulation	  was	   detected	   also	   early	  
after	  DOX	  administration	  seems	  to	  hint	  a	  more	  direct	  correlation.	  	  
A	   subsequent	   investigation	   of	   TF	   binding	   sites	   in	   the	   proximities	   of	  miR-­‐30	   genes	  mining	  
ChIPBase	  database	  revealed	  intriguing	  binding	  sites	  for	  GATA-­‐6	  (on	  human	  CaCo-­‐2	  cells)	  359.	  
Four	   clusters	   form	   the	  miR-­‐30	   family:	  miR-­‐30a,	  miR-­‐30b/miR-­‐30d,	  miR-­‐30e/miR-­‐30c-­‐1	   and	  
miR-­‐30c-­‐2.	  This	  cluster	  organisation	  is	  conserved	  between	  human	  and	  rat,	  although	  genomic	  
locations	  vary	  (Figure	  45C).	  Overlapping	  TFs	  were	  detected	  when	  the	  lists	  of	  all	  TFs	  identified	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to	   bind	   each	  miR-­‐30	   gene	   were	   retrieved.	   TFs	   able	   to	   regulate	   the	   promoters	   of	   several	  
miRNA	   family	   members	   are	   likely	   to	   have	   a	   more	   powerful	   effect	   on	   the	   target	   genes.	  
Besides,	   taking	   into	   account	   our	   findings	   indicating	   that	   DOX	   is	   able	   to	   down-­‐regulate	  
multiple	  miR-­‐30	  members	   (Figure	   26),	   we	   hypothesized	   that	   putative	   TFs	   involved	  would	  
regulate	   several	   miR-­‐30	   promoters.	   Two	   TF	   (FOXA1	   and	   E2F4)	   were	   annotated	   as	  
modulators	   for	   all	   miR-­‐30	   clusters,	   while	   GATA-­‐6	   binding	   sites	   had	   been	   detected	   in	   all	  
cluster	  promoters	  except	  in	  the	  miR-­‐30e/miR-­‐30c-­‐1	  (Figure	  45C).	  Given	  that	  FOXA1	  and	  E2F4	  
do	  not	  belong	  to	  the	  subset	  of	  ‘cardiac	  TF’	  and	  are	  substantially	  less	  expressed	  in	  the	  heart	  
than	   GATA-­‐6,	   we	   continued	   investigating	   the	   role	   of	   GATA-­‐6	   in	   mediating	   the	   observed	  
effects	  of	  DOX	  on	  miR-­‐30.	  
We	   next	   evaluated	   the	   expression	   of	   two	   miR-­‐30	   family	   members	   encoded	   in	   different	  
clusters	   (miR-­‐30d	   and	   miR-­‐30e)	   upon	   GATA-­‐6	   silencing.	   Increased	   levels	   of	   both	   mature	  
miRNAs	   were	   observed	   when	   repressing	   GATA-­‐6.	   Importantly,	   this	   observation	   was	  
comparable	   at	   the	  primary	   stage	  of	  miRNA	  processing	   (Figure	   46B).	   These	   results	   suggest	  
that	  GATA-­‐6	  represses	  miR-­‐30	  transcription.	  Particularly,	  the	  effects	  on	  pri-­‐miR-­‐30d	  and	  pri-­‐
miR-­‐30e	  indicate	  that	  GATA-­‐6	  is	  directly	  implicated	  in	  the	  transcriptional	  regulation	  of	  miR-­‐
30	  rather	  than	  having	  an	  indirect	  interference	  with	  the	  processing	  machinery.	  The	  absence	  
of	   GATA6	   ChIP-­‐seq	   signal	   in	   the	   promoter	   of	  miR-­‐30e/miR-­‐30c-­‐1	   retrieved	   from	   ChIPBase	  
database	  could	  be	  due	   to	   the	  different	   cell	   lines	  used	   (CaCo-­‐2	  versus	  H9c2),	   although	   this	  
should	   be	   demonstrated	   by	   further	   experimental	   investigation.	   Despite	   our	   attempts	   to	  
confirm	   the	   direct	   interaction	   of	   GATA-­‐6	   with	   miR-­‐30	   promoters	   by	   chromatin	  
immunoprecipitation	  ChIP-­‐seq	  in	  H9c2	  cardiac	  cells,	  we	  failed	  to	  achieve	  potent	  and	  specific	  
GATA-­‐6	  immunoprecipitation	  with	  three	  different	  antibodies	  (Figure	  63).	  Another	  important	  
handicap	   that	   we	   faced	   was	   the	   limited	   amount	   of	   information	   available	   in	   the	   USCS	  
Genome	  Browser	  for	  the	  rat	  genome	  in	  comparison	  to	  the	  human	  (Figure	  58)	  398.	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Figure	  58.	  USCS	  Genome	  Browser	  information	  on	  gene	  expression	  regulation	  for	  human	  and	  rat	  genomes.	  	  
	  
Despite	  the	  inability	  to	  perform	  ChIP-­‐sequencing	  on	  GATA-­‐6	  binding	  regions,	  we	  were	  able	  
to	   produce	   additional	   data	   that	   was	   in	   agreement	   with	   our	   previous	   results.	   GATA-­‐6	  
inhibition	   lead	   to	   decreased	   miR-­‐30	   target	   gene	   expression,	   which	   was	   reversible	   when	  
simultaneously	   inhibiting	  miR-­‐30	  family.	  Moreover,	  caspase	  activity	   in	  treated	  cultures	  was	  
reduced	  after	  GATA-­‐6	  repression	  (Figure	  47).	  This	  evidence	  is	  consistent	  with	  the	  suggested	  
role	  for	  GATA-­‐6	  as	  negative	  transcriptional	  regulator	  for	  miR-­‐30.	  Accordingly,	  we	  propose	  a	  
sequence	  of	  events	  involving	  DOX-­‐induced	  GATA-­‐6	  expression,	  which	  in	  turn	  inhibits	  miR-­‐30	  
transcription	   (miR-­‐30	   detected	   as	   down-­‐regulated	   by	   DOX)	   leading	   to	   increases	   in	   target	  
gene	  (β1AR,	  β2AR,	  BNIP3L,	  and	  Giα-­‐2)	  expression.	  	  
Notably,	  elevated	  GATA-­‐6	  expression	  has	  been	  associated	  with	  the	  development	  of	  cardiac	  
hypertrophy.	   Therefore,	   in	   spite	   of	   being	   crucial	   during	   cardiac	   development,	   GATA-­‐6	  
expression	   should	   not	   surpass	   physiological	   levels	   in	   adult	   cardiomyocytes	   399,	   400.	   We	  
speculate	  that	  this	  is	  in	  agreement	  with	  the	  miR-­‐30	  down-­‐regulation	  observed	  in	  our	  models	  
of	   post-­‐MI	   hypertrophy	   and	   failure	   (Figure	   26	   and	   Figure	   28),	   given	   the	   inversely	  
proportional	   relation	   between	   GATA-­‐6	   and	   miR-­‐30	   levels.	   TFs	   and	   miRNAs	   are	   known	   to	  
complement	  each	  other	  in	  complex	  regulatory	  circuits	  that	  constitute	  a	  whole	  new	  level	  for	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might	  contribute	  to	  unravel	  the	  mechanisms	  behind	  DOX	  cardiotoxicity,	  by	  partly	  explaining	  
the	  link	  between	  DOX	  exposure	  and	  the	  miR-­‐30	  expression	  changes	  observed.	  	  
	  
3.13.4 miR-­‐30	  plays	  an	  important	  role	  in	  breast	  cancer	  
	  
In	  the	  light	  of	  the	  presented	  data	  revealing	  miR-­‐30’s	  impacts	  on	  essential	  cardiac	  processes,	  
we	   envision	   potential	   therapeutic	   applications	   for	   this	   miRNA.	   With	   this	   translational	  
perspective	   in	   mind,	   it	   is	   vital	   to	   assess	   the	   effects	   that	   exogenously	   increasing	   miR-­‐30	  
expression	  may	  have	  in	  the	  patients’	  tumours.	  
There	   have	   recently	   been	   a	   number	   of	   publications	   highlighting	   an	   encouraging	   tumour	  
suppressor	   role	   for	   miR-­‐30	   360.	   These	   studies	   demonstrate	   the	   implication	   of	   miR-­‐30	   at	  
different	   levels	   of	   cancer	   progression	   including:	   targeting	   of	   oncogenes	   402,	   inhibition	   of	  
proteins	  involved	  in	  invasion	  and	  metastasis	  362,	  403,	  promoting	  apoptosis	  in	  tumour	  initiating	  
cells	  361	  and	  minimizing	  resistance	  to	  chemotherapy	  404.	  	  
Upon	   investigation	   of	   MDA-­‐MB-­‐231	   BCC	   proliferation	   in	   our	   laboratory,	   no	   significant	  
changes	  were	  detected	  in	  response	  to	  miR-­‐30	  modulation	  (Figure	  48).	  Admittedly,	  Bockhorn	  
et	   al.	   reported	   the	   same	   result	   last	   year	   404.	   However,	   there	   was	   a	   reproducible	   inverse	  
correlation	   between	  miR-­‐30	   expression	   levels	   and	  migration	   of	   MDA-­‐MB-­‐231	   BCC,	   which	  
proposes	   an	   anti-­‐metastatic	   activity	   for	   this	   miRNA	   (Figure	   49A).	   The	   steady	   decrease	   in	  
miR-­‐30	  expression	  measured	  at	   different	   stages	  of	   cancer	  progression	   in	   an	  MDA-­‐MB-­‐231	  
xenograft	  model	   supports	   this	  hypothesis	   (Figure	   49B).	   Corroborating	  our	   findings,	  potent	  
anti-­‐metastatic	   effects	   through	   the	   regulation	   of	   genes	   involved	   in	   epithelial-­‐to-­‐
mesenchymal	  transition	  (EMT)	  have	  been	  demonstrated	  by	  others	  for	  miR-­‐30	  both	   in	  vitro	  
and	  in	  vivo	  360,	  362,	  403.	  
Bioinformatic	  analysis	  of	  miR-­‐30	  levels	  in	  a	  breast	  cancer	  patient	  cohort	  comparing	  biopsies	  
from	  breast	  carcinoma	  cases	  to	  relapse-­‐free	  mammoplasty	  controls	  showed	  a	  trend	  of	  miR-­‐
30	  down-­‐regulation	  in	  cancer	  (Figure	  50A).	  Expression	  levels	  of	  miR-­‐30a	  and	  miR-­‐30e	  family	  
members	  were	  statistically	  reduced	  in	  the	  disease	  group	  (Figure	  50B),	  as	  well	  as	  in	  the	  high	  
Discussion	  –	  Part	  II	  
	   172	  
risk	   group	   compared	   to	   the	   low	   risk	   group	   of	   another	   large	   breast	   carcinoma	   database	  
analysed	   (Figure	   50C).	   Correlating	   with	   this,	   data	   from	   PROGmiR	   database	   confirmed	  
significantly	  more	  favourable	  prognosis	  for	  those	  BC	  patients	  with	  high	  miR-­‐30a	  expression	  
(Figure	  50C).	  	  
Remarkably,	   reduced	   BC	   progression	   and	   expanded	   relapse-­‐free	   survival	   have	   been	  
observed	   in	  patients	  under	  non-­‐selective	  β-­‐blocker	   treatment	   405,	  406.	   In	  a	  mouse	  model	  of	  
BC,	  stress-­‐induced	  neuroendocrine	  activation	  was	  found	  to	  mediate	  metastatic	  progression	  
through	   βAR-­‐induced	   expression	   of	   pro-­‐metastatic	   gene	   patterns	   407.	   Concurring	   results	  
were	   reported	   in	   prostate	   cancer	   in	   mice	   under	   stress,	   in	   which	   cancer	   progression	   was	  
impaired	   by	   treatment	   with	   non-­‐selective	   or	   β2-­‐selective	   antagonists	   408,	   409.	   Similarly,	  
behavioural	   stress	   applied	   to	   an	   ovarian	   cancer	   murine	   model	   resulted	   in	   βAR-­‐mediated	  
increased	   cAMP	   levels	   in	   the	   tumour	   and	   triggered	   enhanced	   angiogenesis	   and	   disease	  
progression	  410.	  	  	  
The	  expression	  of	  βAR	  has	  proven	  to	  be	  far	  more	  widespread	  across	  diverse	  cell	  types	  than	  
initially	   predicted	   411.	   In	   addition	   to	   the	   aforementioned	   evidence	   suggesting	   a	   positive	  
correlation	   between	   βAR	   stimulation	   and	   cancer	   progression	   in	   both	   human	   patients	   and	  
animal	  models,	  β-­‐adrenergic	  signalling	  has	  been	  described	  to	  mediate	  DNA	  damage	  and	  p53	  
reduction	  412.	  Consequently,	  βARs	  have	  emerged	  as	  a	  central	   link	  between	  (catecholamine-­‐
mediated)	  stress	  and	  cancer	  as	  well	  as	  attractive	  therapeutic	  targets	  in	  the	  oncology	  field	  in	  
addition	  to	  their	  current	  cardiovascular	  applications	  (Figure	  59)	  410,	  413.	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Figure	  59.	  Stress-­‐induced	  cathecholamine/β-­‐adrenergic	  effects	  in	  the	  tumour	  microenvironment.	  Responses	  
to	   stress	   involve	   activation	   of	   the	   central	   nervous	   system	   and	   of	   the	   hypothalamic–pituitary–adrenal	   axis.	  
Subsequently,	  catecholamines	  and	  other	  stress	  hormones	  are	  released	  by	  the	  adrenal	  gland	  (neuroendocrine	  
activity).	  Catecholamines	  will	  then	  activate	  β-­‐adrenergic	  signalling	  in	  the	  tumour	  microenvironment	  and	  trigger	  
alterations	   in	   the	   various	   components	   of	   the	   tumour,	   enhancing	   tumour	   growth	   and	   progression.	  Modified	  
from	  413.	  
	  
The	   exciting	   anti-­‐tumour	   activity	   revealed	   for	   β-­‐adrenergic	   antagonists	   complements	   our	  
results	   and	   seems	   to	   partly	   unravel	   the	   reason	   behind	   the	   pleiotropic	   effects	   of	   miR-­‐30	  
discovered	   during	   this	   thesis.	   Overall	   we	   have	   demonstrated	   that	   miR-­‐30	   acts	   like	   a	   β-­‐
blocker	   agent	   in	   cardiomyocytes	   while	   correlating	   with	   less	   aggressive	   tumours.	   Taken	  
together,	   our	   data	   in	   conjunction	   with	   supportive	   published	   evidence	   strongly	   suggest	   a	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3.13.5 Establishment	  of	  an	  AAV-­‐based	  miR-­‐30	  gene	  therapy	  model	  	  
	  
Gene	  therapy	  is	  a	  powerful	  therapeutic	  approach	  that	  can	  be	  applied	  to	  a	  variety	  of	  serious	  
conditions.	   Extensive	   research	   has	   been	   devoted	   to	   optimising	   safety	   and	   efficacy	   of	  
therapeutic	  gene	  transfer,	  although	  it	  is	  only	  recently	  that	  the	  approach	  has	  begun	  to	  live	  up	  
to	   its	   initial	   promise.	  Recombinant	  AAVs	   in	  particular	  have	   successfully	  delivered	   safe	   and	  
long-­‐term	  transgene	  expression	  to	  target	  post-­‐mitotic	  tissues	  in	  a	  variety	  of	  animal	  models	  
as	  well	  as	  in	  clinical	  trials	  414.	  	  
With	   the	   objective	   of	   demonstrating	   a	   cardioprotective	   role	   for	  miR-­‐30,	  we	   proceeded	   to	  
establish	   a	   novel	   AAV-­‐based	   gene	   therapy	  model.	  We	   used	   the	   serotype	   9	   for	  maximum	  
cardiac	  tropism,	  which	  has	  been	  successfully	  trialled	  in	  the	  clinic	  for	  heart	  failure	  treatment	  
(CUPID	  clinical	   trial,	  SERCA2a	  delivery)	   98,	  107.	   In	  our	  case,	  a	  AAV9.LacZ	   reporter	  vector	  was	  
used	   in	   a	   test	   experiment	   to	   define	   an	   appropriate	   viral	   dose.	   Dose	   escalation	   is	   often	  
carried	  out	  in	  the	  logarithmic	  scale	  in	  clinical	  trials;	  a	  half	  log	  increase	  being	  3.16-­‐fold,	  and	  a	  
full	  log	  increase	  corresponding	  to	  10	  times	  higher	  dose	  415,	  416.	  Three	  doses	  in	  the	  logarithmic	  
scale	  were	  chosen	  according	  to	  the	  previous	  experience	  of	  Dr.	  Lyon	  and	  his	  collaborators	  105-­‐
107	   and	   relevant	   published	   studies	   98,	   105,	   417.	   The	   doses	   selected	   for	   these	   studies	   ranged	  
between	  1011	  and	  1013	  viral	  genomes	  (vg)	  per	  animal/patient.	  Taking	  this	  as	   reference,	  we	  
tested	  three	  AAV9.LacZ	  doses:	  4.5x1011	  vg/rat	  (‘Low	  dose’),	  1.45x1012	  vg/rat	  (‘Half	  Log’)	  and	  
4.5x1012	  vg/rat	  (‘High	  dose’).	  
The	  metabolism	   of	   X-­‐Gal	   by	   the	   LacZ	   reporter	   gene	   could	   be	  measured	   as	   blue	   staining,	  
which	   indicated	   that	   highest	   viral	   transduction	  was	   achieved	   at	   the	   intermediate	  Half	   Log	  
dose	   (1.45x1012	  vg/rat)	   (Figure	  53	  and	  Figure	  54).	  No	  LacZ	  expression	  was	  detected	   in	   the	  
liver	  or	  skeletal	  muscle	  of	  treated	  animals,	  suggesting	  that	  the	  AAV	  tropism	  (serotype	  9)	  and	  
intra-­‐jugular	   administration	   route	   chosen	  were	   appropriate	   to	   direct	   gene	   transfer	   to	   the	  
heart	  (Figure	  55).	  We	  allowed	  three	  weeks	  for	  transgene	  expression	  before	  LacZ	  signal	  was	  
assessed,	   as	   2-­‐4	   weeks	   are	   usually	   allowed	   for	   viral	   transduction	   and	   previous	   work	   has	  
indicated	  2	  weeks	   to	  be	  sufficient	   for	  AAV9	  to	  achieve	  substantial	   transgene	  expression	   in	  
transduced	  cells	  102,	  105,	  312.	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AAVs	   can	   induce	   immune	   responses	   directed	   either	   to	   the	   viral	   capsid	   or	   to	   the	   genome	  
itself.	   Immunogenicity	  highly	  depends	  on	  the	  tolerance	  of	   the	  tissue	  being	  targeted	  to	  the	  
transgene	  product	  370.	  The	  administration	  route	  used	  seems	  to	  also	  be	  a	  determining	  factor,	  
as	   intravascular	   injection	  has	  been	  demonstrated	   less	   likely	   to	   induce	  an	   immune	  reaction	  
than	   the	   intramuscular	   route	   418.	   We	   followed	   the	   intravascular	   route	   considered	   ‘less	  
immunogenic’	   and	   observed	   a	   dose-­‐response	   in	   viral	   transduction	   between	   the	   Low	   dose	  
and	   the	  Half	   Log.	  However,	   this	  dose-­‐response	  was	  not	  maintained	   in	   relation	   to	   the	  High	  
dose,	   which	   resulted	   in	   extremely	   low	   gene	   transfer	   to	   the	   myocardium	   (Figure	   53	   and	  
Figure	   54).	   Interestingly,	   substantial	   infiltration	   of	   inflammatory	   cells	  was	   detected	   in	   the	  
H&E	  staining	  of	  hearts	  receiving	  the	  high	  viral	  dose	   (Figure	  54).	  Although	   investigating	  the	  
nature	  of	  the	  infiltrated	  cells	  was	  beyond	  the	  scope	  of	  this	  thesis,	  H&E	  is	  routinely	  used	  as	  
one	  of	  the	  methods	  to	  detect	  myocarditis	  (infection	  of	  the	  myocardium)	  in	  tissue	  biopsies	  on	  
the	  basis	  of	   infiltrated	  nuclei	  419,	  420.	  This	  suggested	  that	  an	   immune-­‐mediated	  clearance	  of	  
the	   infected	   cells	   could	   have	   been	   responsible	   for	   the	   extremely	   low	   LacZ	   expression	  
achieved	  by	  High	  dose	  administration.	  If	  this	  was	  the	  case,	  the	  immune	  response	  could	  have	  
been	  triggered	  by	  either	  the	  capsid	  or	  the	  transgene	  of	  our	  AAV9.LacZ.	  Given	  that	  the	  rAAV	  
designed	   for	   miR-­‐30e	   overexpression	   shares	   the	   same	   AAV9	   capsid,	   we	   would	   expect	   a	  
similar	   degree	   of	   immunogenicity	   if	   the	   capsid	   were	   the	   triggering	   factor.	   Nevertheless,	  
AAV.miR30e	   could	   potentially	   be	   well	   tolerated	   at	   the	   High	   dose	   and	   transduce	   a	   high	  
percentage	  of	  cells	  if	  the	  LacZ	  transgene	  was	  the	  cause	  of	  the	  immune	  reaction	  suggested	  by	  
the	  H&E	  staining.	  Therefore,	  treatment	  arms	  for	  both	  Half	  Log	  and	  High	  dose	  were	  included	  
in	   the	   AAV9.miR30e	   experiment	   in	   order	   to	   exclude	   a	   potential	   transgene-­‐mediated	  
immunotoxicity	  caused	  by	  the	  LacZ	  reporter.	  
Notably,	  the	  AAV9.miR30e	  vector	  does	  not	  encode	  a	  reporter	  gene.	  This	  vector	  design	  was	  
conceived	  to	  avoid	  any	  undesired	  interfering	  effects	  of	  an	  additional	  transgene	  and	  also	  to	  
approximate	   a	   clinically	   acceptable	   rAAV.	   Consequently,	   evaluation	   of	   miR-­‐30e	   levels	   in	  
treated	   hearts	   was	   the	   method	   used	   to	   assess	   gene	   transfer.	   Unfortunately,	   no	   miR-­‐30e	  
overexpression	  was	  detected	   for	  AAV9.miR30e	  treated	  hearts	   in	   relation	  to	   the	  AAV9.LacZ	  
control	  group	  at	  any	  of	  the	  tested	  doses	  (Figure	  56).	  Moreover,	  no	  evidence	  of	  viral	  particle	  
clearance	   to	   the	   liver	   was	   detected,	   as	   miR-­‐30e	   levels	   remained	   comparable	   across	  
treatment	  arms	  (Figure	  56C).	  No	  conclusion	  could	  be	  drawn	  from	  these	  results	  with	  regard	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to	   the	   potential	   immunoreaction	   generated	   in	   the	   host	   by	   the	  High	   viral	   dose,	   given	   that	  
none	  of	  the	  doses	  triggered	  a	  measureable	  increase	  in	  mature	  miR-­‐30e.	  Supposedly,	  capsid-­‐
mediated	   immune	   reaction	   scenario	   would	   have	   resulted	   in	   less/none	   miR-­‐30e	  
overexpression	  at	   the	  High	  dose	   -­‐as	   seen	   for	  AAV9.LacZ-­‐,	  while	   transgene-­‐induced	   toxicity	  
for	  miR-­‐30e	  might	  differ	  to	  that	  of	  LacZ	  and	  be	  better	  tolerated.	  
Having	   precluded	   a	   possible	   block	   in	   the	   processing	   of	   the	   pre-­‐miR-­‐30e	   transgene	   into	  
mature	   miR-­‐30e	   (Figure	   57),	   an	   obvious	   reason	   that	   could	   explain	   the	   absent	   miR-­‐30e	  
overexpression	   detected	   at	   both	  mature	   and	   precursor	   level	   is	   a	   lack	   of	   infectivity	   of	   the	  
AAV9.miR30e	   vector	   itself.	   Additionally,	   the	  miR-­‐30e	   overexpression	   achieved	   could	   have	  
been	  diluted	  by	   a	  bulk	  of	   non-­‐transduced	   cells	   in	   the	   sample,	   provided	   that	   infected	   cells	  
cannot	   be	   specifically	   measured.	   Alternative	   explanations	   for	   our	   results	   refer	   to	   miR-­‐30	  
being	   a	   highly	   abundant	  miRNA	   family	   in	   the	   heart,	   entailing	   potential	   added	  difficulty	   to	  
achieve	   miR-­‐30	   overexpression	   via	   exogenous	   manipulation.	   Indeed,	   discussion	   with	   the	  
authors	  that	  recently	  achieved	  therapeutic	  cardiac	  rescue	  by	  AAV-­‐mediated	  miR-­‐1	  delivery	  
106	  confirmed	  that	  miR-­‐1	  overexpression	  was	  not	  assessed	  in	  healthy	  animals	  but	  only	  in	  the	  
disease	  model	  where	   said	  miRNA	   is	   known	   to	  be	  down-­‐regulated.	  Notably,	   an	   increase	   in	  
miR-­‐1	   expression	   by	   only	   1.5	   folds	   in	   the	   disease	   model	   was	   sufficient	   to	   reverse	   the	  
pathologic	  phenotype.	  Also	   supporting	   this	   last	  explanation,	   in	  another	   study	   investigating	  
an	   AAV.SERCA2a-­‐based	   HF	   treatment	   which	   was	   published	   by	   our	   collaborators	   105,	  
successfully	  therapeutic	  transgene	  overexpression	  was	  only	  shown	  in	  the	  disease	  model	  but	  
not	  in	  the	  control	  arm.	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4.1 Summary	  of	  findings	  
	  
Despite	   our	   initial	   aim	   to	   characterise	  miRNA	   alterations	   that	   could	  mediate	   the	   adverse	  
cardiac	  effects	  of	  HER2	  TKI,	  we	  discovered	  an	  absence	  of	  acute	  changes	  in	  miRNA	  expression	  
in	  LAP-­‐treated	  cultured	  ARVCM.	  By	  contrast,	  susceptible	  BCC	  showed	  LAP-­‐induced	  aberrant	  
miRNA	   levels,	   which	   tentatively	   suggested	   that	   TKIs	   produce	   minimal	   miRNA-­‐mediated	  
effects	  in	  the	  heart.	  This	  evidence	  prompted	  us	  not	  to	  pursue	  the	  optimisation	  of	  an	  in	  vivo	  
LAP	   model	   and	   to	   re-­‐direct	   the	   project	   towards	   the	   investigation	   of	   ANT	   (DOX)	  
cardiotoxicity.	   Indeed,	   substantial	   alterations	   in	   miRNA	   expression	   were	   detected	   in	  
cardiomyocytes	  upon	  DOX	  treatment	  both	  acutely	  (in	  vitro)	  and	  following	  chronic	  exposure	  
in	  vivo.	  One	  miRNA	  (miR-­‐30)	  family	  particularly	  caught	  our	  attention,	  with	  several	  members	  
down-­‐regulated	   in	   both	   DOX	   models	   and	   also	   in	   HF	   following	   MI	   injury.	   Bioinformatic	  
predictions	   hinted	   at	   a	   significant	   enrichment	   of	   miR-­‐30	   target	   genes	   implicated	   in	  
cardiomyopathy.	   We	   were	   able	   to	   experimentally	   validate	   four	   genes	   tightly	   related	   to	  
myocardial	  function	  and	  disease	  (β1AR,	  β2AR,	  BNIP3L	  and	  Giα-­‐2)	  as	  miR-­‐30	  targets.	  Moreover,	  
we	  identified	  the	  TF	  GATA-­‐6	  to	  closely	  correlate	  with	  the	  mediation	  of	  DOX-­‐induced	  changes	  
in	   miR-­‐30	   expression.	   Unfortunately,	   while	   we	   completed	   three	   ChIP	   experiments	  
attempting	  to	  confirm	  GATA-­‐6	  interaction	  with	  various	  miR-­‐30	  promoters,	  we	  were	  unable	  
to	   successfully	   immunoprecipitate	  such	  TF	  with	  any	  of	   the	   three	  antibodies	   independently	  
used.	  Further	  investigation	  into	  the	  contractile	  phenotype	  of	  ARVCM	  overexpressing	  miR-­‐30	  
revealed	   a	   β-­‐blocker	   like	   activity	   for	   this	  miRNA.	   Importantly,	   the	   negative	   feedback	   loop	  
formed	  by	  miR-­‐30’s	  simultaneous	  inhibition	  of	  Giα-­‐2	  is	  likely	  to	  contribute	  to	  the	  fine-­‐tuning	  
of	  the	  balance	  of	  the	  circuit,	  a	  distinctive	  capacity	  of	  certain	  miRNAs	  and	  one	  that	  can	  buffer	  
cellular	  responses	  to	  prevent	  overreactions.	  We	  were	  also	  able	  to	  demonstrate	  a	  protective	  
effect	  of	  miR-­‐30	  against	  caspase-­‐mediated	  DOX	  toxicity	  in	  vitro.	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Figure	  60.	  Proposed	  model	  of	  the	  studied	  mechanisms	  implicated	  in	  DOX-­‐induced	  cardiotoxicity.	  	  
	  
When	   assessing	   the	   implications	   of	   miR-­‐30	   with	   regards	   to	   BC,	   we	   –and	   other	   authors-­‐	  
described	  alterations	  in	  BCC	  migration	  being	  caused	  by	  miR-­‐30.	  Our	  gain	  and	  loss-­‐of-­‐function	  
experiments	   demonstrated	   an	   inverse	   relationship	   between	   miR-­‐30	   levels	   and	   BCC	  
migration.	   In	  addition,	  maintenance	  of	  high	  miR-­‐30	  expression	  seems	  to	  be	  a	  biomarker	  of	  
good	  prognosis	  in	  patients.	  	  	  	  	  	  
In	  an	  effort	  to	  test	  the	  therapeutic	  potential	  of	  miR-­‐30	  in	  a	  translational	   in	  vivo	  setting,	  we	  
designed	   an	   experimental	   design	   involving	   AAV-­‐mediated	   gene	   transfer	   of	   our	   candidate	  
miR-­‐30e	   into	   the	   myocardium.	   Subsequently,	   this	   model	   would	   be	   combined	   with	   DOX	  
administration	   as	   per	   the	   pre-­‐existing	   model	   of	   DOX	   cardiomyopathy.	   This	   model	   was	  
initially	   developed	   during	   the	   course	   of	   this	   thesis.	   However,	   the	   combination	   treatment	  
studies	   (AAV9.miR30e+DOX)	   have	   been	   delayed	   and	   no	   data	   regarding	   the	   expected	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4.2 Limitations	  of	  the	  study	  
	  
Some	  limitations	  of	  this	  work	  should	  be	  taken	  into	  account,	  starting	  with	  the	  LAP	  pilot	  study.	  
We	  are	  aware	  that	  no	  alteration	  in	  miRNA	  expression	  levels	  might	  have	  been	  detected	  due	  
to	   an	   insufficient	   dose	   or	   exposure	   time	   to	   the	   TKI	   utilised.	   However,	  we	   do	   not	   seek	   to	  
further	   investigate	   this	   model	   in	   the	   near	   future.	   In	   our	   opinion,	   a	   more	   interesting	  
experiment	  for	  the	  future	  would	  be	  to	  combine	  ANT	  (DOX)	  administration	  with	  LAP	  to	  mimic	  
the	  adjuvant	  therapy	  commonly	  prescribed	  to	  patients.	  Particularly	  given	  the	  higher	  risk	  of	  
cardiac	   dysfunction	   reported	   after	   combination	   treatment,	   establishing	   a	   novel	   model	   of	  
study	  that	  mirrors	  this	  clinical	  situation	  seems	  more	  relevant.	  	  
With	  regard	  to	  the	  studies	  focusing	  on	  miR-­‐30	  and	  DOX	  cardiotoxicity,	  there	  are	  also	  some	  
limitations	  to	  consider.	  Even	  though	  our	  results	  are	  compatible	  with	  the	  targeting	  of	  the	  four	  
described	   genes	   by	  miR-­‐30,	   additional	   gene	   silencing	   experiments	   could	   be	   performed	   in	  
order	  to	  fully	  assess	  the	  effect	  directly	  mediated	  by	  our	  targets	  on	  the	  phenotype.	  It	  would	  
also	   be	   worth	   addressing	   the	   subtype-­‐specific	   (β1	   or	   β2)	   βAR	   responses	   to	   miR-­‐30	  
modulation.	  Nevertheless,	  the	  expected	  impact	  of	  miR-­‐30	  is	  clear	  given	  the	  opposing	  effects	  
observed	   upon	   exogenous	   overexpression	   and	   inhibition	   throughout	   the	   experiments	  
performed.	   Admittedly,	   our	   primary	   interest	   was	   to	   unravel	   the	   global	   effects	   of	  
dysregulated	  miR-­‐30	  expression	  -­‐	  as	  caused	  by	  DOX-­‐.	  	  
Finally,	  proving	  the	  direct	  binding	  of	  GATA-­‐6	  to	  miR-­‐30	  promoters	  remains	  challenging	  given	  
the	   technical	   obstacles	   discussed.	   Similarly,	   until	   our	  model	   for	  miR-­‐30	   cardiac	   delivery	   is	  
fully	  established,	  the	  magnitude	  of	  the	  miR-­‐30	  target-­‐mediated	  mechanisms	  in	  maintaining	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4.3 Future	  directions	  
	  
The	   administration	   of	   miR-­‐30	   in	   vivo	   will	   provide	   significantly	   deeper	   insight	   into	   the	  
functions	  of	  the	  described	  target	  genes	  in	  relation	  to	  DOX	  injury.	  Therefore,	  the	  imperative	  
study	  in	  our	  future	  work	  section	  is	  the	  establishment	  of	  a	  relevant	  model	  to	  prove	  the	  miR-­‐
30	  mechanisms	  discovered	   in	  vitro	  and	  return	  to	  the	  original	   in	  vivo	   setting	  of	  the	  project.	  
This	   would	   complete	   the	   full	   circle	   of	   this	   research	   and	   allow	   us	   to	   draw	   meaningful	  
conclusions	  about	  a	  possible	  translational	  use	  for	  miR-­‐30.	  	  
The	   experimental	   design	   for	   the	  planned	   in	   vivo	  model	   comprises	   pre-­‐treatment	  with	  our	  
rAAV	   (AAV9.miR30e),	   followed	  by	   the	   reproduction	  of	   the	  existing	  DOX-­‐induced	  HF	  model	  
(Figure	  61).	  The	  rationale	  behind	  the	  order	  of	  the	  treatment	  combination	  relies	  on	  the	  start	  
of	  chemotherapy	  being	  one	  of	  few	  clinical	  scenarios	  where	  the	  date	  of	  initial	  exposure	  to	  the	  
toxic	  agent	  is	  known.	  Also,	  this	  schedule	  allows	  sufficient	  time	  for	  the	  therapeutic	  transgene	  
to	  be	  expressed	  prior	  to	  the	  insult.	  The	  high	  toxicity	  of	  the	  DOX	  model	  is	  also	  an	  important	  
factor	  that	  contributed	  to	  the	  timeline	  design.	  DOX-­‐induced	  cardiotoxicity	  develops	  steadily	  
after	  cumulative	  dosing	  and	  once	  the	  heart	  becomes	  dysfunctional	  the	  window	  to	  examine	  
animals	  prior	  to	  sudden	  death	  is	  extremely	  narrow.	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The	   phenotypic	   characterization	   at	   the	   endpoint	   will	   entail	   echocardiography	   to	   assess	  
cardiac	   function	   across	   treatment	   groups,	   histochemistry	   to	   check	   cell	   morphology	   and	  
arrangement,	  molecular	  studies	  (PCR	  and	  Western	  Blot)	  for	  miRNA	  and	  target	  levels,	  as	  well	  
as	  cardiomyocyte	  contractility	  measures	  ex	  vivo.	  Having	  already	  depicted	  the	  effects	  of	  high	  
miR-­‐30	  expression	  on	  contractility	  using	  transfected	  ARVCM,	   it	   is	   intriguing	  to	  resolve	  how	  
this	   would	   translate	   to	   AAV.miR30e-­‐treated	   animals.	   However,	   considering	   that	   the	   gene	  
transfer	   will	   be	   performed	   in	   combination	   with	   DOX,	   we	   expect	   opposing	   effects	   on	  
contractility	   in	   vivo	   to	   counterbalance	   each	   other.	   Bearing	   in	  mind	   the	   recently	   proposed	  
activity	  of	  miRNAs	  as	  paracrine/endocrine	  signals,	  as	  well	  as	  their	  potential	  as	  non-­‐invasive	  
biomarkers,	   it	   would	   also	   be	   interesting	   to	   measure	   circulating	   miR-­‐30e.	   In	   addition,	  
measures	   of	   other	   serum	   biomarkers	   that	   are	   currently	   used	   to	  monitor	   cardiac	   function	  
(BNP,	  TpnI)	  could	  be	  incorporated	  into	  the	  study	  too.	  	  
The	  described	  AAV9.miR30e+DOX	  model	  is	  a	  challenging	  one,	  with	  numerous	  variables	  to	  try	  
to	  control.	  Apart	  from	  the	  on-­‐going	  optimisation	  of	  the	  gene	  therapy,	  troubleshooting	  is	  also	  
in	  progress	  with	  reference	  to	  the	  DOX-­‐induced	  HF	  model.	  Even	  though	  the	  total	  DOX	  dose	  
used	   in	   this	   project	   (15mg/kg)	   is	   widely	   used	   and	   has	   long	   been	   established	   -­‐and	   even	  
increased	   up	   to	   18	   or	   20mg/kg-­‐	   154,	   319,	   321,	   421,	   animal	   welfare	   issues	  were	   raised	   deriving	  
from	   the	   high	   toxicity	   of	   this	   15mg/kg	  model.	   Admittedly,	   high	  mortality	   rates	   have	   been	  
reported	  by	  other	  authors	  researching	  the	  DOX-­‐induced	  cardiotoxicity	  model,	  ranging	  from	  
30-­‐60%	   when	   applying	   15mg/kg	   cumulative	   doses	   or	   higher	   422,	   423.	   This	   is	   particularly	  
relevant	  in	  our	  case,	  since	  a	  second	  potential	  source	  of	  discomfort	  (recovery	  surgery	  for	  AAV	  
administration)	  will	  be	  incorporated.	  Aiming	  to	  mitigate	  this	  problem,	  we	  generated	  another	  
cohort	   where	   animals	   were	   treated	   with	   a	   cumulative	   DOX	   dose	   of	   10mg/kg.	   After	   four	  
weeks,	   no	   reduction	   in	   LVEF	   was	   observed	   (not	   shown)	   and	   miR-­‐30e	   levels	   were	   not	  
dysregulated	   (Figure	   64).	   As	   a	   result,	   we	   are	   currently	   investigating	   an	   intermediate	  
12.5mg/kg	  dose,	  as	  it	  has	  been	  proved	  to	  be	  sufficient	  to	  trigger	  cardiac	  dysfunction	  424,	  425.	  	  
Eventually,	  we	  believe	  that	   it	  would	  be	   interesting	  to	  combine	  a	  xenograft	  model	  with	  the	  
evaluation	   of	   CO.	   Given	   the	   present	   and	   published	   evidence	   showing	   the	   anti-­‐tumour	  
activity	   of	   miR-­‐30	   and	   the	   dual	   benefits	   of	   β-­‐blockers	   in	   a	   cardioncology	   context,	  
administration	  of	  both	  DOX	  and	  miR-­‐30	  mimics	  could	  potentially	  have	  synergic	  anti-­‐cancer	  
effects	  with	  minimal	   cardiac	   side.	  This	  model	  would	   require	  adapting	   the	  DOX-­‐induced	  HF	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protocol	   to	   immunocompromised	   mice,	   and	   also	   an	   alternative	   formulation	   for	   miR-­‐30	  
delivery	   that	   is	   not	   exclusively	   cardiotropic	   in	   order	   to	   target	   the	   tumour	   as	   well.	   Still,	   it	  
would	   provide	   the	   most	   accurate	   indication	   of	   the	   postulated	   dual	   benefits	   of	   miR-­‐30	  




This	   research	   has	   unveiled	   novel	  mechanisms	   that	   seem	   to	   play	   vital	   roles	   in	   the	   adverse	  
cardiac	   effects	   of	   DOX.	   The	   discovery	   of	   aberrant	   miR-­‐30	   expression	   in	   the	   myocardium	  
upon	  DOX	  treatment	  has	  proven	  to	  be	  biologically	  relevant,	  given	  its	  sustained	  alteration	  in	  
a	  model	  of	  late	  stage	  HF	  as	  well	  as	  its	  demonstrated	  impacts	  on	  the	  targets	  validated	  here.	  	  
Overall,	  the	  present	   investigation	  underlines	  a	  miR-­‐30-­‐induced	  dampened	  response	  to	  βAR	  
stimulation	   and	   a	   protective	   effect	   against	   DOX	   insult	   in	   cardiomyocytes.	   From	   a	  
translational	  perspective,	  the	  β-­‐blocker	  activity	  of	  miR-­‐30	  would	  be	  beneficial	  as	  it	  replicates	  
the	  effects	  of	  common	  pharmacological	  therapy	  routinely	  given	  to	  HF	  patients.	  The	  fact	  that	  
miR-­‐30	   acts	   as	   a	   β-­‐adrenergic	   antagonist	   is	   relevant	   beyond	   DOX	   cardiomyopathy,	  
considering	  the	  widespread	  application	  of	  β-­‐blockers	  in	  cardiovascular	  disease.	  On	  the	  other	  
hand,	  high	  miR-­‐30	  expression	  seems	  to	  correlate	  with	  less	  aggressive	  tumours,	  supporting	  a	  
dual	  therapeutic	  use	  for	  miR-­‐30.	  Importantly,	  in	  keeping	  with	  our	  results,	  published	  research	  
indicates	   anti-­‐cancer	   effects	   for	   β-­‐blockers,	   further	   predicting	   a	   two-­‐pronged	   therapeutic	  
role	  for	  miR-­‐30.	  
Harnessing	  miRNA	  biology	  could	  bring	  huge	  benefits	  to	  the	  clinic,	  both	  for	  the	  development	  
of	   biomarker	   assays	   and	   as	   part	   of	   therapeutic	   approaches.	   The	   findings	   described	   in	   this	  
project	  highlight	  the	  power	  of	  miRNA	  as	  master	  gene	  expression	  regulators	  and	  propose	  yet	  
another	   scenario	   in	   the	   growing	   list	   of	   uses	   of	   miRNA	   manipulation	   in	   disease.	   From	   a	  
holistic	  or	  systems	  biology	  point	  of	  view,	  the	  data	  obtained	  in	  this	  thesis	   interestingly	   links	  
cardiac	  disease	  and	  cancer	  biology	  through	  regulation	  by	  common	  miRNAs.	  Ultimately,	  we	  
believe	  that	  the	  improvement	  of	  DOX-­‐based	  regimes	  is	   likely	  to	  come	  from	  two	  directions:	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optimisation	   of	   the	   drug	   formulation	   itself	   in	   conjunction	   with	   complementary	  
cardioprotective	  strategies.	  We	  foresee	  the	  use	  of	  appropriately	  formulated	  miR-­‐30	  mimics	  
as	   an	   attractive	   option	   for	   adjuvant	   treatment	   to	   achieve	   the	   second	   goal,	   as	   well	   as	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5.1 Additional	  miR-­‐30	  target	  validation	  by	  3’UTR	  luciferase	  assays	  
	  
Initial	   validation	   by	   luciferase	   assay	   was	   performed	   also	   for	   those	   four	   genes	   that,	   even	  
though	  not	  chosen	  for	  further	  experimentation,	  were	  identified	  in	  the	  Cytoscape	  interaction	  




Figure	  62.	  ATP2A2,	  DMD,	  DTNA	  and	  TRDN	  3’UTRs	  are	  regulated	  by	  miR-­‐30.	  Luciferase	  assays	  performed	  on	  
H9c2	   cultures,	   by	   co-­‐transfecting	   the	   corresponding	   3’UTR-­‐containing	   vector	   for	   each	   target	   (ATP2A2,	  DMD,	  
DTNA,	   TRDN)	   and	   the	   miR-­‐30e	   mimic	   (pre-­‐30e,	   100nM)	   for	   24h.	   Averaged	   values	   of	   three	   independent	  
experiments	  (±SEM)	  expressed	  as	  ratios	  to	  3’UTR+pre-­‐NC	  transfected	  cultures.	  (*p<0.05).	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5.2 Western	  blots	  indicate	  unsuccessful	  GATA-­‐6	  ChIP	  
	  
Western	  blots	  were	  performed	  in	  order	  to	  confirm	  GATA-­‐6	  immunoprecipitation	  to	  continue	  
with	   the	   ChIP	   protocol,	   aiming	   to	   carry	   out	   sequencing	   on	   the	   enriched	   DNA	   fragments	  
(ChIP-­‐seq).	   Three	   different	   antibodies	   recommended	   for	   ChIP	   experiments	   were	   tested	  
without	  achieving	  specific	  GATA-­‐6	  pull	  down:	  
	  
	  
Figure	  63.	  Lack	  of	  specific	  GATA-­‐6	  immunoprecipitation	  with	  three	  different	  antibodies.	  Evaluation	  of	  GATA-­‐6	  
immunoprecipitation	  (IP)	   for	  ChIP	  experiments	  by	  Western	  Blot.	  Left	  panel,	   IP	  with	  the	  anti-­‐GATA-­‐6	  antibody	  
sc-­‐7245x	   seems	   to	   pull	   down	   a	   protein	   band	   of	   the	   right	  molecular	  weight	   (GATA-­‐6:	   56kDa,	   red	   rectangle).	  
However,	   no	   band	   was	   observed	   in	   the	   input	   lane	   (dashed	   rectangle).	   Right	   panel,	   no	   specific	   bands	   were	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5.3 Lower	   doxorubicin	   cumulative	   dose	   (10mg/kg)	   does	   not	   trigger	  
myocardial	  miR-­‐30e	  down-­‐regulation	  
	  
In	   order	   to	   test	   whether	   a	   lower	   dose	   of	   DOX	  would	   still	   cause	   a	   reduction	   in	   LVEF	   and	  
down-­‐regulated	   miR-­‐30	   without	   causing	   high	   rates	   of	   sudden	   death,	   we	   administered	   a	  
lower	   cumulative	   dose	   of	   DOX	   (10mg/kg	   instead	   of	   the	   usual	   15mg/kg)	   and	   allowed	   for	  
cardiac	   adverse	   effects	   to	   develop	   over	   4	   weeks.	   Echocardiography	   failed	   to	   reveal	  




Figure	   64.	   miR-­‐30e	   expression	   is	   unchanged	   4	   weeks	   after	   10mg/kg	   DOX	   cumulative	   dose.	  Animals	  were	  
treated	   with	   10mg/kg	   (5	   doses	   of	   2mg/kg	   spaced	   over	   2weeks).	   4weeks	   after	   the	   last	   injection,	   rats	   were	  
echocardiographed	  and	  hearts	  were	  then	  harvested	  for	  RNA	  extraction.	  A	  30%	  mortality	  was	  observed	  in	  the	  
last	  week	  of	  the	  study.	  RT-­‐qPCR	  data	  shows	  quantification	  of	  miR-­‐30e	  levels	   in	  hearts	  from	  the	  saline	  control	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